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CHAPTER 1 
OSTEOSARCOMA 
 
Introduction 
 
In the following chapter Osteosarcoma (OS), current treatment and novel 
therapeutics will be discussed. OS is the name given to a heterogeneous group of 
malignant tumors that have as their common feature the production of immature 
bone, also known as osteoid. This overview and thesis focuses on classic high 
grade OS (75% of all OS) and in this context the next topics will be described: 
demographics, classification, clinical presentation, staging, aetiology, current 
treatment and novel therapeutics including gene therapeutic approaches. In this 
latter paragraph an update on gene therapy for OS will be presented in view of 
this thesis.  
 
History 
 
The term OS was first introduced by Alexis Boyer in 1805 (Boyer 1805), shortly 
afterwards the demographics and natural history were described by Guillaume 
Dupuytren (Dupuytren 1847). Next Joseph Recaimier introduced the difference 
between primary bone lesion and secondary lesions in the lungs and the term 
“metastasis” in 1829 (Recamier 1829). That same year Jean Cruveilheir 
(Cruveilhier 1829) published a detailed work on OS and the pathologic anatomy. 
Despite these advances in understanding OS, this did not contribute to 
improvement of clinical outcome of the patients. Primary amputation remained the 
principal surgical treatment and survival rates of that time were around 5-10%.  
The discovery of x-rays in 1895 was a landmark in the diagnoses and treatment of 
bone tumors. Furthermore the description of the Codman’s triangle (area of new 
periostal bone formation) by Ernest Codman in 1909 contributed to the diagnostic 
characteristics of OS and is still used (Codman 1909). Surgeons of the Rizzoli 
Institute in Bologna, Italy contributed significantly to the understanding of bone 
tumors. First under Vittorio Putti (1880-1940) and later by Campanacci 
(Campanacci, 1999), this institute developed innovative surgical treatments for 
OS. In addition, surgical techniques and bone pathology further improved and 
these were described in an overview by Henry Jaffe (Phemister 1940; Jaffe 1958). 
Since the 1970’s dramatic changes in the field of oncology and surgery 
revolutionized the treatment of patients with OS. These changes include; the 
development of chemotherapy (Cortes, Holland et al. 1974); the improvements in 
diagnostic radiographic techniques; the advances in reconstructive surgery 
(Volkov 1970); the improvements in orthopaedic oncology surgical expertise and 
the establishment of multidisciplinary oncology referral centres. Patient survival 
since these developments further improved with the use of different 
chemotherapeutic regiments and aggressive surgical techniques, a discovery made 
at the Memorial Sloan-Kettering cancer Centre. Moreover, the introduction of a 
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surgical staging system by W. F. Enneking for musculoskeletal sarcomas helped to 
organize the orthopaedic surgical approach and define tumor resection for 
amongst others OS (Enneking, 1980). 
These new methods continued to develop and by 1990 the entire management 
and prognosis of OS had changed. Patients diagnosed with OS received 
neoadjuvant and adjuvant chemotherapy and amputations became the exception 
rather than rule. It became clear that limb-salvaging surgery combined with 
reconstructive surgery had no more risk than amputation (Simon et al. 1986). 
Eventually, this led to a significant improvement in patient survival rate from 
under 10% to 60% (Link, Goorin et al. 1991; Winkler, Bielack et al. 1993; 
Souhami, Craft et al. 1997; Meyers, Gorlick et al. 1998; Lindner, Ramm et al. 
1999; Bacci, Briccoli et al. 2001). (Source: (Enneking 2000)) 
 
Demographics and Location 
 
OS is the most frequent malignant primary bone tumor in both children and adults 
(Marcove, Heelan et al. 1991;Huvos 1991; Unni 1996; Dorfman 1997). The overall 
incidence of OS is 0.3 cases/100000/year (Siegal 2002). In the Netherlands there 
are approximately 30 new patients with OS per year. The incidence is slightly 
higher among the Negroid compared to Caucasian populations as well as among 
males compared to females (National Cancer Institute NCI). The peak incidence, 
corresponding with a growth spurt, is in adolescence with a median age at 
diagnosis of 16 years and an additional smaller peak after the age of 50 (Dorfman 
1997). 
OS is most often localized in the extremities; non-extremity tumors are more 
frequent in elderly patients. There is a predilection for the metaphyses of the large 
long bones in adolescents and it is most common in the distal femur, the proximal 
tibia, the proximal humerus and the distal radius in that order (Dahlin and 
Coventry 1967; Marcove, Mike et al. 1970) see figure 1. 
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Figure 1 Incidence and predeliction sites of OS (from Mosbey Bone tumors) 
 
 
One-half of the tumors arise in the femur, with 80% of these arising around the 
knee joint in young patients. Localized tumors are limited to the bone of origin, 
although local skip metastases may be apparent within the bone, indicating a 
worse prognosis (Wuisman, 1990). Systemic metastases have a predilection site 
for the lungs. The bones are the second most common site of metastasis and 
usually become involved only after pulmonary metastases have occurred.  
 
Macroscopy, Microscopy and Classification 
 
The gross appearance of OS is quite variable. The tumor usually involves the 
methapysis of a long bone; the epiphyseal plate may be seen as a relative barrier 
to the tumor. Necrosis and haemorrhage may be present. Sometimes a large 
amount of bone formation may be seen. However tumors may also exhibit large 
amounts of cartilage or only small amounts of matrix. An OS grows in a radial 
manner, forming a ball-like mass. When it penetrates the bony cortex, it 
compresses the surrounding muscles into a pseudo-capsular layer.  
OS is thought to be a malignant tumor of mesenchymal origin. Sarcomatous 
stromal cells directly producing “tumor osteoid” characterize OS. Despite the 
different histological appearances of OS the malignant osteoblast is generally seen 
as its “basic tumor cell type”. OS consists of spindle-shaped cells with high grade, 
cytological changes producing a syncytium of osteoid around them. Bars of 
tumorous bone are immature, amorphous, and not stress oriented (Wuisman, 
Enneking et al. 1992). Areas of cartilaginous and/or fibrous differentiation are 
common (Inwards and Unni 1995; Vander Griend 1996). Tumor bone may fill the 
marrow spaces without destroying adjacent trabeculae, thus producing an 
"osteoblastic" appearance radiographically (Dorfman 1997; Siegal 2002). OS 
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commonly is sub-classified by whether it is primary or secondary and by the site 
of origin. Roughly there are 3 subtypes of OS, which then can be further 
subdivided; intramedullary (high-grade 75%), juxtacortically (15%) and 
secondary (10%) summarized in table 1 (Schajowicz 1993). Among the classic 
high grade (intramedullary) OS several subtypes are recognized. The clinical and 
biological significance of these subtypes are controversial discussed in literature, 
since data based upon large enough controlled randomized studies recognizing 
these subtypes as separate entities are lacking (Hauben, Weeden et al. 2002).  
 
Osteosarcoma types 
Central 
High-grade  
 Conventional 
 Osteoblastoma like 
 Chondroblastom like 
 Fibroblastic 
 Epithelioid 
 Telangiectatic 
 Small cell 
Low-grade  
 Low grade central 
   Fibrous dysplasia like 
   Desmosplastic fibroma like 
Surface 
 Low-grade 
   Parosteal 
Intermediate-grade 
 Periosteal 
High-grade 
 Dedifferentiated parosteal 
 High grade surface  
Intracortical 
Gnathic 
Extraskeletal 
 High-grade 
 Low-grade 
Secondary 
 OS associated with Paget’s diseases of bone 
 Postirradiation OS 
 Secondary OS arising in other skeletal neoplasms 
Multifocal OS  
 
Table 1 Os types and classification of OS 
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Clinical presentation Complains and physical examination 
 
 
Classic intramedullary high-grade OS usually presents as a painful, hard, enlarging 
mass. Patients typically present with dull, aching pain of several months' duration 
that may suddenly become more severe. The increase in pain severity may 
correlate with tumor penetration of cortical bone and irritation of the periostium. 
Night pain is common and may awaken the patient from sleep. Patients frequently 
have a history of a minor injury, sprain or muscle pull incurred while participating 
in a sport (Dorfman 1997). At presentation pathologic fracture is uncommon; a 
painful swelling is frequently present, serum levels of alkaline phosphatase are 
often elevated. When the patient seeks medical attention at the hospital in 20% of 
the cases lung metastasis have been formed (Meyers, Heller et al. 1993; Mialou, 
Philip et al. 2001; Bacci, Briccoli et al. 2003). 
 
Radiology 
Imaging studies of OS are focused on the primary tumor and the possible 
presence of lung metastasis. Radiographic examination starts with plain 
radiographs, which are taken from the primary tumor and thorax. 
Radiographically, OS most frequently is a destructive lesion with areas of 
amorphous ossification. Sclerosis is the result of tumor osteoid production and 
typically appears as small, irregular, cloud like densities. This area of periosteal 
new bone formation is called “Codman’s triangle”. OS lesions can be purely 
osteolytic (approximately 30% of cases), purely osteblastic (approximately 45% of 
cases) or a mixture of both (Inwards and Unni 1995; Unni 1998). Plain 
radiographs are used to differentiate between the possible causes of a bone mass; 
OS, Ewing’s sarcoma, osteomyelitis, osteoblastoma, giant cell tumor, aneurysmal 
bone cyst and fibrous dysplasia. It is also used to detect pulmonary metastasis on 
a plain thoracic anterior-posterior and lateral view, however, chest Computer 
Tomography (CT) is more sensitive in this regard. 
In addition, CT scan of the primary lesions delineates the location and extent of 
the tumor. When extensive necrosis and surrounding edema are present, CT scan 
is superior to Magnetic Resonance Imaging (MRI), in establishing the extent of 
soft tissue involvement. In addition, when contrast medium is used, adjacent 
vascular structures can be identified. CT scan of the chest is essential for 
assessing pulmonary metastasis. Patients with OS should ondergo CT scan 
repeatedly to detect pulmonary disease.  
To asses the extent of intramedullar extension as well as soft tissue extension or 
skip lesion, MRI of the primary lesion is performed. With standard T1 and T2 
weighted and fat suppressed images the affected bone and the joint can be 
assessed. MRI studie permits accurate planning of the osteotomy site. 
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Other imaging studies include bone scans, PET scans and angiography. Bone 
scintigraphy is usefull in determining the sites of metastatic disease and the 
intraosseous extent of the tumor. Bone scans (nuclear scintigraphy) and FDG-PET 
are useful adjuncts, but are more pertinent to staging than for evaluation of the 
primary lesion. The most valuable use of bone scan for evaluation of osteosarcoma 
is the detection of metastatic deposits within the skeleton. Angiography can assist 
in surgical planning and in estimating the response of the tumor to preoperative 
chemotherapy. 
In order to complete the diagnosis of OS a biopsy procedure is a prerequisite for 
type and grading the OS. Biopsy procedures include open or closed biopsies. The 
latter can be a true cut or a fine needle aspiration. Regardless of the type of 
biopsy procedure considering general oncological principals is warranted. Recent 
studies have shown that fine-needle aspiration in a mulitdisiplinary setting can be 
as valuable as an open incisional biopsy (Kilpatrick, Ward et al. 2001). A fine-
needle aspiration can be sufficient to provide the diagnosis of OS prior to definitive 
treatment when interpreted in conjunction with imaging studies and clinical 
findings. In those cases where fine-needle aspiration fails to yield a diagnostic 
sample, a traditional biopsy should be performed (Dodd, Scully et al. 2002).  
 
Staging 
 
The purpose of staging tumors is to stratify risk groups. Conventional staging used 
in solid tumors is not appropriate for skeletal tumors since these tumors rarely 
involve lymph nodes or spread regionally. In 1980, Enneking introduced a staging 
system for musculoskeletal tumors; the section for primary malignant tumors is 
summarized in table 2 (Enneking, Spanier et al. 1980). Key components to the 
staging system are histological grade, anatomic localization and the absence or 
presence of metastatic disease. This staging system is applicable for OS. 
 
Stage Grade and anatomic extent 
I Low-grade tumor 
IA Intracompartimental 
IB Extracompartimental 
II High-grade tumor 
IIA Intracompartimental 
IIB Extracompartimental 
III Either grade with metastases  
 
Table 2: Staging of musculoskeletal tumors according to Enneking (Enneking, Spanier et al. 
1980) 
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E iologyt  
 
The exact cause of OS is unknown. During the past decades many factors in 
conjunction with the development of OS have been identified. It is not (yet) clear 
how these initiating agents and genetic events are related. Etiologic agents such 
as chemical agents, radiation, viruses and other miscellaneous ( trauma, electrical 
burn), may play a role in OS development.  
Next to etiologic agents there are numerous inherited syndromes in which OS 
develops more frequently. For instance, the Rothmund Thomson syndrome 
(Rothmund 1887; Thomson 1923) is associated with an increased risk for cancer. 
The Bloom syndrome (Bloom 1954), charaterized by prenatal and postnatal 
growth retardation is also associated with increased risk of developing cancer, 
including OS. The third syndrome associated with OS is the Li-Fraumeni syndrome 
(Li, Fraumeni et al. 1988) known to have the risk for development of multiple 
cancers. Subsequently, OS frequently occurs in patients with an inherited 
mutation in the retinoblastoma gene (Rb). Patients affected with hereditary Rb 
mutations have a 1000-fold higher change of developing an OS (Hansen, Koufos 
et al. 1985). In addition underlying abnormalities such as Paget’s disease or 
fibrous dysplasia have apredeliction for the development of OS. 
OS are tumors with complex unbalanced karotypes and chromosomal aberrations. 
Identification of genes within the amplified sites is crucial for understanding the 
biology of OS. The introduction of comparative genomic hybridisation has enabled 
the high throughput quantitative measurements of DNA copy number changes 
throughout the genome (Tarkkanen, Karhu et al. 1995; Hulsebos, Bijleveld et al. 
1997; Tarkkanen, Elomaa et al. 1999; Stock, Kager et al. 2000; Zielenska, Bayani 
et al. 2001).  
The search for genes associated with the development of cancer has led to 
characterization of the signal transduction pathway deficits associated with the 
pRb gene and the p53 gene. By now, a large body of evidence suggests that p53 
and pRb are significant altered in a wealth of different tumors as well as OS. Both 
these genes encode proteins which directly (pRb) or indirectly (p53) participate in 
the control of the cell cycle, see figure 2. 
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Figure 2: cell cycle, pRb and p53 regulation 
 
The Rb gene functions as a tumor suppressor gene. Cell cycle progression is 
regulated by cyclin dependent kinases (Cdks). The Rb gene regulates expression 
of Cdks in the cell cycle progression phase from G1 to S. The Rb protein acts by 
binding to and thereby suppressing the function of the E2F transcription factor. 
This process is controlled by phosphorylation, which is mediated by D-type Cdks, 
especially the cyclin D1/CDK4 complex. Several inhibitors of this process have 
been identified; the INK4 family which includes p16 and the CIP/KIP family.  
OS show alterations of the Rb gene in approximately 70% of the cases (Hansen, 
Koufos et al. 1985; Fuchs and Pritchard 2002). Loss of heterozygosis (LOH) at the 
Rb gene locus on chromosome 13 is present in about 65% of tumors (Feugeas, 
Guriec et al. 1996). In addition LOH has been identified as a poor prognostic factor 
in OS (Feugeas, Guriec et al. 1996; Benassi, Molendini et al. 1999). Structural 
rearrangements and point mutations occur less frequently. 
Other frequently observed abnormalities in the Rb pathway in OS are anomalies of 
p16, CDK4 and cyclin D1. These anomalies account for approximately 10-15% of 
the tumors. The loss of p16 expression has been correlated with decreased 
survival in pediatric OS (Maitra, Roberts et al. 2001). Taken together the pRb 
pathway plays a significant role in OS. 
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One of the key components of the DNA damage sensor that induces the apoptotic 
effector cascade is p53 (Anderson and Snyderman 1997; Hung and Anderson 
1997). P53 binds directly to DNA, recognizing DNA damage and mediates at least 
two important cellular responses; cell cycle arrest and apoptosis. P53 promotes 
cell cycle arrest through upregulation of p21 protein. The p53 gene is located on 
chromosome 17p13, an area frequently identified as abnormal in OS (McBride, 
Merry et al. 1986). Many studies have identified abnormalities, allelic loss, gene 
rearrangements, or point mutations of the p53 gene in OS, in up to 50% of the 
cases (Guo, Wang et al. 1996;Masuda, Miller et al. 1987; Lonardo, Ueda et al. 
1997). Several groups have investigated the clinical significance of p53 gene 
alterations and its implications for response to chemotherapy and disease 
progression. Studies addressing this subject are grouped in a meta-analysis by 
Pakos et al. (Pakos, Kyzas et al. 2004); overall conclusion is that  p53 alteration 
could not be associated with the response to chemotherapy, and that there might 
be an association with decreased survival.  
Wild type p53 can also be inactivated by the murine double minute-2 (MDM2) 
(Wunderlich and Berberich 2002). The MDM2 gene encodes a nuclear 
phosphorprotein that inhibits p53 mediated transactivation (Momand and Zambetti 
1997) (Zauberman, Barak et al. 1993) and promotes the degradation of p53 
(Haupt, Maya et al. 1997) (Kubbutat, Jones et al. 1997). The MDM2 gene has 
shown to be amplified preferential in sarcomas including OS. Although the 
percentage of MDM2 amplification varies, and some authors found amplifications 
especially in subtypes or metastatic OS (Maitra, Roberts et al. 2001), collective 
data suggest that the prevalence of high-level MDM2 amplification in OS is 
between 4-7% (Oliner, Kinzler et al. 1992; Nakayama, Toguchida et al. 1995) 
(Ladanyi, Cha et al. 1993; Florenes, Maelandsmo et al. 1994). In conclusion the 
p53 apoptotic pathway has an essential role in the malignant behaviour of OS.  
 
Above, a summary of the most important “players” in the cell cycle pathway are 
described in the perspective of this thesis. In addition, several other families are 
involved in downstream regulation of apoptotic signals, such as Bax and Bcl-2, 
caspases, death receptors and Fas ligand. However, in view of the scope of this 
thesis, these will not be further discussed. 
Despite the fact that much remains unclear concerning the pathogenesis and 
etiology of OS, much progress has been made in the past decades. Eventually, 
this will lead to understanding of the molecular events, the relationship of certain 
gene expression profiles to prognosis and response to treatment. In addition to 
this further discoveries will provide information on possible tumor targets for 
selective therapy. 
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Current treatment modal ties and prognosis i
 
Current treatment of OS involves an integrated strategy incorporating 
chemotherapy and surgery. Surgery aims at removing the primary tumor whith 
wide tumor margins and if present, removal of lung metastasis. Since the primary 
tumor most frequently is localized in the extremity, in the past amputations were 
frequently performed. But the improvement of imaging techniques, surgical skills, 
the responsiveness of the tumor to chemotherapy and the advances in biomedical 
engineering, nowadays, have led to the majority of limb-saving surgery (Simon, 
Aschliman et al. 1986; Brosjo 1999; Lindner, Ramm et al. 1999). Limb-saving 
surgery aims at preserving a useful and functioning limb, which still is a challenge, 
especially in the pediatric setting (Grimer 2005; Finn and Simon 1991).  
In contrast to amputation tumor margins are smaller in limb salvage surgery. 
Direct comparison between limb salvage and amputation did not show a difference 
in survival (Simon, Aschliman et al. 1986). There is, however, an increased risk of 
local recurrence in patients undergoing limb-salvage surgery, but no increased 
mortality (Grimer, Taminiau et al. 2002; Meyers, Heller et al. 1992; Hosalkar and 
Dormans 2004). Several surgical options have been described after resection of an 
OS in the extremity; amputation, endoprosthetic replacement, allograft, 
sterilisation and reimplantation of bone, vascularised fibula graft, vascularised 
graft combined with allograft, bone distraction and rotationplasty (Kotz, Dominkus 
et al. 2002; Meyer and Mackenzie 2004).  
The value of neoadjuvant and adjuvant chemotherapy for treatment of OS is well 
established (Link, Goorin et al. 1986;Meyers, Heller et al. 1992). Randomized 
clinical trials have established that both neo-adjuvant and adjuvant chemotherapy 
are effective in OS (Eilber, Giuliano et al. 1987; Link, Goorin et al. 1991). 
Standard regimens now include preoperative and postoperative chemotherapy 
(Picci 1992). Drugs that have been shown to be most effective against OS include 
doxorubicin, cisplatin, ifosfamide with mesna, and high-dose methotrexate. The 
mechanisms of action and side effects of these chemotherapeutic agents are 
summarized in table 3. 
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Agent Mechanism of action Side effects 
Doxorubicin  Doxorubicin intercalates at 
points of local uncoiling of 
the DNA double helix; it also 
inhibits the synthesis of DNA 
and RNA. 
Cardiomyopathy, transient 
electrocardiographic 
abnormalities,emesis, 
alopecia,mucositis, 
myelosuppression 
Cisplatin  Cisplatin inhibits the 
synthesis of DNA through 
the formation of DNA cross-
links; it binds directly to 
tumor DNA and denatures 
the DNA double helix. 
Acute renal failure, chronic renal 
failure, peripheral 
neuropathy,ototoxicity, emesis, 
myelosuppression, alopecia, 
hypomagnesemia 
Ifosfamide with 
mesna  
Ifosfamide causes cross-
linking of DNA strands, 
inhibiting the synthesis of 
DNA and protein. 
Hemorrhagic cystitis, renal 
failure, myelosuppression, 
alopecia,emesis, encephalopathy 
High-dose 
methotrexate 
Methotrexate is a folate 
antimetabolite; it inhibits 
the synthesis of purine and 
thymidylic acid by binding 
dihydrofolate reductase. 
Renal failure, mucositis, mild 
myelosuppression; rarely, central 
nervous system effects 
 
Table 3: chemotherapeutic agents and their working mechanism and side effects 
 
The prognosis for patients with OS depends obviously on the state of the disease 
at time of diagnosis. Patients can be divided in three sub groups: (I) patients with 
localized OS, (II) patients with metastatic OS either to the lungs or the bone and 
(III) patients with recurrent disease.  
Localized tumors (I) limited to the bone of origin have the best prognosis, 5 year 
survival varies between 60-75% (Link, Goorin et al. 1991; Meyers, Gorlick et al. 
1998; Lindner, Ramm et al. 1999; Renard, Veth et al. 1999; Sluga, Windhager et 
al. 1999; Bacci, Briccoli et al. 2001; Bacci, Ferrari et al. 2001); patients are 
treated with preoperative chemotherapy usually followed by limb-saving surgery. 
After surgery the response of the tumor to chemotherapy is evaluated by degree 
of necrosis, the histological response to chemotherapy. In most clinics responses 
are expressed as percentages of necrotic tissue, thus good responder patients 
were those with tumor necrosis > 95%. This is associated with higher survival 
rates than a lesser response (Fuchs and Winkler 1993; Bacci, Briccoli et al. 2001). 
A recent study by Bacci et al. (Bacci, Mercuri et al. 2005) showed in 881 patients 
necrosis to be a significant prognostic value regardless of the type of 
chemotherapy performed. In an attempt to improve survival of patients with 
localized OS, several groups have studied intensification and changes in the 
chemotherapeutic protocols. For instance, Ferrari et al. (Bacci, Mercuri et al. 2005) 
analysed the efficacy of addition of high-dose ifosfamide to methotrexate, cisplatin 
and doxorubicin in the preoperative phase and state that major renal and 
hematologic toxicities occur and survival rates are similar to those obtained with 
four-drug regimens using standard dose ifosfamide. Furthermore, Meyers et al. 
(Meyers, Schwartz et al. 2005) questioned whether the addition of ifosfamide 
and/or muramyl tripeptide in addition to standard regiments improved event-free 
20 
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survival. The addition of ifosfamide to their schedule did not enhance event free 
survival but muramyl tripeptide improved patients event free survival although the 
mechanism remains to be cleared.  
Patients with metastatic disease (II) are treated by (pre-operative chemotherapy) 
surgical ablation of the primary tumor and resection of metastatic disease. This 
surgical treatment is followed by post operative combination chemotherapy. Untill 
now neither the optimal management of these patients nor the assessment of 
their prognosis is well established. Despite the improvement of prognosis in 
patients with OS of the extremity, patients with metastatic disease still have a 
poor overall two year survival of 55% (Bacci, Briccoli et al. 2003). Kager et al. 
(Kager, Zoubek et al. 2003) showed that the number of metastases at diagnosis 
and the completeness of surgical resection of all clinically detected tumor sites are 
of independent prognositc value in patients with proven primary metastatic OS. 
Patients persistently free of the primary OS who develop recurrent resectable 
metastatic disease of the lung should be considered for reoperation a second, 
third, or fourth time, as this results in a prolonged disease free survival (Briccoli, 
Rocca et al. 2005). Apart from lung metastatsis metastatic disease within the bone 
(skip metastasis) also indicate a worse prognosis (Wuisman and Enneking 1990; 
Sajadi, Heck et al. 2004).  
In patients with recurrent disease (30% of the patients with OS) 5-year survival 
has been reported as being <30% (Ferrari, Bacci et al. 1997; Meyers, Gorlick et 
al. 1998; Bacci, Briccoli et al. 2001; Chi, Conklin et al. 2004; Strauss, McTiernan 
et al. 2004). In patients with local recurrences complete surgery and aggresive 
chemotherapy with more than one agent seems to contribute to limited 
improvements of outcome (Kempf-Bielack, Bielack et al. 2005). In addition, an 
analysis of Chou et al. (Chou, Merola et al. 2005) showed that patients may 
benefit from the addition of ifosfamide, however, the role of chemotherapy in 
recurrent OS continues to be undefined.  
In conclusion since the addition and intensification of systemic adjuvant 
chemotherapy, and the improvement of surgical techniques, survival is prolonged. 
These improvements may possibly have led to a change in the patterns of relapse. 
However, an analysis of the Memorial Sloan-Kettering group (Chi, Conklin et al. 
2004) did not support this hypothesis. Analysis of survival of a large, unselected 
cohort of intensively pre-treated patients confirmed the poor prognosis of 
recurrent OS and revealed no changes in relapse pattern.  
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NOVEL THERAPEUTICS 
 
Despite the fact that chemotherapy has improved the survival of patients with OS 
significantly, there are still patients who cannot benefit from these improvements. 
Therefore, new approaches and concepts are important to further improve the 
outcome of patients having OS. Apart from improving chemotherapeutic 
approaches and investigating drug resistance mechanisms novel therapeutics are 
being explored. In the past decade several experimental therapeutics in the 
context of OS have been developed and evaluated in a (pre) clinical setting. These 
new treatment strategies include growth hormone blockade, radiation therapy with 
a bone seeking isotope samarium, antibody based immunotherapy strategies, 
gene therapy and inhalation therapy with GM-CSF for the delivery of cytokines to 
lung metastasis. In the following paragraph the role and possibilities regarding 
therapeutic strategies concerning growth factors will be discussed in more detail. 
This is followed by a detailed description and discussion on gene therapy 
strategies in OS. 
 
Growth factors 
 
It became clear that growth factors play an important role in tumor genesis and 
metastatic potential of tumor cells. In this process angiogenesis plays a key role. 
It elicits proliferation and migration of endothelial cells to allow the formation of 
new capillaries. Since solid tumors depend on neovascularization for continuous 
growth, angiogenesis is of fundamental importance, to the tumor and to the 
formation of metestasis. It has become clear that solid tumors produce several 
growth factors that have angiogeneic properties and thereby stimulate growth and 
metastatic capacity. OS depends on growth factors that act by autocrine or 
paracrine mechanisms. These growth factors are attractive hallmarks to direct 
anticancer therapeutics too.  
 
Vascular Endothelial Growth Factor (VEGF) is a protein identified as a mitogen for 
endothelial cells in vitro and an angiogenesis promoting factor in vivo (Keck, 
Hauser et al. 1989; Folkman 1995). VEGF activates endothelial cells via interaction 
with its receptors, Flk-1 and Flt-1, which are selectively expressed in the 
endothelium (Ferrara, Carver-Moore et al. 1996; Lee, Dublin et al. 1998). The 
importance of VEGF in tumor growth has been indicated by the correlation 
between VEGF expression in the tumor and poor prognosis for patients with 
certain malignant tumors, such as gastric carcinoma (Mattern, Koomagi et al. 
1996), colorectal carcinoma (Berse, Brown et al. 1992) and breast carcinoma 
(Desruisseau, Palmari et al. 2004). The clinical significance of VEGF in OS has 
been investiaged by Kaya et al. (Kaya, Wada et al. 2000) their data show that 
VEGF expression in untreated osteosarcoma is predictive for pulmonary metastasis 
and poor prognosis. Next to VEGF expression, intratumoral microvessel density 
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(MVD) is assessed as a measure for angiogenesis. Wang et al. (Wang, Chen et al. 
1997) showed evidence for decreased overall survival in OS patients with high 
MVD in contrast, Mantadakis et al. (Mantadakis, Kim et al. 2001) failed to 
demonstrate such a correlation. Kreuter et al. evaluated the prognostic relevance 
of MVD for response to chemotherapy and long-term outcome in OS. They showed 
that patients with a tumor with a high MVD had higher survival rates when treated 
with intensive chemotherapy regimens. To a certain extent this can be explained 
by the fact that high MVD may contribute to a better chemotherapeutic 
distribution. 
Strategies, which exploit VEGF overexpression are not yet tested in the context of 
OS. The anti-VEGF agent bevacizumab, a humanized monoclonal antibody against 
VEGF, is approved for treatment of different kind of cancers. Future studies will 
probably evaluate this agent in the context of OS. An other anti VEGF therapeutic 
strategy uses COX-2 inhibitors. COX-2 inhibitors, such as celcoxib, decrease VEGF 
production and VEGF induced endothelial cell activation. Studies in OS cell lines 
and animal models with celecoxib have shown modest effects (Takahashi, Ogawa 
et al. 2004; Takahashi, Ogawa et al. 2004; Tsai, Wu et al. 2005). A recent studie 
by Naruse et al. demonstrated that meloxicam (COX-2 inhibitor) reduces SAOS-2 
derived lung metastasis in vivo and showed that this effect was more prominent in 
cells with high levels of COX-2 (Naruse, Nishida et al. 2005). A case report of Tsai 
et al. (Tsai et al. 2005) report that a patient with OS refractory to current 
chemotherapeutic approaches showed smaller tumor nodules on chest radiography 
after one month with celecoxib and thalidomide (an immunomodulatory agent). 
The effects described in this case report however may also be due to the effect of 
thalidomide. Next to these developments in OS in other solid tumor types a wide 
range of antiangiogenetic therapeutics have been developed, which may hold 
promise for the treatment of OS.  
 
Platelet-derived growth Factor (PDGF) plays a central role in regulating cell 
proliferation, chemotaxis and survival in normal cells as well as in various disease 
states. The PDGF family exerts their cellular effects by differential binding to two 
receptor tyrosine kinases, PDGFR-α and PDGFR-β. Autocrine growth is suggested 
to occur in cells expressing both ligand and its cognate receptor, as is the case in 
OS. Several studies have confirmed the expression of PDGF and PDGFR in OS cell 
lines (Benini, Baldini et al. 1999) as well as in OS tissue samples (Sulzbacher, 
Traxler et al. 2000; Kubo 2002). Compounds have been developed that inhibit 
PDGFR kinases. ST1571 (Gleevec) is such a compound, it inhibits tyrosine kinase 
receptors and c-Kit. More recently McGary et al.(McGary, Weber et al. 2002) have 
shown that Gleevec inhibition leeds to apoptosis of OS cell lines. However, in their 
in vivo model the combination with Taxol did not show significant anti tumor 
efficacy. PDGF was reported to cause high interstitial fluid pressure in tumor 
tissues. High interstitial fluid pressure acts as a barrier to tumor transvascular 
transport, decreasing the uptake of chemotherapeutics. Taking this into account, 
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Pietras et al. reported that inhibition of PDGF by Gleevec enhanced the efficacy of 
chemotherapeutic treatment by decreasing the tumor interstitial fluid pressure 
(Pietras, Rubin et al. 2002). This may also be applicable in the context of 
adenoviral vector based gene therapy.  
 
Transforming growth factor-β (TGF-β) is a prototype of the cytokines of the TGF-β 
family which includes TGF-β and Bone Morphogenic Proteins (BMP). TGF-β acts as 
a potent growth inhibitor for divergent cell types. TGF-β binds to two different 
types of tyrosine kinase receptors and thereby eventually down-regulating the 
expression of c-Myc and up regulation of CDKIs and p21 (Massague, Blain et al. 
2000). Loss of TGF-β mediated growth inhibition is thought to play a role in 
tumorgenesis. Bone is an organ that produces and stores large amounts of TGF-β 
(Ragland, Bell et al. 2002). Recent findings suggest that TGF-β is involved in 
progression of OS; TGF-β stimulates the growth of OS cell lines in culture (Reed, 
Zerwekh et al. 1993; Kloen, Jennings et al. 1994), and in OS tissue samples over 
expression of TGF-β is observed and may be involved in determining the 
aggressive clinical behavior of OS (Franchi, Arganini et al. 1998). TGF-β may 
induce growth factor secretion from stromal cells, and the secreted growth factors 
may enhance proliferation of cancer cells in turn. TGF-β stimulated proliferation of 
OS cells was found to be inhibited by SB-431542, a TGF kinase inhibitor, as well 
as Gleevec (Matsuyama, Iwadate et al. 2003). 
The hepatocyte growth factor (HGF) receptor MET regulates invasive growth. HGF 
is also a strong angiogenic factor both in vivo and in vitro (Boros and Miller 1995). 
The receptor of HGF, MET was originally identified as a transforming oncogene in a 
human OS cell line (MNNG-HOS), which acquired tumorgenicity after treatment 
with a chemical carcinogen (Cooper, Park et al. 1984; Park, Gonzatti-Haces et al. 
1986). In OS high levels of MET are detected (Scotlandi, Baldini et al. 1996). MET 
is expressed in tumors that synthesize and secrete HGF, suggesting a autocrine 
loop which contributes to the pathogenesis of sarcomas. Recently it has been 
shown that endogenous HGF induces a constitutively active, autocrine mitogenic 
loop in OS cells. The known antiproliferative effect of 1,25(OH)(2)D(3) on OS cells 
can be accounted for by the concomitant 1,25(OH)(2)D(3)-induced inhibition of 
HGF production (Chattopadhyay, MacLeod et al. 2003)  In addition, Cotella et al. 
showed a response to the K252a (biological inhibitor of HGF) in blocking HGF 
dependend proliferation (Coltella, Manara et al. 2003). 
Altogether developments mentioned above may hold promise for future 
therapeutic developments in OS and may be well combined with gene therapeutic 
strategies. 
 
Gene therapy 
 
Gene therapy relies on the delivery of foreign DNA into human cells. This has led 
to the engineering of effective and efficient vehicles for transferring genes into 
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cells. Nonviral vectors or viral vectors can accomplish this transfer of DNA. The 
simplest method to deliver DNA is by plasmid DNA expression vectors driven by 
eukaryotic promoters. The advantage of nonviral gene vectors are lack of immune 
response and ease of formulation and assembly. Nonviral vectors for delivery of 
DNA can be classified into 2 major types: polymeric delivery systems (DNA 
polymer complexes) and liposomal delivey systems (DNA entrapped in and/or 
complexed to liposomes). Viral vectors are genetically modified viruses, which are 
still able to transfer their genetic material to a host cell. The viral vectors used in 
experimental OS studies include integrating vectors based on retroviruses (Rv) 
and adeno-associated viruses (AAV), as well as non-integrating vectors based on 
adenoviruses (Ad), herpes viruses, and lentiviruses. These vectors apart from the 
adenovirus will not be discussed in greater detail, important characteristics are 
summarized in tabel 4. 
 
 
Vector Packaging 
capacity 
Genetic 
Material 
Genome 
size (kb)
Host range Features 
Retrovirus 8 kb Linear 
single 
stranded 
RNA 
7-11 Constricted, 
dividing cells 
only 
Long term 
expression genome 
integration 
Adeno-
associated 
virus 
4 kb Linear 
single 
stranded 
DNA 
4 Extensive, 
both non-
dividing and 
dividing cells 
Genome integration 
Long term 
expression 
Inefficient large 
scale production 
 
Adenovirus 8-9 kb Linear 
double 
stranded 
DNA 
36 Extensive, 
both non-
dividing and 
dividing cells 
 
Transient 
expression Strong 
immunogenicity 
Herpes virus 30 kb Linear 
double 
stranded 
DNA 
152 Extensive Longterm 
expression Low 
toxicity Latent 
infection 
Lenitivirus 8 kb Linear 
double 
stranded 
DNA 
7-11 Extensive, 
dividing and 
non-dividing 
cells 
Genome integration 
Longterm 
expression 
Inefficient 
production Safety 
concerns 
 
Tabel 4: viral vectors used for gene delivery 
 
Since the scope of this thesis is on adenovirus a more detailed description is 
included in the next paragraph. 
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Adenovirus 
 
In cancer gene therapy adenoviruses (Ads) have gained widespread popularity. 
Ads are commonly known because they cause respiratory, intestinal and eye 
infections in human. Up till now there are more than 50 human serotype 
adenoviruses known among which the Ads 2 and 5 are studied extensively. The 
molecular genetics and virology of Ads have been well characterized and the entire 
genome sequences are known (Genbank accessin number BK000408). Ad is a 
non-enveloped virus that carries a linear, double-stranded 36 kilo base (kb) DNA 
genome that can be divided into early (E1-E4) and late (L1-L5) transcription 
regions. The E1 region is activated upon entry of the viral genome into the nucleus 
and it encodes proteins involved in other early functions. The E2 region encodes 
adenoviral DNA replication. The E3 region is involved in reducing the antiviral 
immune response. and in effective lysis of the cell after viral replication. The E4 
region encodes proteins with functions to control the viral replication. The late 
genes encode viral structural proteins. 
The major proteins of the adenovirus capsid are the hexon, fiber and penton. The 
fiber capsid protein consists of three distinct domains-tail, shaft, and knob. The 
tail domain anchors the fiber to the Ad capsid through association with the penton 
base. The shaft domain extends away from the virion surface and increases 
opportunities for host receptor binding. The knob is responsible for binding to the 
host primary cellular receptor (Henry, Xia et al. 1994). 
The mechanism by which the Ad enters a cell can be divided in two steps and is 
depicted in figure 3.  
 
 
Figure 3:adenoviral binding and internalization via CAR and integrins  
 
To enter the cell the adenovirus binds with its binding domain (fiberknob) to the 
Coxsackie Adenovirus Receptor (CAR) (Bergelson, Cunningham et al. 1997). 
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Following viral attachment, internalization is potentiated through cellular αv 
integrins (cell adhesion molecules) (Wickham, Mathias et al. 1993). Uptake of viral 
particles is done in a process called endocytosis. In the endosome the fibers are 
removed from the viral particle, after disruption of the endosome the viral particle 
is transferred to the cytosol and to the nucleus. In the nucleus the viral DNA 
including the therapeutic gene is transcribed in mRNA. The mRNA is translated 
into viral proteins and finally, after assembling in the nucleus, the newly generated 
adenoviruses are released by cellular lysis. 
Gene delivery vectors derived from adenoviruses exhibit a number of features that 
make them particularly useful for gene-transfer purposes. The adenovirus genome 
is characterized in great detail, it has very high transfection efficiency ex vivo and 
in vivo. In addition, adenoviral vectors can transfect proliferating and non-
proliferating cells. Furthermore, Ad is the easiest viral vector for production. It 
allows the production of large quantities with high titre and in relatively robust 
formations. 
The first generation adenoviral vectors were generated by deletions in one or more 
critical genes (e.g., E1 and E4), these modifications rendered the Ad replication 
incompetent. These deletions made more space available for the insertion of 
therapeutic genes. (7-8kb). These vectors allow delivery of a variety of trans-
genes, including tumor-suppressor genes, prodrug-activating enzymes, or 
cytokines (depicted in figure 4) to target tissues and have demonstrated clear 
therapeutic benefit and safety in a variety of pre-clinical neoplastic animal models.  
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Gene Therapy Strategies 
Based on the transferred genes, three main categories of gene therapy in the OS 
field can be distinguished thus far; mutation compensation of tumor suppressor 
genes, suicide gene therapy, and immuno-potentiation. 
 
Figure 4: gene therapy strategies; mutation compensation, suicide gene therapy and 
immuno-potentiation 
 
Mutation Compensation gene therapy 
 
Mutation compensation is based on the idea that a disease results from single 
gene alteration. Since this is not the case in cancer, where the disease is the 
result of a cascade of genetic abnormalities (rearrangements, deletions, frame 
shifts mutations etc), gene repair by transducing the wild type gene to the tumor 
cell only works when it concerns genes pivotal in the cancer development cascade, 
such as p53 or pRb. By adding the wild type gene to the tumor cell its original 
function will be restored.  
OS are known to have complex unbalanced karyotypes, and alterations of the p53 
and retinoblastoma (Rb) pathways in most cases (Masuda, Miller et al. 1987; 
Feugeas, Guriec et al. 1996; Guo, Wang et al. 1996; Lonardo, Ueda et al. 1997). 
These tumor suppressor pathway anomalies provide significant opportunities for 
compensation of disrupted cell functions in OS tumor cells.  
Several groups have tried to repair the pRb pathway by the use of a replication-
deficient recombinant adenovirus vector encoding the full length pRB (Xu, Zhou et 
al. 1996) or p16INK4A (Craig, Kim et al. 1998). These strategies were able to 
suppress tumorgenicity in nude mice. However this treatment was less effective in 
well-established xenografts. It became rapidly clear that the effect was strongly 
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associated with the presence of functional pRb in the cancer cells, and that the 
most pronounced effect could be observed in pRb null tumor cells. Moreover, 
improved transfection efficiency and expression of the pRb gene was warranted. 
Since p53 alterations are common in OS (Miller, Aslo et al. 1990; Florenes, 
Maelandsmo et al. 1994; Miller, Aslo et al. 1996; Hung and Anderson 1997), 
restoring p53 function is another attractive target in cancer gene therapy. In 
several cancer models, p53 gene transfer reduced DNA damage, enhanced 
induction of apoptosis, inhibited tumor growth and increased survival of tumor-
bearing mice (Gallardo, Drazan et al. 1996; Harris, Sutjipto et al. 1996; Nielsen, 
Dell et al. 1997; Nielsen and Maneval 1998). In OS, the group of Phelan et al. 
(Phelan, Elliott et al. 1998) delivered functional p53 by the herpes protein VP22 in 
OS cell lines. They showed that this protein efficiently induced apoptosis in p53 
negative human OS cells. Moreover in an established OS lung tumor model, nude 
mice were treated with aerosol delivery of plasmid DNA containing the p53 gene. 
This resulted in a significant reduction of tumor nodules and in the average size of 
the tumors (Densmore, Kleinerman et al. 2001). Since SAOS-LM6 was used to 
develop this tumor model, these results were not entirely unexpected, as SAOS-
LM6 cells are derived from SAOS-2, a p53 null line. 
Another interesting feature of restoring wild type p53 is in increasing sensitivity of 
OS cells to chemotherapeutic agents. This improvement in sensitivity was 
observed in combination with cisplatin (Tsuchiya, Mori et al. 2000) and adriamycin 
(Song and Boyce 2001). In addition, Ganjavi et al. (Ganjavi, Gee et al. 2005) 
showed that cell viability decreased after treatment with an adenoviral vector 
encoding p53 and that the sensitivity of the OS cell lines to cisplatin and 
doxorubicin increased. 
Despite the fact that these strategies show efficacy in vitro and in vivo, the 
concept of mutation compensation mandates transduction of every tumor cell, in 
the absence of lateralization or a bystander effect (see below), in order to 
eradicate a complete tumor population. Furthermore, the application of wild type 
tumor-suppressor gene therapy on genetically variable OS may only be effective in 
genetic subgroups of this tumor, reducing but not eliminating the entire tumor 
population (Hellwinkel, Muller et al. 2005). 
 
Suicide gene therapy 
 
Suicide gene therapy (also called; gene-directed enzyme prodrug therapy, 
molecular chemotherapy) relies on the capacity of the gene product of a 
transduced cell to convert a non-toxic prodrug into a toxic compound. This 
approach has the advantage that not every single tumor cell needs to express this 
product to eradicate a tumor population, due to the so called ‘bystander effect’. 
This phenomenon can be explained by diffusion (extracellular or via gap junctions) 
of toxic compounds, formed in the transduced cell, to neighbouring, non-
transduced or transfected cells. 
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Several prodrug-converting enzymes have been studied extensively, including 
Herpes Simplex Thymidine Kinase (HSV-TK), bacterial cytosine deaminase (CD), 
Carbocylesterase-2 (CE-2), bacterial nitroreductase/CB1954 and cytochrome 
P450/cyclophosphamide. The latter two have not been applied to the field of OS 
and will not be discussed further. 
 
Herpes Simplex thymidine Kinase: 
The HSV-TK gene is the most widely studied suicide gene therapy system. 
Expression of the HSV-TK gene confers enhanced tumor sensitivity to nucleoside 
analogues such as ganciclovir (GCV) and acyclovir (ACV). HSV-TK converts GCV or 
ACV to their non-phosphorylated form, which is trapped in the cytoplasm and 
subsequently, becomes further phosphorylated to the triphosphorylated (GCV-
3P/AVC-3P) form by cellular kinases of the host cells. Upon division of the tumor 
cell, GCV-3P or ACV-3P will be incorporated into the cellular DNA, thereby 
inhibiting DNA replication and RNA polymerase activity, eventually leading to cell 
death. The HSV-TK/GCV strategy has demonstrated strong anti-tumor activity in 
numerous tumor models including ovarian carcinoma, malignant glioma, 
hepatocellular carcinoma and prostate cancer (Rosenfeld, Feng et al. 1995; 
Rosenfeld, Wang et al. 1996; Rancourt, Rogers et al. 1998; Cheon, Kim et al. 
2000; Rainov 2000; Stefani, Barzon et al. 2005). This system was tested in OS 
first by Grossin et al. (Charissoux, Grossin et al. 1999). Using a retroviral vector, 
they were able to sensitize OS cell lines and generate a strong bystander effect, 
which for this class of compounds is due to gap junction-mediated diffusion of the 
toxic drug to neighbouring tumor cells. With the use of ex vivo transduced tumor 
cells inoculated in xenografts on a rat hind limb they showed that this system 
reduced the tumor mass and prevented the appearance of lung metastases 
(Charissoux, Grossin et al. 1999). The group of Ketola et al. studied the efficacy of 
adenoviral/lentiviral delivery for HSV-TK/GCV gene therapy in OS cell lines and 
report sufficient HSV-TK expression for cytotoxicity and bystander effect (Ketola, 
Maatta et al. 2004).  
 
Bacterial cytosine deaminase: 
A second enzyme prodrug therapy is based on the conversion of the prodrug 5-FC 
to the cytotoxic drug 5-fluorouracil (5-FU) by the enzyme cytosine deaminase. 5-
FC is deaminated by CD into the cytotoxic drug 5-FU. Administration of 5-FU 
causes toxic side effects and high doses are required for tumor response. 
Designing therapies where CD is expressed in localized areas of cancer is attractive 
as such treatments could deliver very high local concentrations of 5-FU to tumor 
sites while avoiding toxic systemic levels. CD genes from Escherichia coli and 
Saccharomyces cerevisiae have been evaluated and found effective in various 
experimental
 
 animal models for enzyme/prodrug therapy of tumors (Huber, Austin 
et al. 1993; Mullen, Coale et al. 1994; Ohwada, Hirschowitz et al. 1996; Kanai, 
Lan et al. 1997). The main advantage of CD/5-FC suicide gene therapy is that no 
30 
Osteosarcoma And Evolving Gene Therapy Approaches for OS 
cell-to-cell contact is required for the bystander effect, since 5-FU can diffuse in 
and out of cells by non-facilitated diffusion. A study of Ramnaraine et al. 
(Ramnaraine, Pan et al. 2003) showed that using this suicide gene therapy 
approach, bone sarcomas in 9 of 10 treated mice could be eliminated. In addition 
they studied the efficacy of osteoclast precursor cells transduced with the CD gene 
as a gene delivery system. Their results indicate that transduced osteoclasts can 
promote killing of cancer cells and that the bystander effect remained present 
(Ramnaraine, Pan et al. 2005). 
  
Carboxylesterase: 
The third prodrug converting enzyme that has been incorporated into gene 
therapeutic strategies is carboxylesterase (CE), which is involved in the conversion 
of the prodrug CPT-11 to its toxic derivative SN-38. CPT-11 is a semi-synthetic, 
water-soluble derivative of camptothecin that belongs to the class of 
topoisomerase I inhibitors. Topoisomerase I acts through stabilization of a drug-
induced cleavable complex, and formation of irreversible double-stranded DNA 
breaks which are toxic for the cell. CPT-11 is a prodrug that undergoes de-
etherification into the much more potent topoisomerase I inhibitor SN-38. 
Although SN-38 can be detected in the plasma of cancer patients only minutes 
after the administration of CPT-11, 90% of the administered CPT-11 is not 
converted. Conversion of CPT-11 is achieved by carboxylesterase (CE) which has 
been found in liver and lung (Satoh and Hosokawa 1998). Koijma et al. and Wierdl 
et al. have shown that certain solid tumors could be sensitized to CPT-11 after 
adenoviral vector mediated CE gene transfer (Kojima, Hackett et al. 1998) 
(Wierdl, Morton et al. 2001). Since conversion of CPT-11 to SN-38 in the 
extracellular space between cells would allow a larger bystander effect than would 
be possible when relying only on intracellular conversion alone, Oosterhoff et al. 
constructed an adenoviral vector encoding a secreted form of CE (sCE). This 
construct was successfully used on cells originating from various tumor types  
(Oosterhoff, Pinedo et al. 2002). 
 
 
Immunopotentiation gene therapy 
The third main category of gene therapeutic approaches applied in OS research, 
involves strategies to achieve anti-tumor immunity. Although tumors display a 
variety of tumor-associated antigens that can be recognized by T cells, most of 
them escape from host cellular immune surveillance. Therefore, two basic 
approaches can be identified: (i) enhancing tumor cell recognition; and (ii) 
augmenting the efficacy of the immune system. 
Tumor cell recognition can be enhanced by improving tumor antigen presentation 
by transduction with MHC-class I molecules, or by transferring tumor antigens to 
antigen presenting (dendritic) cells (Frolkis, Fischer et al. 2003; Nencioni, Muller 
et al. 2003).  
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In the context of OS, research has focused on enhancing the efficacy of the 
immune system. Examples of this approach include; genetically modifying T-
lymphocytes to enable their receptors to recognize tumor cells more efficiently, or 
boosting of the immune system by introducing genes coding for cytokines and 
other co-stimulatory molecules (Worth, Jia et al. 2000; Lafleur, Jia et al. 2001; 
Tsuji, Kawaguchi et al. 2002). The cytokine IL-12 is a key component in numerous 
immune functions including stimulation of T cells and NK cells and regulation of 
several cell adhesion molecules. It promotes the production of IFN-gamma by T 
and NK cells. The mechanisms underlying this anti tumor activity are understood 
incompletely but may be related to the ability of IL-12 to inhibit angiogenesis or 
stimulate T cells and NK cells. The transduction of OS cells with the IL-12 gene 
reduced the ability of these cells to form lung metastases in nude mice (Worth, Jia 
et al. 2000; Lafleur, Jia et al. 2001). Aerosol gene therapy with PEI (a liposomal 
DNA carrier) showed effective gene transfer of IL-12. Mice bearing OS lung 
metastasis treated with PEI:IL-12 had significant tumor regression (Jia, Worth et 
al. 2002; Jia, Worth et al. 2003). 
Liebau et al. studied immunotherapy strategies using plasmid-mediated gene 
transfer extensively. The effect of NK-mediated tumor cell lysis in vitro was 
studied. The results demonstrate that IL-12 can enhance the expression of ICAM-1 
in the presence of IFN-gamma and, with IL-18, enhances NK anti-tumor activity 
(Liebau, Merk et al. 2002). Of the cytokines IL-12, IL-18 and IL-23, the last 
appeared to be a less effective immuno-therapeutic agent for adjuvant treatment 
of OS than IL-12 and IL-18 (Liebau, Roesel et al. 2004). 
Co-stimulatory molecules promote T-cell proliferation and cytokine production and 
thereby induce a more potent anti-tumor immune response. One of the co-
stimulatory molecules that is well-characterized is B7-1 (CD80). Successful 
induction of an anti-tumor immune response has been reported in a number of 
tumor models. Tsuji et al. found that adenovirus-mediated rat B7-1 gene transfer 
induced expression of B7-1, curative immunity against pre-established primary 
OS, systemic immunity against pre-established pulmonary metastasis and 
activation of regional lymph nodes CD4+ T cells (Tsuji, Kawaguchi et al. 2002). In 
order to increase the efficacy of this approach, a B7-1/Fas chimeric gene was 
transferred via adenoviral vector to OS cells. This resulted in expression, 
activation of T-cells, apoptosis of OS cells and a stronger inhibitory effect on the 
development of pulmonary metastasis compared to B7-1 alone (Tsuji, Kawaguchi 
et al. 2003). 
 
Together, the results of above-described gene therapeutic strategies for treatment 
of OS have yielded promising results. However, efficient gene transfer to tumor 
cells has proven to be more difficult than originally foreseen. Moreover, gene 
delivery to non-target tissue with possible resultant side-effects remains an issue 
requiring attention. In Addition, in the adenoviral context it has become apparent 
that a major determinant of gene transfer efficacy is the expression of CAR, on 
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target cells. It has become evident that CAR expression is limited on tumor cells. 
This has predicated the practical and biological need to develop new vectors. 
Strategies to improve these vectors are to target gene delivery Ad to tumor cells, 
thereby also inducing a more tumor specific gene transfer.  
 
 
 
Targeting to tumor cells 
The broad tropism of adenoviral vectors can be a potential disadvantage, since in 
cancer gene therapy, more selective gene transfer in specific cell types is 
warranted. In the context of osteogenesis for example, others have shown the 
utility of adenovirus-mediated gene therapy in osteoblasts (Mehrara, Saadeh et al. 
1999; Zhu, Rawlins et al. 2004; Xu, Tang et al. 2005). These studies have shown 
effective adenovirus transfection ex vivo as well as in vivo of normal bone cells, 
with minimal toxicity. Therefore in order to establish an effective and safe gene 
therapy approach, tumor selectivity of the gene transfer or expression is a 
prerequisite. In addition retargeting allows for the administration of lower vector 
dose to achieve a similar therapeutic effect while minimizing the direct cytotoxic 
effects of adenoviral vectors. Furthermore, retargeting might prevent inadvertent 
adenoviral transduction into antigen-presenting cells and consequently diminish 
inflammatory responses to the vector (Chuah, Collen et al. 2003). This retargeting 
can be achieved by limiting the infection to the tumor cell (transductional 
targeting) or by limiting the gene expression to the tumor cell (transcriptional 
targeting). 
 
Transductional targeting 
Transductional targeting involves the modification of viral tropism in order to limit 
infection to certain cell types, and to improve infection efficiency of cancer cells. 
This can be achieved by redirecting binding of the vector to molecules highly 
expressed on tumor cells. This approach has been applied most widely in the 
context of Ad, as reviewed by Everts et al. (Everts and Curiel 2004).  
Studies on various types of tumors have shown that application of adenoviral 
vectors for cancer gene therapy is hampered by the lack of CAR expression on 
primary tumor cells (Douglas, Rogers et al. 1996; Li, Pong et al. 1999; Grill, Van 
Beusechem et al. 2001; Wesseling, Bosma et al. 2001). The recognition that CAR 
deficiency is a nearly universal feature of primary tumors has predicated the need 
for adenoviral vectors capable of “CAR independent” gene delivery. Furthermore, 
to enhance the selectivity of transduction of tumor cells vectors should be targeted 
towards specific tumor cell receptors.  
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Selectivity can be achieved by using ligands for cellular receptors or by using 
antibodies against cellular antigens linked to an antibody against the binding 
domain of the viral vector. Such complexes; known as bispecific antibodies, were 
first described by Douglas et al. (Douglas, Rogers et al. 1996). An alternative 
approach was presented by Krasnyck et al. (Krasnykh, Dmitriev et al. 1998), who 
incorporated the targeting peptide Arg-Gly-Asp (RGD-4C) into the HI loop of the 
fiber knob of the adenoviral vector. These strategies are depicted in figure 5. 
 
 
 
Figure 5: adenoviral cell attachment and targeting principles 
 
 
Epidermal Growth Factor Receptor (EGFR): 
The erbB family of type I protein receptor tyrosine kinases consisting of EGFR, 
Her-2, Her-3 and Her-4  plays an important role in the carcinogenesis of many 
human malignancies and is therefore an attractive target. EGFR is 
characteristically expressed on cells derived from all three germ layers and at 
particularly high levels on epithelia (Gullick, Marsden et al. 1986). EGFR is over 
expressed in a large number of tumors, including head and neck, breast, 
colorectal, lung, protstate, kidney, ovary, brain, pancreas and bladder carcinomas 
(reviewed by Kim et al. (Kim, Khuri et al. 2001)). Morris et al. studied the 
expression of EGFR as a possible prognostic factor for patients with OS. In 
patients over expressing EGFR a significantly higher percentage with a poor 
histologic response after preoperative chemotherapy could be observed (Morris, 
Gorlick et al. 2001). These findings were in agreement with data presented by Oda 
et al. (Oda, Wehrmann et al. 1995). Furthermore, Hughes et al. showed that cell 
surface expression of Her-2 and EGFR may be contributing to OS pathogenesis 
(Hughes, Thomas et al. 2004). In tumors over expressing EGFR, production of 
ligands for EGFR principally transforming growth factor alpha, lead to activation of 
 
34 
Osteosarcoma And Evolving Gene Therapy Approaches for OS 
survival pathways via autocrine loops. For a detailed overview on tumor biology 
and EGFR we refer to a review by Normano et al. (Normanno, Bianco et al. 2001). 
In short it has become clear that EGFR plays an essential role in the signal 
transduction cascade and tumorigenesis. Pal et al. have summarized EGFR and the 
efficacy of EGFR blockade (Pal and Pegram 2005). The ERBB1 (EGFR) inhibitor, 
gefitinib (iressa; ZD1839) is a small molecule that acts by inhibiting EGFR 
phosphorylation and therefore receptor activation and signal transduction. A study 
by Stewart et al. (Stewart, Leggas et al. 2004) demonstrated that growth of four 
OS xenografts was not inhibited by this agent alone but combined with irrinotecan 
(CPT-11) it caused enhanced anti tumor activity. This combination therapy 
resulted in maintained complete responses.  
Of the tumor cell receptors, EGFR has been studied extensively in the context of 
redirecting Ad. Targeting adenoviral vectors towards EGFR was achieved by using 
a bispecific single-chain antibody (scFv), which targets adenoviral vectors towards 
tumor cells that express the EGFR (425-s11). The molecular adapter 425-s11 
binds to the knob of the adenovirus and to the EGFR on the (tumor) cell 
membrane (Haisma, Grill et al. 2000) thereby increasing transduction efficiency. A 
comparable approach uses a recombinant soluble form of truncated CAR (sCAR) 
and a targeting ligand towards EGFR (Dmitriev, Kashentseva et al. 2000). This 
approach was found to be effective in meningioma, bladder cancer, pancreatic 
cancer, squamous cell carcinoma and glioma (Blackwell, Miller et al. 1999; Grill, 
Van Beusechem et al. 2001; Wesseling, Bosma et al. 2001; Dirven, Grill et al. 
2002; van der Poel, Molenaar et al. 2002). An other system developed is the 
doubly ablated Adv with a bispecific targeting moiety. This has the advantage that 
neutralizing antibodies to circumvent native receptor binding are no longer 
warranted (van Beusechem, Grill et al. 2002). Taken together EGFR appears to be 
an interesting cell receptor, which may hold promise for targeting in OS.  
 
Integrins: 
The heterodimeric integrin receptor is composed of an α subunit of 120-1280kDa 
and an β subunit of 90-110 kDa. A ligand binding is calcium dependent. 
Expression of adhesion molecules such as integrins are associated with metastatic 
potential of tumor cells. Duan et al. (Duan, Jia et al. 2004) showed in a range of 
sub lines from human OS cell line SaOs-2 with progressively increasing potential 
to form lung metastasis, that this was correlated with the alpha v beta 3 integrin 
expression. Furthermore, alpha v beta 3 integrins are expressed on activated but 
not quiescent endothelial cells (Hood, Bednarski et al. 2002; Brooks, Montgomery 
et al. 1994). This might merit the gene transfer to tumor endothelial cells. The 
RGD-4C peptide sequence is known to interact strongly with αv integrins. RGD-4C 
modified adenoviral vectors demonstrated highly efficient infection efficiencies on 
various tumors such as glioma, meningioma, ovarian and pancreatic cancer 
(Dmitriev, Krasnykh et al. 1998; Grill, Van Beusechem et al. 2001; Wesseling, 
Bosma et al. 2001; Dirven, Grill et al. 2002). The mutant vector constructed by 
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Koizumi et al. (Koizumi, Mizuguchi et al. 2001) infected the cells, which lacked 
CAR expression but showed alpha(v) integrin expression, about 10-1000 times 
more efficiently than the vector containing wild type fiber via an RGD-integrin 
(alpha(v)beta3 and alpha(v)beta5) -dependent, CAR-independent cell entry 
pathway. In Squamous cell cancer (SCC) a modified RGD adenovirus increased the 
efficacy of transfection in specific CAR negative, cell lines and in the nude mouse 
model (Lalonde, Beyer et al. 2002). In addition in SCC IL-2 gene therapy with 
enhanced infection efficiency proved to be more effective compared to the 
parental vector (Dehari, Ito et al. 2003). Intravenous administration of the RGD 
infectivity enhanced vector showed in vivo ehananced gene transfer in melanoma 
xenografts bearing mouse (Gao, Inoue et al. 2004). Hemminki et al. showed that 
a vector containg the HSV-TK gene and the expanded tropism towards RGD 
exhibited a greater transduction efficiency in ovarian cancer cell lines also in the 
presence of ovarian cancer derived ascites containing Ad antibodies (Hemminki, 
Belousova et al. 2001). In addition Wu et al. explored the efficacy of a polylysine 
and RGD infectivety enhanced adenoviral vector in ovarian carcinoma. Their 
results demonstrate that the combination of both strategies exhibited the highest 
efficacy in the subcutaneous tumor model (Wu, Han et al. 2004).  
In conclusion integrins are valuable in redirecting adenoviral vectors towards 
tumor cells. 
Alternative molecules that have been proven as useful for redirecting adenoviral 
attachment and entry and which may be of potential interest to targeting OS, 
include the fibroblast growth factor receptor (Gu, Kuntz-Simon et al. 1999), folate 
receptor (Douglas, Rogers et al. 1996), transferrin receptor (Xia, Wang et al. 
2000) and vascular endothelial growth factor receptor (Fischer 2001). Targeting 
towards the transferrin receptor was shown  to be effective in OS: Nakase et al. 
studied liposome-p53 gene delivery targeted towards transferrin in vitro and in 
vivo and demonstrated reduced tumor growth of established xenografts (Nakase, 
Inui et al. 2005).  
 
Transcriptional targeting 
 
Specific gene expression may also be achieved by delivering genes under the 
control of an appropriate tissue- or cell type-specific promoter. Several tissue and 
tumor specific promoters have been reported (reviewed by Haviv et al. (Haviv and 
Curiel 2001)) such as Survivin, COX-2 and PSA. In OS, the Osteocalcin (OC) 
promoter is of particular interest. OC is a major noncollagenous bone protein 
which expression is limited almost exclusively to osteotropic tumors and mature 
calcified tissue. Osteocalcin is expressed in several solid tumors, including OS 
(Koeneman, Kao et al. 2000). The efficacy and specificity of OC promoter-driven 
therapeutic gene constructs for treatment of OS were shown in vitro (Cheon, Ko et 
al. 1997) as well as in vivo (Cheon, Ko et al. 1997) (Shirakawa, Ko et al. 1998). In 
the latter case, 80% of animals bearing subcutaneous OS xenografts that were 
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treated with an adenovirus encoding HSV-TK under the OC promoter (Ad-OC-Tk) 
survived, and survival rates were 100% when this gene therapeutic approach was 
combined with metrotrexate (Cheon, Ko et al. 1997). Furthermore, Ad-OC-TK in 
combination with ACV was also effective in treating OS lung metastatic disease in 
mice, as treated animals showed a significant decreased number of tumor 
nodules, decreased net lung weight, and significantly increased survival rates 
(Shirakawa, Ko et al. 1998). Of note is the finding of Pollmann et al. (Pollmann, 
Kabisch et al. 2004) that OS-specific promoters should not only be evaluated for 
the target cells, but also for neighbouring normal tissues. In addition despite 
promising results described above using the OC promoter it should be well 
emphasized, OS being a highly mixed phenotype tumor with an unstable and 
poorly mineralized matrix, that OC gene transcription is likely to be extremely 
variable. Cell lines used in the studies mentioned above are not representative for 
the tumor cells in the in vivo situation. Therefore studies using alternative and 
more tumor specific promoters are warranted.  
Barnet et al. (Barnett, Tillman et al. 2002) combined transductional and 
transcriptional targeting by using a bispecific antibody conjugate redirecting 
towards EGFR and placing the reporter gene under the control of osteocalcin. They 
demonstrated a higher level of specificity for cancer cells (including OS cell lines) 
than either approach alone. Nagi et al. constructed an adenoviral vector with both 
enhanced infection efficiency and a tumor specific promotor for 
cholangiocarcinoma. In this setting the Cox-2 promoter demonstrated a favorable 
selectivity profile and RGD-modification further enhanced transduction efficiency 
(Nagi, Vickers et al. 2003).  
 
 
 
Virotherapy 
The main difficulties encountered in solid tumor therapy with replication-
incompetent viruses, has been the inability to efficiently disperse and infect the 
majority of tumor cells within the tumor mass. Replication and spread of a virus 
within a solid tumor could overcome the problem of inefficient cancer cell infection 
seen with non-replicating viruses.  
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Since viral replication leads to amplification of the input dose of the virus and after 
tumor cell lyses, these progeny viruses will spread and infect surrounding cells. By 
several rounds of replication the tumor will be destroyed eventually. 
Schematically, this is depicted in figure 6. 
 
 
Figure 6: CRAd infection, replication, tumor cell lysis and lateral spread 
 
This idea of using replication competent viruses for treatment of cancer, originates 
from the 1950’s. Oncolytic viral vectors based on adenovirus, herpes virus, 
poliovirus, measles and reovirus have all been described as therapeutic agents for 
various malignancies. In particular, oncolytic adenoviruses have received 
widespread attention and were translated rapidly from pre-clinical to clinical 
testing. (Kirn 2001). Oncolytic adenoviruses, or conditionally replicating 
adenoviruses (CRAds) with tumor specificity, have been obtained in two ways; 1) 
by deletions in viral genes encoding proteins that interact with cellular proteins 
necessary to complete the viral lytic cycle in normal cells, but not in tumor cells, 
and 2) By placing the control of early viral genes under a tumor specific promoter.  
Strategies to Increase the oncolytic potency of CRAds has led to development of a 
new generation of oncolytic viruses. These generations of oncolytic viruses are 
combining the cytotoxic effects of the lytic cycle with the delivery of transgenes 
with established anti-tumor efficacy and are known as armed therapeutic viruses. 
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Deletion of essential early genes: 
Wild type adenovirus  replication consists of an early and al late phase. A major 
function of the adenoviral early gene is to provoke the infected cell to enter cell 
cycle and progress to S-phase. The adenovirus can use the cell cycle machinery 
for its own replication. In order to let the cell progress to S-phase the adenovirus 
needs to inactivate the cellular pRb and p53 tumor suppressor genes (depicted in 
figure 7A).  
 
 
Figure 7A: Wild type adenoviral replication in a normal cell 
 
This is achieved by the E1 adenoviral gene by binding to pRb and thereby 
releasing E2F and thereby stimulating cell cycle progression. In order to prevent 
apoptosis of the infected cell the adenoviral E1B55KD protein inhibits the p53 
function. Then the E2 gene involved in DNA synthesis and the E3 gene involved in 
modulation of host immune response and cell lysis, and the E4 gene involved in 
replication and apoptosis are activated. CRAds are designed to replicate in cancer 
cells and not in normal cells. In the first approach, specific mutations or deletions 
are made in the E1 region of the adenoviral genome (figure 7B and 7C).  
 
  39  
CHAPTER 1 
 
Figure 7B: impaired CRAd replication in a normal cell 
 
 
Figure 7C: CRAd replication in a cancer cell 
 
This region contains two genes, E1A and E1B, which encode proteins required for 
a productive adenovirus lytic cycle. Bischoff et al. were the first to describe the 
construction of a CRAd based on a deletion of the E1B-55kDa gene (Bischoff, Kirn 
et al. 1996). This gene product was known to bind p53 (in complex with E4orf6), 
leading to p53 inhibition and/or degradation. In theory,  E1B-55 kDa-deleted 
adenoviruses such as dl1520 (Onyx-015) would not be able to inactivate p53 in 
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normal cells and, as a result, the viral replication cycle would not be completed 
(Heise, Sampson-Johannes et al. 1997). In cancer cells lacking normal p53 
function, however, replication was predicted to proceed. In this way, replication 
would be restricted to tumor cells.  
Controversy exists as to whether or not this is the sole mechanism by which 
ONYX-015 achieves selective replication capacity in malignant cells (Goodrum and 
Ornelles 1998; Hall, Dix et al. 1998). Nevertheless, this oncolytic adenovirus 
proved to be very effective in a wide range of preclinical models for various tumor 
types, including cervical carcinoma, laryngeal carcinoma, colorectal carcinoma, 
head and neck cancer, and glioma, with reports on complete regression of 
xenografts tumors and long-term survival (Bischoff, Kirn et al. 1996; Heise, 
Sampson-Johannes et al. 1997; Heise, Williams et al. 1999; Geoerger, Grill et al. 
2002). 
Employing a similar approach, adenoviruses were engineered to replicate 
selectively in tumor cells with lesions in the retinoblastoma tumor repressor (pRb) 
pathway. In wild type adenovirus E1A binds to pRb and this results in release of 
the transcription factor E2F which can subsequently activate the adenovirus E2 
promoter as well as several cell cycle genes. This allows the cell to enter S-phase 
and viral replication can take plase. PRb binding deficient CRAds were 
accomplished by deleting 24 bp from the E1A gene, which abolishes the pRb 
binding capacity of the E1A protein (Fueyo, Gomez-Manzano et al. 2000; Heise, 
Hermiston et al. 2000). Since these CRAds have a defective pRb binding capacity, 
E2F release has to be by other means. Since in most cancers the pRb pathway is 
altered (pRb deficiency) this will be the case. Therefore, this adenovirus mutant, 
known as Ad∆24 or Addl922-947, demonstrated greatly reduced replication in 
non-proliferating normal cells relative to other gene-deleted and wild type 
adenoviruses. The anti-cancer efficacy of these agents was confirmed in vitro and 
in heterotopic xenograft animal models of human glioma and breast cancer 
(Fueyo, Alemany et al. 2003)  
 
Promoter-driven viral replication: 
Additional means to achieve tumor selectivity is by transcriptionally regulating the 
expression of essential early viral genes by using tumor specific promoters. 
Conditional replication may be enforced on the virus by placing the transcription of 
replication-essential genes under the control of tumor-specific promoters (TSP) 
(Siders, Halloran et al. 1996) (Figure 8A and 8B). The first CRAd developed via 
this approach was CN706 (CV706) that specifically replicates in prostate-specific 
antigen (PSA) expressing cells (Rodriguez, Schuur et al. 1997). Based on the 
same principle CRAds with the viral essential genes under the COX-2 promotor, 
the human tyrosinse promotor, the midkine promotor and the hTERT promoter 
demonstrated efficacy in respectively pancreas cancer and gastric cancer 
(Yamamoto, Davydova et al. 2003; Ono, Davydova et al. 2005), metastatic 
melanoma (Nettelbeck, Rivera et al. 2002) pediatric solid tumors (Adachi, 
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Reynolds et al. 2001) and small cell lung cancer (Uchino, Takayama et al. 2005). 
The hTERT promoter-driven CRAd is a possible candidate for OS as telomerase 
expression is frequently observed in OS and correlates with a poor prognosis 
(Sanders, Drissi et al. 2004). 
Another CRAd which embodies this principle, and of special interest for OS, uses 
the bone matrix osteocalcin (OC) promoter to drive expression of E1A (AdOC E1a) 
(Matsubara, Wada et al. 2001). OC is expressed in several solid tumors including 
OS. Another example of one such replicative agent is the OCaP1, this is a CRAd 
with the essential genes under the control of OC (Benjamin, Helman et al. 2001). 
In 2001, a phase I/II dose escalation and activity study of intravenous injections 
of OCaP1 for subjects with refractory OS metastases to the lung was proposed. 
Yamamura et al. exploited this concept to develop a conditionally replicating 
herpes vector. The calponin (expressed in OS) promotor drives expression of ICP4, 
a major trans-activating factor for viral genes. In vivo data demonstrated that this 
vector promotes oncolysis in tumor cells and spares normal vascular smooth 
muscle cells, Furthermore, mice treated with this vector showed replication in the 
distant non-treated tumor (Yamamura, Hashio et al. 2001). 
In order to study oncolytic virotherapy in a large animal model, Hemminki et al. 
(Hemminki, Kanerva et al. 2003) developed a nonhuman canine CRAd. Since OS 
in dogs has a close resemblance to human OS this can be a valuable model to 
increase the understanding and translate CRAd effectivety to the human situation 
and provide a unique immunocompetent context. In this field work has advanced 
by demonstrating that chimeric fiber derived from both Canine Adenovirus Types 1 
and 2 display novel tropism (Stoff-Khalili, Rivera et al. 2005) (Glasgow, Kremer et 
al. 2004). Furthermore, Le et al. have shown that the canine adenovirus can be 
fluorescently tagged four use in imaging studies (Le, Li et al. 2005) and that novel 
constructs result in infectivity enhancement of canine OS cells (Le, Rivera et al. 
2005). Lastly, Ternovoi et al. have discovered that human type 5 Ad can engage 
in productive replication in canine OS cells, suggesting cross-species CRAd therapy 
may be possible for OS (Ternovoi, Le et al. 2005). 
 
Targeting CRAds 
 
As with non replicative Adenovirus, CRAd infection of host cells is based on the 
same two-step process; binding with the CAR receptor and internalization via 
receptor-mediated endocytosis, involving interactions between the Arg-Gly-Asp 
(RGD) sequence. Therefore, also in CRAd virotherapy CAR deficiency hampers the 
efficacy enormously. Strategies used to modify Ad tropism in the context of 
replication deficient adenoviral vectors are also being explored in the contex of 
CRAds. In short, these consist of pseudotyping (replacement of the tropism 
determing fiber knob domain),bispecific targeting moiety (inserting an expression 
cassette for a targeting moiety in the CRAd genome) and insertion of a ligand. The 
latter two will be discussed in more detail. 
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The construction of CRAds producing a targeting adapter molecule, capable of 
retargeting towards EGFR results in a single agent module. The construction of a 
CRAd with the ∆24 E1A mutation which produces a bispecific single-chain antibody 
directed towards the adenovirus fiber knob and the EGFR, killed primary human 
CAR-deficient brain tumor specimens that were refractory to the parent control 
virus (van Beusechem, Mastenbroek et al. 2003). In contrast it was also shown 
that a CRAd that replicates in cancer cells and codes for sCAR-EGF had a equal 
oncolytic potency compared to nontargeted controls in vitro or in vivo (Hemminki, 
Wang et al. 2003). This finding might be explained by the fact that expression of 
large protein can be counterproductive to virus replication. 
Insertion of a targeting ligand was made by the construction of the CRAd Ad5-
∆24RGD by Suzuki et al.(Suzuki, Fueyo et al. 2001). This infectivity enhanced 
CRAd incorporated the cyclic RGD peptide motif in the fiber HI-loop. This CRAd 
showed to have an increased oncolytic effect in vitro and in vivo compared to Ad5-
∆24. The CRAd Ad5-∆24RGD was also evaluated in the context of 
rhabdomyosarcoma, ovarian carcinoma and glioma and exhibited more efficient 
tumor cell kill in vitro and in vivo compared to Ad5-∆24 (Cripe, Dunphy et al. 
2001; Bauerschmitz, Lam et al. 2002; Lamfers, Grill et al. 2002; Fueyo, Alemany 
et al. 2003). This could, however, not only be contributed to the enhanced 
infection efficiency since the other difference appeared to be that Ad5-∆24 lacked 
the E3 region in comparison with Ad5-∆24RGD. This E3 region includes the 
Adenovirus Death Protein (ADP) which is involved in lysis of the infected cell 
(Tollefson, Scaria et al. 1996). Hence Suzuki et al. conducted a new set of 
experiments to investigate whether effects could be contributed to E3 or the 
infectivety enhancement. They found that the increase efficacy of Ad5-∆24RGD 
was mostly due to the incorporation of E3, but in CAR negative cells the infectivety 
enhancement as contributed to the increased efficacy (Suzuki, Alemany et al. 
2002). The effects and interactions of the E3 region are studied extensively by 
Wold et al. They demonstrated that E3 is an important component of the anti 
apoptosis arsenal encoded by the E3 transcription unit (Lichtenstein, Toth et al. 
2004; Toth, Djeha et al. 2004). Liu et al. designed a CRAd containing a TSP, 
tyrosinase (Tyr), and RGD-4c in the fiber knob. In melanoma tyrosinase-positive 
cell lines the Ad.Tyr-E1A(RGD) vector was as potent in its cytotoxic effect as a 
tumor nonselective vector (Ad.CMV-E1A). In addition, the Ad.Tyr-E1A(RGD) vector 
produced a higher vector particle yield in tumor cells than the Ad.Tyr-E1A vector 
did. Intratumoral injection of the Ad.Tyr-E1A(RGD) vector into xenotransplanted 
human melanoma tumors led to tumor regression in vivo. 
Altogether, these strategies to enhance infection efficiency of CRAds have shown 
to be effective in multiple (pre) clinical tumor models. 
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Armed Therapeutic viruses 
 
To enhance therapeutic efficacy, "armed" replicative viruses (ATV), incorporating 
therapeutic transgenes, have been introduced for cancer gene therapy. These ATVs 
embody two potential advantages. First, the gene product can enhance the 
oncolytic capacity, second the CRAd has a very potent level of transgene 
expression relative to the replication-defective vector counterparts. However, 
premature cell death during viral DNA replication compromises virus production, 
therefore timing of apoptosis induction is essential. Increased oncolytic capacity 
has been shown by van Beusechem et al. The expression of p53 in the E3 region 
(Ad∆24-p53) exhibited enhanced oncolytic potency compared to the control vector 
on a majority of tumor cell lines and xenografts models (van Beusechem, van den 
Doel et al. 2002; Geoerger, Vassal et al. 2004). Sauthoff et al. constructed a CRAd 
that expressed p53 during the late replication phase of an Ad without E3 and 
showed that the CRAd expressing p53 compared to a wild type CRAd was more 
effective in tumor cell killing (Sauthoff, Hu et al. 2003). The approach which 
combines oncolytic properties of a CRAd with an anticancer therapeutic gene was 
first exploited in the context of HSV-TK in combination with ganciclovir. This 
approach was shown to be effective and increased oncolytic potency (Wildner, 
Morris et al. 1999; Wildner, Blaese et al. 1999). In addition, Conrad et al. showed 
that the expression of CD (∆24-hyCD) in combination with 5-FC resulted in 
improved oncolytic tumor activity compared to the CRAd therapy alone (Conrad, 
Miller et al. 2005). Subsequently, Barton et al. constructed a second-generation, 
replication-competent adenovirus containing an improved CD and HSVTK fusion 
gene and the ADP gene (Barton, Paielli et al. 2005). This construct was compared 
to their earlier construct (Freytag, Khil et al. 2002) in preclinical models and 
exhibited greater tumor cell kill but no greater toxicity. 
Oosterhoff et al. designed a CRAd Ad5-∆24.E3-sCE2 which in combination with 
CPT-11 showed augmented cytotoxicity against colon cancer cell lines. However, 
low concentrations CPT-11 inhibited propagation (Oosterhoff, Pinedo et al. 2005). 
Based on the observations we showed with CE/CPT-11 in a non replicative viral 
vector against OS, this may be a promising agent against OS tumor cells. The fact 
that increased oncolytic capacity should not interfere with viral propagation has 
led to the development of ATVs expressing transgenes with an indirect anti-tumor 
activity. An example of those ATVs are Ad5-∆24TIMP-3 which showed enhanced 
oncolytic activity on a panel of primary cell cultures and two glioma cell lines 
compared with the control oncolytic virus Ad∆24Luc (Lamfers, Gianni et al. 2005).  
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Gene therapy and administration 
 
The effectivity of gene therapy is not only determined by the efficiency of the 
vector but also by the efficiency of vector delivery to the tumor cells. To date 
several routes of administration have been evaluated, including intratumorally, 
intraperitoneally, intra-arterially or intravenously. Initially, clinical trials with 
adenoviral vectors or CRAds were limited to cancers for which intra tumoral 
injection was feasible in order to maximize safety. In this regard, head an neck 
cancer or prostate cancer were studied extensively (Khuri, Nemunaitis et al. 2000; 
DeWeese, van der Poel et al. 2001; Nemunaitis, Khuri et al. 2001). Next, 
intraperitoneal injections were performed in patients with ovarian carcinoma 
(Vasey, Shulman et al. 2002). Since this appeared safe and feasible the next step 
was taken and intravascular administration was contemplated. The feasibility of 
vascular delivery to tumors was unknown due to the innate immunity and 
neutralizing antibodies.  
The tragic death of a patient, Jesse Gelsinger, on an adenoviral gene therapy trial 
for ornithine transcabamylase deficiency at the University of Pennsylvania 
eventually raised serious concerns about the safety. From that period Reid et al. 
summarized clinically of intravascular delivery in cancer patients (Reid, Warren et 
al. 2002). Based on those studies, it became clear that adenoviruses can be 
administrated into the bloodstream at doses that result in gene 
transduction/replication. Most common reported toxicity are flu-like symptoms, 
this was reported highest among patients receiving intra vascular administration 
of adenovirus. There has been no clinical evidence of progressive hepatotoxicity 
from administration of CRAds. In the case of Jesse  Gelsinger it became clear that 
he experienced an acute immune response to the Ad because of a previous 
infection.  
In the context of OS delivery of gene therapy can basically be placed in the 
perspective of the primary tumor and/or the lung metastasis. However since 
pulmonary metastasis is the major reason for the fatal outcome of OS, delivery 
studies should be adapted to target these metastasis. In this context intra 
vascular administration or aerosolized gene therapy are valuable strategies. Of 
which intravascular delivery also is suitable for the primary tumor. The advantages 
of aerosolized gene therapy are the non-invasive means for targeted delivery to 
different regions of the lung; moreover this route of administration delivers a high 
dose to the target site.  
To increase delivery efficiency in the primary tumor Isolated Limb Perfusion (ILP) 
may be optional. Locoregional administration of gene therapy by means of in situ 
isolated perfusion (IP) of a target organ or extremity is a method that may 
increase in vivo efficacy. Isolated limb perfusion with a chemotherapeutic agent 
was first described by Creech et al. in 1958 (Creech, Krementz et al. 1958). 
Vascular isolation and perfusion minimizes systemic exposure and thereby reduces 
unwanted side effects. In pre-clinical setting, ILP with adenoviral vectors was 
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shown to be effective in delivery of recombinant adenovirus carrying therapeutic 
gene constructs (de Roos, de Wilt et al. 2000). Furthermore, soft tissue sarcoma-
bearing rats treated with interleukin 3 beta gene therapy showed significant tumor 
growth delay (de Roos, de Wilt et al. 2000; de Wilt, Bout et al. 2001). Reports 
from Roos et al. and Milas et al. (Milas, Feig et al. 1997; de Roos, de Wilt et al. 
2000) have demonstrated that effective gene transfer to solid tumors using non-
replicative adenoviral vectors can be achieved by delivery by ILP, contrary to 
direct intratumoral injection which resulted in expression only around the needle 
tract.  
The pre clinical evaluation of new agents and the delivery methods used warrant 
validated OS xenograft models. The group of Kleinerman et al. have developed a 
lung metastasis model in which delivery methods and effectivety can be studied 
extensively (Jia, Worth et al. 1999). In addition the canine model developed by 
Hemminki et al. (Hemminki, Kanerva et al. 2003) will be a valuable model to 
study delivery in an immune competent context. 
 
CONCLUSION 
 
In conclusion this chapter has summarized the incidence, molecular alterations, 
pathogenesis, clinical management and prognosis in OS. Next novel therapeutics 
are described and discussed of which in greater detail, (adenoviral vector based) 
gene therapy in OS.  
In short the main challenge will be to develop novel gene therapy and oncolytic 
virology therapies for OS and to combine the expanding knowledge and 
techniques of basic molecular biology with modern evidence-based medical anti-
tumor treatments. The understanding of OS biology by array data may lead to 
customized information for each tumor. This will increase the potential of tumor 
specific treatment strategies. The development of valid animal tumor models will 
provide the much-needed means to study new treatment options in a pre-clinical 
phase. However, the important limitations regarding the in vitro and in vivo 
models discussed here should be well recognized. The unbalanced karotypes and 
chromosomal aberrations in OS are underexposed in cell culture and xenograft 
animal models. Therefore, translation of these results to the clinical situation 
should be done with reticence.  
Eventually the ultimate goal of gene therapy is to prolong and improve the 
survival of patients with OS. Ultimately the efforts in this field of cancer research 
will result in progression towards clinical application for OS. 
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OUTLINE THESIS 
 
It is the aim of this thesis to explore and investigate different adenoviral vector 
based gene therapy strategies in Osteosarcoma (OS). OS is one of the most 
common, non-hematological primary bone tumors. OS can occur at any age but 
most patients are between 12 and 25 years of age. A second peak occurs above 
the age of 50 years.  
The tumor arises typically in the metaphysical regions of long bones and most 
frequently metastasizes to the lungs. The definition of OS is deceptively 
straightforward. It is a malignant tumor of connective tissue (mesoderm) origin 
within which the tumor cells produce bone or osteoid.  
Patients with OS usually have no specific clinical symptoms, the most common 
symptom being pain during several weeks or months. The most general clinical 
sign is a firm and tender mass at the primary tumor site. Apart from the effects 
caused by the primary tumor the malignant nature of OS becomes obvious with 
the appearance of lung metastases.  
Over the past decades management of OS has dramatically changed. Amputation 
of the extremity was a standard treatment, with an overall survival of 5-20%. 
Current use of neo adjuvant and adjuvant chemotherapy has improved survival 
significantly. The overall survival with an aggressive chemotherapy regimen before 
and after surgery now varies between 50-70%. In addition, improvements in 
surgical techniques and the advances in biomedical engineering have led to a 
substantial progress in treatment. However, despite these improvements there are 
still patients who cannot benefit from current treatment modalities. Therefore, 
there is a need to develop novel therapeutic approaches. 
This thesis focuses on the investigation of adenoviral based gene therapy as a 
possible therapeutic option for OS. Gene therapy aims to deliver therapeutic 
genetic material (DNA) in a safe and efficient manner to cells, where expression of 
the foreign gene results in a biological effect. The ability of adenoviruses to 
generate high-titer stocks and the high-level heterologous gene expression has 
made the adenovirus a popular gene therapy vector. Adenoviral vectors are 
largely derived from adenovirus serotype 5 that causes mild upper respiratory 
infections. The adenovirus is a non-enveloped virus consisting of a single piece of 
linear double stranded DNA. Next to using adenoviruses as a vector they can also 
be used as a therapeutic agent as such. The concept of using adenoviruses 
(oncolytic adenoviruses) for the treatment of cancer originates form the 1950’s. 
This concept has regained widespread attention and has been translated from pre-
clinical testing to clinical testing in various tumor types. 
Both gene therapy approaches mentioned above may be valuable in the context of 
OS. Therefore both these adenoviral based gene therapy strategies are explored in 
the context of OS in vitro and in vivo xenograft models. Neither denying nor 
underestimating the clinical significance of lung metastasis in OS the work on 
which this thesis is based focuses at first on the primary tumor. Results from 
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these studies can possibly be translated into future research projects for OS lung 
metastasis. 
In chapter 1 OS; the histological and biologic features as well as current treatment 
modalities and perspectives have been described. Furthermore, gene therapeutic 
strategies applied for OS in vitro and in pre-clinical models are reviewed. Studies 
specifically using gene therapy for OS as well as a broad discussion of some 
aspects of gene therapy that may impact upon future developments are discussed. 
Specific attention is given to gene complementation, suicide gene therapy 
approaches and immunopotentiation In addition strategies to enhance tumor-
specific expression; increasing infection efficiency and viro-therapy are discussed 
in more detail. 
In chapter 3 the suicide gene expression system, carboxylesterase (CE)/CPT-11, 
as a concept and as an anti OS agent is explored. Suicide gene therapy (also 
called; gene-directed enzyme pro-drug therapy, molecular chemotherapy) relies 
on the capacity of the gene product of a transduced cell to convert a non-toxic 
pro-drug into a toxic compound. CPT-11 is a clinically approved pro-drug that 
needs to be metabolized into the active drug SN-38 by CE. This suicide gene 
expression system aims at high production of CE at the tumor site, resulting in 
efficient local conversion of CPT-11 in SN38. In this chapter the construction of a 
non-replicating adenoviral vector expressing the secreted form of CE is described. 
The utility of this vector in combination with CPT-11 for the treatment of OS cell 
lines and primary cultures (cells deriving directly from patient tumor material) are 
evaluated. Next this adenoviral vector expressing secreted CE in combination with 
CPT-11 is tested in a nude mouse model with human OS MG-63 subcutaneous 
tumors. In this chapter several aspects of a suicide expression system are 
addressed as well as intra tumoral delivery of an adenoviral vector in combination 
with a pro-drug. 
The broad tropism of adenoviral vectors can be a potential disadvantage, since in 
cancer gene therapy; more selective gene transfer in specific cell types is 
warranted. Therefore in order to establish an effective and safe gene therapy 
approach, tumor selectivity of the gene transfer or expression is a prerequisite. In 
addition retargeting allows for the administration of lower vector dose to achieve a 
similar therapeutic effect while minimizing the direct cytotoxicity effects of 
adenoviral vectors. Further more retargeting might prevent inadvertent adenoviral 
transduction into antigen-presenting cells and consequently diminish inflammatory 
responses to the vector. In addition the recognition that one of the main 
limitations of adenoviral-based gene therapy in OS is the relatively low expression 
of the adenovirus receptor CAR, has led to exploration of alternate and more 
effective pathways for adenoviral entry. This could not only improve infection 
efficiency but also result in the identification of specific cell membrane receptors in 
order to enhance tumor selective gene therapy for OS. As described in chapter 4, 
one such alternate pathway targets the Epidermal Growth Factor Receptor (EGFR). 
EGFR is known to be expressed in a large number of tumors and plays a role in OS 
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pathogenesis. In this study we examined and confirmed the presence of EGFR on 
primary tumor cells and OS cell lines. Next an alternate suicide gene therapy 
system was evaluated; the herpes simplex virus thymidine kinase (HSV-TK) in 
combination with ganciclovir. HSV-TK converts ganciclovir into its toxic metabolite. 
In this chapter the efficacy of the adenoviral vector containing HSV-TK targeted 
towards the EGFR is described. This was accomplished by using a bi-specific single 
chain antibody linking the adenovirus to this receptor and allowing CAR 
independent viral entry. The efficacy and feasibility of this bi-component system is 
explored in chapter 4. 
Based on these studies it became apparent that adenoviral-based gene therapy 
strategies for OS require CAR independent infection methods. Furthermore, it also 
became clear that adenoviral vector based gene therapy studies despite the fact 
that tumor cell kill could clearly be accomplished needed to be enhanced. The 
main difficulties encountered in solid tumor therapy with replication-incompetent 
viruses, has been the inability to efficiently disperse and infect the majority of 
tumor cells within the tumor mass. Replication and spread of a virus within a solid 
tumor could overcome the problem of inefficient cancer cell infection seen with 
non-replicating viruses. Specifically since in vivo studies did not reveal complete 
tumor regression. The development of conditionally replicating adenoviruses 
(CRAds) addressed these limitations, since CRAds selectively replicate in and 
destroy tumor cells. Cancer cells are turned into in situ factories producing 
thousands of copies of the therapeutic agent; the produced viruses will then kill 
the cancer cell and be released to attack neighboring cancer cells. Therefore in 
chapter 5 the oncolytic capacity of the CRAd Ad5-∆24RGD was tested on primary 
OS cells in vitro and in vivo. In addition to its oncolytic capacity, this virus utilizes 
integrins as a primary adenovirus attachment site. In this study we confirmed 
integrins present on primary OS tumor cells and OS cell lines. In this chapter the 
infection efficiency of Ads targeted towards integrins is evaluated. Furthermore the 
effectiveness of Ad5-∆24RGD in OS cells lines and primary OS cells was tested. 
Next Chapter 5 describes the efficacy of the CRAd Ad5-∆24RGD in vivo in a mouse 
model with a xenograft tumor deriving from a patient not susceptible to 
chemotherapeutic treatment. Finally treated tumors were analyzed on viral 
presence with electron microscopy.  
Towards clinical feasibility and improvement of administration routes, an other 
delivery method, next to intra tumoral injection, was evaluated. Despite the 
findings that intra tumoral injection in the context of head and neck tumors 
appeared to be effective this delivery method will not be feasible in clinical OS 
setting. In the context of OS delivery can basically be placed in the perspective of 
the primary tumor and/or the lung metastasis. Apart from lung specific delivery 
methods both require intra vascular delivery. In addition in perspective of the 
primary tumor localized on the extremity adjuvant local treatment can potentially 
improve local tumor control and enhance the safety of the surgical procedure, 
particularly limb salvage. Furthermore intra-arterial administration via in situ 
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isolated perfusion may increase gene therapy efficacy. Moreover in future 
combination therapies (gene therapy and chemotherapy) this might be a valuable 
approach. In addition isolated perfusion may enclose possibilities for future 
systemic administration of novel therapeutics. 
This led to the assessment of the isolated limb perfusion model for intra-arterial 
CRAd administration as described in chapter 6. To this end a xenograft MNNG-HOS 
rat model was established. Characteristics of this highly aggressive tumor model 
are described. Intra tumoral injections with Ad5-∆24RGD in this fast growing 
tumor model were tested. This did not inhibit tumor growth. We hypothesized that 
isolated perfusion could be more effective. To this end different isolated limb 
perfusion techniques were studied in this model i.e. ligating the femoral artery 
versus restoring the femoral artery. Next the efficacy of the CRAd Ad5-∆24RGD in 
the optimized ILP model was evaluated. In addition tumors were 
immunohistochemically analyzed for viral presence. 
Finally in chapter 7 the results of the studies described in chapters 3 to 6 are 
summarized, discussed and placed in perspective. 
 67

  
 
 
 
 
 
 
 
Chapter 3 
 
 
Gene-Directed Enzyme Prodrug Therapy for 
Osteosarcoma: Sensitization to CPT-11 in 
Vitro and in Vivo by Adenoviral Delivery of a 
Gene Encoding Secreted Carboxylesterase-2 
 
 
 
 
 
 
 
 
 
 
Dinja Oosterhoff*, M. Adhiambo Witlox*, Victor W. van Beusechem, Hidde J. 
Haisma, Gerard R. Schaap, Johannes Bras, Frank A. Kruyt, Bonnie Molenaar, Epie 
Boven, Paul I.J.M. Wuisman, Herbert M. Pinedo and Winald R. Gerritsen. 
*Both authors contributed equally to this manuscript 
Molecular Cancer Therapeutics 2003; 2: 765-771 
CHAPTER 3 
ABSTRACT 
 
Despite improvement in the treatment of osteosarcoma there are still many 
patients who cannot benefit from current treatment modalities. This warrants 
exploration of new treatment options. To that end, we investigated Gene-Directed 
Enzyme Prodrug Therapy (GDEPT) with the use of human liver carboxylesterase-2 
(CE2) and the anticancer agent CPT-11. CPT-11 is a clinically approved prodrug 
that needs to be metabolized into the active drug SN-38 by carboxylesterases, 
which occurs rather inefficiently in humans. GDEPT aims at high production of CE2 
at the tumor site resulting in efficient local conversion of CPT-11 into SN-38. We 
showed that osteosarcoma cells transduced with an adenoviral vector containing 
the cDNA encoding a secreted form of CE2 (Ad-sCE2) expressed and efficiently 
secreted CE2. In vitro, transduction of a panel of osteosarcoma cell lines with Ad-
sCE2 resulted in sensitization up to 2800-fold to CPT-11 treatment. Primary 
osteosarcoma short-term cultures, derived from patients suffering from a classic 
high-grade osteosarcoma, demonstrated increased CPT-11 sensitivity up to 70-
fold after transduction with Ad-sCE2 in vitro. When mice bearing subcutaneous 
MG-63 osteosarcoma xenografts were intratumorally injected with Ad-sCE2 and 
CPT-11, this resulted in a significant difference in time to reach 2000 mm3 in 
tumor volume as compared to animals receiving Ad-sCE2 or CPT-11 treatment 
(p<0.05).   
Together, these data suggest that osteosarcoma cells are sensitive for the 
combination of Ad-sCE2 and CPT-11. 
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INTRODUCTION 
 
Osteosarcoma (OS) is the most common primary bone tumor in children and 
young adults (Renard, Veth et al. 1999). Despite recent improvement in the 
treatment of OS there are still too many patients who cannot benefit from current 
treatment modalities (Lindner, Ramm et al. 1999). The overall survival of primary 
OS with combined treatment, consisting of neoadjuvant chemotherapy and 
surgery, now varies between 50-65% (Bacci, Briccoli et al. 2001). Attempts to 
treat OS with multiple new agents have not increased survival rates. Therefore, 
new treatment options have to be explored for this type of disease. 
Camptothecin derivatives have been explored in phase I-II trials including patients 
with OS refractory to standard treatment protocols. In these trials partial 
responses have been observed (Kushner, Kramer et al. 2000; Saylors, Stine et al. 
2001). Pratesi et al have shown complete tumor response and cures in 70% of 
animals bearing subcutaneous U2OS OS. The tumor variant selected for resistance 
against cisplatin was still responsive to camptothecin treatment (Pratesi, Cesare et 
al. 2002).  
CPT-11 is a semi-synthetic, water-soluble derivative of camptothecin that differs 
from other camptothecin analogues, in that it is a prodrug that undergoes de-
esterification to the much more potent topoisomerase I inhibitor, SN-38 (7-ethyl-
10 hydroxycamptothecin) (Satoh, Hosokawa et al. 1994). A class of enzymes that 
converts CPT-11 to SN-38 is the human carboxylesterases CEs. CE-activity can be 
detected in human liver, intestines and other sites (Satoh and Hosokawa 1998). 
Although patients do express CE, the amount of CPT-11 administered systemically 
that is converted to the active drug SN-38 is in the range of only 5 to 10% 
(Gupta, Mick et al. 1997). Furthermore, the usefulness of CPT-11 is hampered by 
dose-dependent toxicity, primarily diarrhea. A strategy to increase the antitumor 
effects of CPT-11, while decreasing the unwanted side-effects, is to express the 
cDNA encoding CE specifically at the site of the tumor. After systemic 
administration of CPT-11, this will lead to tumor-specific conversion and therefore 
tumor-specific toxicity. This approach is called Gene-Directed Enzyme Prodrug 
Therapy (GDEPT). 
Another GDEPT approach previously described for OS in experimental models uses 
the viral enzyme thymidine kinase in combination with the prodrug acyclovir. The 
efficacy of this approach was shown in vitro (Ko, Cheon et al. 1996), as well as in 
vivo (Cheon, Ko et al. 1997; Shirakawa, Ko et al. 1998). In the latter case, 80% 
of gene treapy-treated animals bearing s.c. OS xenografts survivied, whereas 
survival rates increased to 100% when gene therapy was combined with 
methotrexate. The advantage of using CE/CPT-11 GDEPT approaches is that 
human isoforms of CE can be used that should not result in an immunological 
response and subsequent enzume inactivation. Therefore repeated administration 
should be possible. 
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We have screened a panel of human malignant cell lines originating of different 
tissues to explore which cell lines could be sensitized to CPT-11 by addition of CE 
into the culture medium. All osteosarcoma cell lines tested became highly sensitive 
for CPT-11 in the presence of extracellular CE (unpublished results). To explore 
the effect of CPT-11 on osteosarcoma cells in a GDEPT approach, we constructed 
an adenoviral vector containing the cDNA encoding secreted human 
carboxylesterase isoform-2 (Ad-sCE2). A secreted form of CE2 might have the 
advantage that it will likely spread through a solid tumor mass, resulting in 
extracellular conversion of CPT-11. This may lead to antitumor effects to 
untransduced neighboring tumor cells, also designated as the ‘bystander effect’.  
In this study, we describe the construction and characterization of the Ad-sCE2 
adenoviral vector and its ability to sensitize osteosarcoma cell lines and primary 
osteosarcoma cells to CPT-11 in vitro. In addition, we report on the usefulness of 
Ad-sCE2 in human OS xenografts grown in nude mice and treated with CPT-11. 
 
 
MATERIALS AND METHODS 
 
Cells and Culture conditions 
 
 
 
MG-63 (courtesy of Dr. C. Löwik, Leiden University Medical Center, the 
Netherlands), MNNG-HOS, SaOs-2, (courtesy of Dr. F. van Valen, Westfalische 
Wilhelms-Universität, Münster, Germany), CAL-72 (courtesy of Dr. J. Gioanni, 
Laboratoire de Cancerologie, Faculté de Medicine, Nice, France) and HEK293 
(ATCC, Manassas, VA) cell lines were maintained in Dulbecco’s Modified Eagle 
Medium supplemented with 10% fetal calf serum (FCS), 50 IU/ml penicillin, 50 
mg/ml streptomycin and 2 mM L-glutamine (all from Gibco BRL, Life Technologies 
B.V., Breda, The Netherlands), at 37°C in a 5% CO2 humidified atmosphere.  
 
Patient material
Fresh tumor material was obtained from patients having a classic high grade OS 
and was brought into culture as described (Witlox, Van Beusechem et al. 2002). 
From patient 6, cells were cultured before (OS-6) and after (OS-6a) 
chemotherapy. From patient 1, only material after chemotherapy was cultured 
(OS-1a). All experiments were performed in cell cultures at passage 0-5.    
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Construction of Ad-sCE2 
 
The adenoviral vector Ad-sCE2 was constructed using the AdEasy method (17). 
The plasmid pSTCF-sCE2 containing the secreted CE2 (sCE2) open reading frame 
with a myc-6xHis tag at the C-terminal ending (Oosterhoff, Pinedo et al. 2002), 
was digested with PmeI and NheI and the sCE2 comprising fragment was cloned 
into XbaI and EcoRV digested pAdTrack-CMV. The resulting plasmid was digested 
with PmeI and recombined with adenoviral backbone plasmid pAdEasy-1 in E. coli 
BJ5183 cells to construct pAdEasy-sCE2. After linearization with PacI, the plasmid 
was transfected into the adenovirus packaging cell line HEK293 and virus was 
further propagated in HEK293 cells according to standard techniques. Purified 
virus stocks were prepared by two successive bandings on CsCl gradients. Viral 
particle (vp) titer  and plaque forming unit (pfu) titer was determined by OD260 
and limiting dilution, respectively. The pfu titer was 1.5*1012 and the vp/pfu ratio 
was 18.1. For all experiments the pfu titer was used and Ad-GFP was taken along 
as a negative control (Van Beusechem, van Rijswijk et al. 2000). 
 
Western blot  
 
Equivalent amounts of supernatant or cellular lysate from SaOs-2 cells infected 
with Ad-sCE2 or Ad-GFP (multiplicity of infection (MOI) 100) were dissolved in 
sample buffer 23 with 5% 2-mercapto-ethanol and boiled at 95°C for 5 min. 
Samples were subjected to electrophoresis through a denaturing 10% sodium 
dodecyl sulphate-polyacrylamide gel and protein bands were electroblotted onto 
PVDF protein membrane (BioRad, Veenendaal, The Netherlands). Proteins were 
detected using mouse anti-myc antibody and horseradish peroxidase-conjugated 
rabbit anti-mouse IgG (DakoCytomation, Heverlee, Belgium). Blots were 
developed with enhanced chemoluminescence (Lumilight Plus, Roche Diagnostics, 
Almere, The Netherlands). 
 
Esterase activity  
 
Cellular lysates or supernatants of SaOs-2 cells infected with Ad-sCE2 or Ad-GFP 
were incubated with 200 ml 100 mM TRIS-HCl pH=8.0 containing 1 mM p-
nitrophenyl-acetate (pNpAc) (Sigma Aldrich, Zwijndrecht, The Netherlands), a 
substrate for CE. Conversion to paranitrophenol was monitored over a 10-min 
period using an ELISA plate reader (BioRad, Veenendaal, The Netherlands) at a 
wavelength of 415 nm at room temperature. 
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In v tro proliferation assayi  
 
OS cell lines and primary OS cell cultures were plated in a 96-wells microtiter plate 
(Greiner Bio-One B.V., Alphen aan den Rijn, The Netherlands) at 5.103 cells per 
well in 100 ml. After 24 h, medium was removed and cells were infected with Ad-
sCE2 at an MOI of 1, 10 or 100 in 50 ml in culture medium with 2.5% FCS. After 1 
h, virus was removed and 200 ml culture medium with or without CPT-11 
(Aventis, Strasbourg, France) in a range of concentrations was added to separate 
wells in triplicate. Control experiments were performed in which the OS cells were 
infected with Ad-GFP and treated with CPT-11 or cells were only treated with CPT-
11 or SN-38 (Aventis). After an incubation period of 6 days, growth was 
determined by incubating the cells with the cell proliferation reagent WST-1 
(Roche Diagnostics) at 37°C. After 2 h the absorbency was measured at a 
wavelength of 450 nm using an ELISA plate reader. The antiproliferative effects of 
treated cells were expressed as percentages of growth from uninfected, untreated 
control cells. 
 
Crystal violet staining 
 
In a separate assay, cytotoxicity in OS cell lines and primary OS cell cultures was 
measured by crystal violet staining. Cells were treated as described for the 
antiproliferative assay. At the end of the experiment, medium was aspirated from 
cell cultures and adherent cells were fixed with 4% formaldehyde in PBS for a 10-
minute period at room temperature. After fixation, cells were washed and 
incubated for 15 minutes with 1% crystal violet dissolved in 70% ethanol. 
Hereafter, cells were washed with water, air-dried and scanned on a BioRad 
GS690  scanner. 
  
In vivo experiments 
 
The experimental protocols adhered to the rules outlined in the Dutch Animal 
Experimentation Act (1977) and the published ‘Guidelines on the protection of 
experimental animals’ by the council of the E.C. (1986). The protocol was 
approved by the committee on Animal Research of the Vrije Universiteit. 
Female athymic nu/nu mice, weighing 25-35 g, obtained from Harlan-CPB 
(Austerlitz, the Netherlands) were housed under pathogen-free conditions and 
were fed ad libitum. Tumor pieces (3x3x3 mm), derived from subcutaneously 
injected MG-63 cells in previous recipients, were implanted under the skin of one 
flank in anesthetized mice. Mice were weighed and tumor size was monitored 
twice a week using digital calipers. The tumor volume was calculated from the 
average of tumor length and width according to the formula: 4/3πr3. The volume 
doubling time of untreated MG-63 tumors was 1.6 days. 
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In order to determine the highest dosage of CPT-11 that had no effect on tumor 
growth, mice were divided in 4 groups of 3 animals each, when the tumor nodules 
reached 200-300 mm3. Mice in each group were intratumorally injected with 0.143 
or 1.43 or 14.3 mg CPT-11 in 25 ml PBS or PBS alone for 7 consecutive days. 
Tumors were measured for a period of 3 weeks. 
In the next experiment, mice were divided into three groups when the tumor 
nodules reached 200-300 mm3 (designated as day 0). Tumors were injected with 
1.109 plaque forming units (pfu) of Ad-sCE2 in 25 ml PBS followed by intratumoral 
injection with 1.43 mg CPT-11 in 25 ml PBS for 7 consecutive days (9 animals). 
Tumors of control mice received PBS on day 1 followed by injection with 1.43 mg 
CPT-11 for 7 consecutive days (6 mice) or 1.109 pfu of Ad-sCE2 on day 1 followed 
by injection with PBS for 7 days (6 mice). The mice were euthanized when the 
tumors reached a size of ≥2000 mm3. The different treatment modalities were 
evaluated by comparing tumor growth delay (time required to reach 5 times the 
initial tumor volume) and comparing the time for the tumors to reach a volume of 
≥2000 mm3, which was regarded as the endpoint of the Kaplan-Meier curves. 
Statistical analyses were performed using SPSS (SPSS inc., Chicago, USA). The 
ANOVA test was used to compare the growth delay between the different 
treatment groups. The Kaplan-Meier curves were calculated and differences in 
time for the tumors to reach ≥2000 mm3  between different treatment groups 
were analyzed using the log-rank test. 
 
RESULTS 
 
An proliferative effects of CPT-11 and SN-38  ti
 
To assess the sensitivity of OS cells to CPT-11 and SN-38, IC50 values (the 
concentrations of prodrug or drug that results in 50% growth inhibition) were 
determined. OS cell lines and short-term cultures, derived from tumors of patients 
with classic high grade OS, were subjected to a range of concentrations of CPT-11 
or SN-38 for 6 days. The IC50 values for CPT-11 and SN-38 and the ratios of 
these values are shown in Table 1. The OS cell lines tested were 625- to 1200-fold 
more sensitive to SN-38 than to CPT-11. In three primary OS cultures, this varied 
between 30- to 125-fold. For the other 3 short-term primary cultures tested the 
ratio was at least >33 times, but could not be determined exactly since the 
highest concentration of CPT-11 used was not toxic to these cells. These results 
indicate that efficient activation of CPT-11 to SN-38 would result in considerable 
antiproliferative effects in OS cells.   
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Table 1: Antiproliferative effects of CPT-11 and SN-38 and for CPT-11 after transduction 
with Ad-sCE2 or Ad-GFP in OS cells. 
* The ratio is expressed as IC50 value for CPT-11 divided by the IC50 value for SN-38.  
** The degree of sensitization (d.o.s.) is expressed as IC50 value for CPT-11divided by the 
IC50 value for CPT-11 after cellular transduction with Ad-sCE2. 
*** The transduction efficiency of the MNNG-HOS cell line was < 5%, which could explain 
the moderate d.o.s. 
 
Construction and characterization of Ad-sCE2 
 
A secreted form of human liver CE2 (sCE2) was obtained by deletion of the cellular 
retention signal HTEL and by cloning it downstream of an IgGk leader sequence. 
At the C-terminus a myc-6xHis tag was cloned for easy detection and purification. 
The expression of sCE2 was driven by the cytomegalovirus (CMV) promoter 
(Oosterhoff, Pinedo et al. 2002). The adenovirus vector Ad-sCE2, was constructed 
by inserting the sCE2 expression cassette adjacent to a Green Fluorescent Protein 
(GFP) expression cassette in place of the adenovirus E1 region (Figure 1). 
 
pA      GFP           CMV pA    mycHis          sCE2           L           CMV                                  Ad5 DNA 
∆E3v
Figure 1: Schematic presentation of the adenovirus Ad-sCE2 that was constructed by 
inserting the sCE2 expression cassette adjacent to a GFP expression cassette in place of the 
adenovirus E1 region. The sCE2 expression cassette includes the CMV promoter (CMV), an 
IgG kappa leader sequence for secretion (L), a C-terminal myc- and 6xHis-tag for detection 
and purification (mycHis) and an SV40 polyadenylation signal (PA).  
 
SaOs-2 cells were infected with either Ad-sCE2 or control virus Ad-GFP (MOI 100) 
and after 6 days supernatant and cellular lysates were analyzed for sCE2 
expression by Western blot. Figure 2A shows that almost all sCE2 was detected in 
the supernatant of infected cells. Functional activity of sCE2 at day 6 after 
transduction was demonstrated by an esterase activity assay (Figure 2B). Again, 
most of the CE activity was detected in the supernatant of SaOs-2 cells infected 
with Ad-sCE2, confirming the results of the Western blot.  
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To follow sCE2 secretion in the supernatant of Ad-sCE2 transduced cells in time, 
SaOs-2 supernatants were harvested at day 1 to 6 after transduction and a CE 
activity assay was performed (figure 2C). A gradual increase of CE activity in time 
after transduction was observed. 
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Figure 2: Characterization of Ad-sCE2 infected SaOs-2 cells by Western blot and by 
esterase activity assay. (A) Western blot of the cellular lysates and supernatants of SaOs-2 
cells infected with Ad-sCE2 at MOI 100. As a negative control, cells were infected with Ad-
GFP at MOI 100. sCE2 was detected using an antibody directed against the myc tag. In 
lanes 1 and 3 cellular lysates (c) and in lanes 2 and 4 supernatants (s) of SaOs-2 cells 
infected with Ad-GFP (lanes 1, 2) or Ad-sCE2 (lanes 3, 4) are shown. sCE2 migrated with 
an apparent molecular weight of 75 kDa and almost all protein was secreted. (B) CE activity 
in cellular lysates and supernatants of SaOs-2 cells untransduced or transduced with Ad-
sCE2 or Ad-GFP at MOI 100. Samples were incubated with 1 mM pNpAc and conversion was 
measured over a 10-minute period. Ad-GFP infected cells did not show enhanced CE-
activity in cellular lysates and culture medium compared to mock infected SaOs-2 cells, 
whereas Ad-sCE2 infected cells clearly expressed the CE enzyme, which was detected 
mainly in the supernatant. (C) CE activity in supernatants of SaOs-2 cells transduced with 
Ad-GFP (dotted line) or Ad-sCE2 (bold line) at MOI 100 at different time points post 
infection. In time, CE activity in supernatants of Ad-sCE2 transduced cells gradually 
increased. 
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An iproliferative ef ects of CPT-11 act va ion in Ad-sCE2 transduced OS cells t f i t
 
To show improved conversion of the prodrug CPT-11 to the toxic drug SN-38 by 
Ad-sCE2 encoded sCE2, OS cell lines or primary OS cells were transduced with Ad-
sCE2 or Ad-GFP as a control, followed by exposure to CPT-11. Six days after 
transduction, surviving cells were visualized by crystal violet staining. 
Antiproliferative effects were quantified with the WST-1 assay. Ad-sCE2 exhibited 
a dose dependent sensitization to CPT-11 (not shown). Figure 3 shows the results 
obtained for the OS cell line SaOs-2 transduced at MOI 100. Ad-sCE2 enhanced 
the sensitivity of SaOs-2 cells to CPT-11 approximately 2800-fold, resulting in 
toxic effects comparable to treatment with SN-38 alone. Table 1 summarizes the 
results of the proliferation assay on all OS cell lines and primary OS cell cultures 
transduced at MOI 100. All OS cells tested could be sensitized to CPT-11 following 
infection by Ad-sCE2, ranging from 10- to 2800 fold for OS cell lines, while 
primary OS cells were up to 2 orders more sensitive.  Interestingly, also primary 
cell cultures from patients resistant against cisplatin and doxorubicin treatment, 
i.e. OS-1a and OS-6a, were sensitized to CPT-11 by infection with Ad-sCE2. In 
general, in this experimental setting, where not all cells were transduced with Ad-
sCE2, CPT-11 prodrug conversion was incomplete, yielding 7-70% cytotoxicity 
compared to SN-38 treatment. 
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Figure 3: Cytotoxicity 
assay on SaOs-2 cells 
infected with AdsCE2 or 
Ad-GFP. Cell survival was 
determined with crystal 
violet staining (A) or WST-
1 proliferation assay (B). 
(A) The SaOs-2 cells were 
transduced with Ad-GFP or 
Ad-sCE2 at MOI 100 as 
indicated and treated for 6 
days with CPT-11 or SN-38 
at the indicated 
concentration. 
Subsequently, adherent 
cells were stained with 
crystal violet and 
photographed. (B) Ad-GFP 
transduced SaOs-2 cells 
( ) did not show further 
inhibition of growth when 
compared to CPT-11 
treated untransduced cells 
(∆). Transduction with Ad-
sCE2 in combination with 
CPT-11 () resulted in 
toxicity comparable to 
exposure to SN-38 (). 
Data are presented as 
mean of triplicates +/- SD 
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In vivo OS tumor growth inhibition 
 
To investigate if OS tumors could be sensitized to CPT-11 after transduction with 
Ad-sCE2 in vivo, nude mice bearing well-established subcutaneous MG-63 tumors 
of 200-300 mm3 were treated by intratumoral injection with 1.109 pfu Ad-sCE2 or 
PBS. Subsequently, tumors were injected on 7 consecutive days with 1.43 mg 
CPT-11, since this was the highest concentration of CPT-11 that did not by itself 
result in tumor growth inhibition as compared to PBS treatment (data not shown), 
or with PBS. CPT-11 was injected intratumorally since mice, in contrast to 
humans, have high esterase activity in their plasma 25. Tumor growth was 
monitored until a volume of ≥2000 mm3 was reached. Tumors treated with Ad-
sCE2 and PBS showed a tumor growth rate (time required to reach 5 times the 
initial tumor volume±SD) of 4.8±1.5 days. For tumors treated with PBS and CPT-
11 the tumor growth rate was 4.6±1.3 days. A significant increase in tumor 
growth delay was observed for the combination treatment with Ad-sCE2 plus CPT-
11 (7.1±1.7 days) as compared to Ad-sCE2 alone (p=0.021) and CPT-11 alone 
(p=0.011) (data not shown).   
Figure 4 shows in Kaplan-Meier curves the time of the tumors to reach a volume 
of ≥2000 mm3. At a volume of 2000 mm3 the animals had to be sacrificed 
according to animal welfare guidelines for these experiments. Curve comparison 
with log-rank analysis showed a significant delay in time to reach ≥2000 mm3 
tumor volume between GDEPT treated animals compared to Ad-sCE2 or CPT-11 
alone (p<0.05). 
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Figure 4: Kaplan-Meier curves showing the time for the tumors to reach a volume of ≥2000 
mm3. Curve comparison with log-rank analysis showed a significant difference in time to 
reach ≥2000 mm3 between GDEPT treated animals compared to Ad-sCE2 or CPT-11 alone 
(p<0.05). 
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DISCUSSION 
 
Despite improvement of the treatment of primary osteosarcoma (OS), the overall 
survival of patients varies between 50-65%. Therefore, new treatment modalities 
are warranted. In several studies using the enzyme-prodrug combination of 
herpes simplex virus thymidine kinase and ganciclovir an anti-tumor response was 
observed in OS models. Both local treatment and systemic treatment of lung 
metastasis resulted in long-term survivors (Ko, Cheon et al. 1996; Cheon, Ko et 
al. 1997; Shirakawa, Ko et al. 1998). In this study, we investigated the utility of 
an adenoviral vector containing the cDNA encoding a secreted form of human liver 
CE2, Ad-sCE2, to sensitize OS cells to the clinically approved prodrug CPT-11. OS 
cells transduced with Ad-sCE2 indeed secreted functional sCE2. Transduction of 
OS cells and primary cell cultures with Ad-sCE2 sensitized OS cells to CPT-11 in 
vitro.  
Several isoforms exist from the human enzyme CE. Kojima et al have described 
the construction of an adenovirus containing the cDNA encoding intracellular 
human liver CE isoform 1 (CE1)  (Kojima, Hackett et al. 1998). Only 3/11 cancer 
cell lines did show a marked (>5 fold) decrease in IC50 value after transduction 
and CPT-11 treatment. Humerickhouse et al. demonstrated that human CE2 has a 
higher affinity and a higher conversion velocity for CPT-11 than CE1 
(Humerickhouse, Lohrbach et al. 2000). Based on the latter studies, we decided to 
use CE2 for our studies. Recently, Wierdl et al. described the construction of an 
adenoviral vector containing the cDNA encoding a secreted form of rabbit liver 
carboxylesterase (Wierdl, Morton et al. 2000), which is probably the most efficient 
isoform of CE (Khanna, Morton et al. 2000). Since a non-human enzyme, such as 
rabbit CE, might elicit an immune response in humans and repeated 
administration of Ad-sCE2 is anticipated in clinical applications, we preferred to 
express a secreted form of a human CE in our study.  Therefore, it was decided to 
use a secreted form of human liver CE2 and as we show herein, the adenovirus 
expressing human sCE2 was highly effective in GDEPT with CPT-11 for OS in vitro. 
We put particular emphasis on including primary short-term cultures. These 
primary OS cells were directly brought into culture after the tumor(piece) was 
surgically removed. Experiments were performed between passage 1 and 5 of 
these cultures. Therefore, these cells can be considered as reliable primary tumor 
cells. Although Coxsackie Adenovirus Receptor (CAR), expression was very low on 
these primary cells (Witlox, Van Beusechem et al. 2002) they could still be 
sensitized to CPT-11 by transduction with Ad-sCE2 at a relatively high MOI.  
Sensitization was not complete, which could be partly attributed to differences in 
transduction efficiency. Interestingly, heavily pretreated primary OS cells (OS-1a 
and OS-6a), which were resistant to doxorubicin and cisplatin, could still be 
sensitized to CPT-11 by Ad-sCE2 infection.  
An in vivo experiment in which MG-63 tumors were infected with Ad-sCE2 and 
treated with CPT-11 showed a significant tumor growth delay and a significant 
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difference in the time to reach a tumor volume of ≥2000 mm3 compared to 
tumors treated with either CPT-11 or Ad-sCE2 alone. Although the results differed 
significantly between the experimental groups, the in vivo treatments did not 
result in cures. The modest effects in vivo could be explained by either low 
transduction efficiency or a relatively low concentration of the prodrug. 
The primary receptor for adenoviral entry CAR is expressed in low amounts on the 
cells surface of the cell line MG-63 (Witlox, Van Beusechem et al. 2002).  During 
the in vitro experiments only 25% of the MG-63 cells were transduced with Ad-
sCE2 as determined by GFP expression. It is hypothesized that the MOI used to 
transduce MG-63 tumors in vivo was lower (1.109 pfu of Ad-sCE2/ 200mm3 
tumor). So probably, only a very small percentage of tumor cells was indeed 
transduced by Ad-sCE2 and this might explain the poor therapeutic effect in vivo. 
To improve this, several possibilities can be explored. First of all, the efficacy of 
Ad-sCE2 and CPT-11 treatment in vivo can perhaps be improved by redirection of 
the adenoviral vector to tumor antigens. We previously demonstrated that 
targeting an adenoviral vector towards the Epidermal Growth Factor Receptor via 
a bispecific antibody improved gene transfer to OS cells in vitro (Witlox, Van 
Beusechem et al. 2002). Another improvement of this approach could be the 
combination of enzyme prodrug therapy with conditionally replicating 
adenoviruses (CRAds). CRAds have shown promising preliminary results in clinical 
trials, especially in combination with chemotherapy. Preliminary experiments in 
which OS cells were transduced with Ad-sCE2 and a CRAd and treated with CPT-
11 showed increased anti-cancer efficacy as compared to viral or enzyme prodrug 
therapy alone (unpublished results). Finally, we expect that a higher dose of CPT-
11 could further enhance the efficacy of this approach. Unlike humans, however, 
mice have high esterase activity in their plasma, which precludes proper xenograft 
studies with higher doses of CPT-11 (Morton, Wierdl et al 2000).  
In clinical applications of GDEPT for human cancer, the adenoviral vector should 
be injected into the tumor lesion, while CPT-11 is given by the intravenous route. 
In this respect, it is questionable whether the tumor concentration of CPT-11 will 
be sufficient for enhanced SN-38 mediated tumor cell damage. This might perhaps 
be investigated in esterase deficient mice (Morton, Wierdl et al 2000).  
High intra-tumor concentrations of CPT-11 in humans, may however also be 
reached in inoperable or recurrent OS injected with Ad-sCE2 after which CPT-11 is 
given by intra-arterial infusion, such as in isolated limb perfusion. 
Altogether, our data suggest that the combination of Ad-sCE2 and CPT-11 could 
be further improved and developed into a new treatment modality for OS.  
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CHAPTER 4 
ABSTRACT 
 
Despite improvements in the treatment of Osteosarcoma (OS) there are still too 
many patients who cannot benefit from current treatment modalities. Therefore, 
new therapeutic approaches are warranted. Here we explore the efficacy of 
targeted adenoviral based suicide gene therapy.  
Immunohistochemistry and FACS analysis detected low or absent expression 
levels of the primary adenovirus receptor CAR on human primary OS and human 
OS cell lines. These results predict a low infection efficiency and thus a reduced 
therapeutic effect. Targeting the adenoviruses to another receptor highly 
expressed on OS could overcome this limitation. We found Epidermal Growth 
Factor Receptor (EGFR) to be widely expressed on primary OS. 
Immunohistochemistry on primary tumor samples and FACS analysis on primary 
short term cultures and four OS cell lines showed that EGFR was consistently 
expressed. The recombinant bispecific single-chain antibody 425-s11 redirects  
adenoviral vectors towards the EGFR. Adenovirus transduction experiments in the 
presence or absence of 425-s11 showed significantly enhanced gene transfer with 
the targeted adenoviral vector compared to the native vector (OS cell lines 2.5 to 
7.2 times enhanced gene transfer and OS primary short term cultures 1.7 to 10 
times enhanced gene transfer). On this basis, targeted suicide gene therapy 
experiments with AdCMVHSV-TK in combination with ganciclovir were performed. 
These experiments demonstrated up to 3.5 fold enhanced kill of OS cell lines and 
primary short term cultures by the EGFR targeted vector.  
Suicide gene therapy with adenovirus targeted towards EGFR may have favourable 
therapeutic characteristics for future gene therapy applications in OS. 
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INTRODUCTION 
 
Osteosarcoma (OS) is the second most common primary malignancy of the bone 
in children and young adults. OS can occur at any age but more than 75% occurs 
in patients between 12 and 25 years of age. A second peak occurs above the age 
of 50 years. Management of OS has dramatically changed over the past two 
decades. Amputation of the extremity was a standard treatment, with an overall 
survival of 5%-20% at 2 years(Marcove, Mick et al. 1966). With current use of 
neoadjuvant chemotherapy, the 5-year survival rate for OS varies from 50-65% 
(Hudson, Jaffe et al. 1990; Link, Goorin et al. 1991; Picci 1992; Renard, Veth et 
al. 1999; Brosjo 1999; Lindner, Ramm et al. 1999; Sluga, Windhager et al. 1999). 
However, despite these recent improvements there are still too many patients who 
do not benefit from current treatment modalities. In addition, patients with 
metastatic OS have poor survival statistics (30% survival) (Marina, Pratt et al. 
1992; Meyers, Heller et al. 1993). Therefore, there is a need to develop novel 
therapeutic approaches. Gene therapy may offer new treatment options for this 
disease.  
Adenoviral vectors are widely applied to transfer genes into tumor cells, since they 
can be produced in high titers and can infect many different cell types.  
Adenoviral vector based suicide gene therapy (Herpes Simplex Virus Thymidine 
kinase (HSV-TK) in combination with ganciclovir) has been described as selective 
in blocking the growth of OS in experimental models. Furthermore, the 
combination of this therapy with metrotrexate showed to have better anti tumor 
effects with reduced toxicity compared to the conventional chemotherapy 
protocols alone (Ko, Cheon et al. 1996; Cheon, Ko et al. 1997; Shirakawa, Ko et 
al. 1998). 
Adenoviral vectors have also shown efficacy in eradicating OS lung metastases. 
Nasal delivery of a vector encoding interleukin-12 resulted in the inhibition of 
pulmonary metastases in a nude mouse xenograft model (Worth, Jia et al. 2000). 
The studies mentioned above suggest that adenoviral vector based gene therapy 
is feasible in OS. This has, however, not yet been confirmed on primary human OS 
tumor material.  
Adenoviruses of human serotype 5 bind to the Coxsackie/Adenovirus Receptor 
(CAR) (Bergelson, Cunningham et al. 1997). Following viral attachment, 
internalization is potentiated through cellular av integrins via the RGD motif of the 
penton base of the virus (Wickham, Mathias et al. 1993). Studies on other types 
of tumors have shown that application of adenoviral vectors for cancer gene 
therapy is hampered due to lack of CAR expression on primary tumor cells 
(Blackwell, Miller et al. 1999; Cripe, Dunphy et al. 2001; Grill, Van Beusechem et 
al. 2001). The lack of this receptor results in low infection efficiency, thus reducing 
the therapeutic efficacy of adenoviral vectors tremendously (Miller, Buchsbaum et 
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al. 1998). It is therefore important to provide adenoviral vectors with alternate 
and more effective pathways to enter into primary tumor cells. Retargeting of 
adenoviruses towards antigens present on tumor cells circumvents low CAR 
expression and increases the efficacy of gene transfer (Douglas, Rogers et al. 
1996; Goldman, Rogers et al. 1997). One such antigen is the human Epidermal 
Growth Factor Receptor (EGFR). EGFR is characteristically expressed on cells 
derived from all three germ layers and at particularly high levels on epithelia 
(Gullick, Marsden et al. 1986). We have developed a bispecific single-chain 
antibody (scFv) which targets adenoviral vectors towards tumor cells via the EGFR 
(Haisma, Grill et al. 2000). This bispecific scFv mediated efficient adenoviral 
transduction of tumor cell lines from various tissue origin (Haisma, Grill et al. 
2000) and of primary human glioma cells(Grill, Van Beusechem et al. 2001; 
Beusechem van V W 2002). 
In this study we investigated CAR and EGFR expression on primary human OS. 
Furthermore, we evaluated EGFR as a possible alternative target for adenoviral 
vector mediated gene transfer into OS. Finally, we carried out experiments to 
assess the efficacy of targeted adenoviral vector based suicide gene therapy for 
OS. 
 
MATERIALS AND METHODS 
 
Immunohistochemistry 
 
Paraffin-embedded and frozen tumor tissue samples from twelve patients with OS 
(pre-chemotherapy) were obtained from the Departments of Pathology of the 
University of Munster (Germany) an the VU University Medical Center 
(Amsterdam, The Netherlands). 
Tumor samples were sectioned at four-micron-thick and stained 
immunohistochemically for EGFR and CAR.  Mouse anti-CAR monoclonal antibody 
RmcB (Bergelson, Cunningham et al. 1997) was obtained from Dr. R. L. Crowell 
(Hahnemann University, Philadelphia, PA). Supernatant of the 425-hybridoma 
culture, purchased from the ATCC (American Type Culture Collection, Manassas, 
USA), was used as a source for MoAb anti-EGFR. In addition, an EGFR antibody of 
Novocastra Laboratories (Newcastle upon Tyne, United Kingdom) was used 
(Gullick, Marsden et al. 1986). 
Frozen or paraffin embedded sections were pre-incubated with normal rabbit 
serum 1:50 (DAKO, Glostrup, Denmark) followed by over night incubation with the 
primary antibody (425 non-diluted, EGFR-novocastra 1:20, RmcB 1:100) at room 
temperature (EGFR) or 4ºC (CAR). Slides were rinsed with phosphate buffered 
saline (PBS) and the biotinylated secondary antibody rabbit-anti-mouse IgG 
(DAKO) 1:500 was applied for thirty minutes. After rinsing, the slides were 
incubated with the avidin-biotin complex 1:200 ( Strep ABComplex, DAKO) for one 
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hour. As substrate, chromogen 3’-diaminobenzidine tetrahydrochloride (DAB 
chromogen, DAKO) was applied for five minutes. The slides were counter stained 
with hematoxilin, dehydrated and cover slipped with entalan (Merck Eurolab B.V. 
Amsterdam, The Netherlands).  
Tissue from normal skin was used as a positive control for EGFR staining, and 
normal brain tissue was used as a positive control for CAR staining. As a negative 
control, the primary antibody was replaced by PBS. Immunohistochemical results 
were evaluated by two independent observers and scored as follows: -, 0 positive 
cells; ±, £10% positive cells; +, 10-30% positive cells; ++, 30-60% positive cells; 
and +++, 60-100% positive cells. 
 
Cells and culture conditions  
 
 
 
 
 
The following human OS cell lines were used: MG-63 (Billiau, Edy et al. 1977)  
courtesy of Dr. Clemens-Lowik, Leiden University Medical Center; MNNG-HOS 
(Rhim, Putman et al. 1977); SaOs-2 (Fogh, Wright et al. 1977), courtesy of Dr. F. 
van Valen, Westfalische Wilhelms-Universitat Munster and CAL-72 (Rochet, 
Dubousset et al. 1999), courtesy of Dr. J. Gioanni, laboratoire de Cancerologie, 
Faculte de Medicine, Nice. 
All OS cell lines were maintained in DMEM supplemented with 10% FCS, 50 IU/ml 
penicillin, 50 mg/ml streptomycin and 2 mM L-glutamine (all from GibcoBRL, Life 
technologies B.V. Breda, The Netherlands), at 37°C in a 5% CO2 humidified 
atmosphere. 
Patient material
 
Tumor material (open biopsy procedure) was received directly after surgery and 
kept under sterile conditions at 4ºC. Biopsies were processed immediately. The 
biopsies were washed in sterile PBS, cut in small pieces and digested with Liver 
Digestion Medium (GibcoBRL, Life technologies) during 4 consecutive 30 minute 
incubations in a watherbath at 37ºC. After each round of digestion the cells were 
collected and washed. Finally, all cells were pooled and washed. Cells were directly 
used for adenoviral vector infection experiments and if possible for FACS analysis 
and brought into culture. OS tumor cell morphology of these short term cultures 
(passage 0-5) was confirmed by a histo-pathologist (author: J.B). 
Fluorescence Activated Cell Sorter (FACS) analysis 
 
Human OS cell lines and cells of primary short term cultures (OS-1 and LOS-5 
cells used directly after digestion and OS-1a, OS-2 and OS-6 cells used after 
passage 1-5) were incubated with anti-EGFR 425 MoAb non-diluted or anti-CAR 
MoAb RmcB 1:100 diluted in PBS containing 0.1% BSA for 1 hour on ice, followed 
by FITC conjugated rabbit anti mouse IgG antibody (DAKO, Glostrup, Denmark) 
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for 1 hour on ice. The samples were fixated in PBS/1% formaldehyde and 
analyzed on a FACscan (Becton Dickinson) using Cell Quest software within 24 
hours after fixation.  
 
Adenoviral vectors and bispecific single chain an ibodyt  
 
 
AdCMVluc (Herz and Gerard 1993), AdCMVHSV-TK (Rosenfeld, Feng et al. 1995) 
and AdCMVGFP are all E1/E3-deleted replication deficient Ad5 vectors which 
express firefly luciferase, HSV-TK and Green Fluorescent Protein, respectively, 
under the control of the immediate-early cytomegalovirus (CMV) promotor. The 
adenoviruses were propagated on the permissive line 293. All virus aliquots were 
stored at -80ºC until use. Adenovirus titers (pfu/ml) were determined by limiting 
dilution titration on 293 cells. All studies were performed with one batch of each 
adenoviral vector. 
Anti-EGFR targeting bispecific single chain antibody 425-s11 has been described 
before  (Haisma, Grill et al. 2000). It has dual specificity for the adenovirus fiber 
knob and human EGFR. Chinese Hamster Ovary (CHO) cells were stable 
transfected with this construct and cultured in an INTEGRA CL 350 cultivation 
system (INTEGRA Biosciences AG, Wallisellen, Switzerland) in CHO-S-SFM II 
medium (GibcoBRL, Life Technologies B.V.). Undiluted culture supernatant of the 
same batch was used for all targeting experiments. 
Targeting experiments 
 
OS cell lines were plated in a 24 wells plate (2.5 x104 cells/well), primary OS 
tumor cells were plated similarly or in a 96 wells plate (104 cells/well). To allow 
adherence, cells were incubated overnight in DMEM 10% FCS medium. Viral 
particles, AdCMVLuc or AdCMVGFP, (108) were diluted in 25ml DMEM 2.5% FCS 
and incubated with 75 ml 425-s11 supernatant or 75 ml  DMEM 2.5% FCS 
(control) for 30 minutes at room temperature. The optimal ratio of 425-s11 to 
AdCMVluc for targeted gene transfer into EGFR positive cells was previously 
determined by titration. Subsequently, virus was diluted in DMEM 2.5% FCS and 
cells were infected in triplicate at a Multiplicity Of Infection (MOI) of 25 pfu/cell for 
OS cell lines or MOIs ranging from 100 pfu/cell to 250 pfu/cell for primary OS 
tumor cells. One hour after infection the virus was removed from the cells and 
fresh DMEM 10% FCS medium was added. Twenty- four hours post infection cells 
were assayed for luciferase or GFP expression. Luciferase activity was measured 
using the Luciferase Assay System (Promega Madison WI). Medium was removed 
from the cells and the lysis buffer was added to the wells followed by a freeze 
thaw step. Luminescence was measured during 10 seconds immediately after 
initiation of the light reaction in a Luminat LB9507 luminometer (EG&G Gerthold, 
Bad Wildbad, GE). Values were protein normalized (Protein Assay, Bio-Rad 
laboratories, Veenendaal, the Netherlands). Results were expressed as relative 
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light units (RLU) per mg protein. GFP expression was measured as percentage 
positive cells by FACS analysis.  
 
 
 
Suicide gene therapy AdCMVHSV-TK experiments 
 
Cells (5 x103/well) were plated in a 96 wells plate and allowed to attach overnight. 
After 24 hours, cells were infected with AdCMVHSV-TK at an MOI of 100 pfu/cell in 
the presence or absence of 425-s11. Twenty-four hours post infection  a range of 
ganciclovir (Cymeveneâ, Roche, Mijdrecht, the Netherlands) concentrations (0-243 
mM) was added. Cell viability was determined by WST-1 Cell Proliferation Reagent 
(Roche Molecular Biochemicals, Manheim, Germany) conversion on day 7 after 
ganciclovir administration. We have observed inherent differences in sensitivity to 
chemotherapeutic reagents between OS cell lines and OS primaries, Therefore, the 
correct concentration of GCV in combination with AdSMVHSV-tk was established in 
pilot experiments; 9mM GCV for OS cell lines and 27mM GCV for primary OS. 
Statistical analysis was performed by using the student’s t-test.  
  
RESULTS 
 
CAR and EGFR expression on OS cell lines and primary OS  
 
CAR and EGFR expression was analyzed on primary OS tumor samples by 
immunohistochemistry (table 1). In all tested cases, CAR expression was found to 
be low (10%) or absent. CAR staining was localized on the membrane and/or in 
the cyptoplasm. EGFR expression was present in 10 of the 12 primary OS 
samples, varying from 30% to >90% of the cells being positive. Positive cells were 
scattered throughout the tumor. EGFR staining was most often localized on the 
membrane and in some cases there was some cytoplasmic staining as well. 
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Code Age M/F Diagnosis CAR* EGFR 
I 10 M High grade OS, lung metastasis ± + 
II 16 M High grade OS, lung metastasis - + 
III 18 M High grade OS - +++ 
IV 65 F High grade OS, chondroblastic component ± ++ 
V 23 M High grade OS, chondroblastic component - ++ 
VI 45 M High grade OS ± ++ 
VII 27 M Low grade OS, Juxtacortical OS - ++ 
VIII 10 F High grade OS, chondroblastic component ND** + 
IX 35 M High grade OS ND - 
X 9 M High grade OS,chondroblastair component ND - 
XI 19 M Small cell OS ND + 
XII 15 F High grade OS ND + 
 
Table 1: CAR and EGFR expression on primary OS tumor samples 
*Expression levels were scored as follows: - accounts for 0 cells positive, 
± ≤10% positive cells, + 10- 30% positive cells, ++ 30-60% positive 
cells and +++  60-100% positive cells. 
ND**Samples 8-12 were not eligible for CAR staining; no frozen  
samples were available 
 
Short term cultures were established from the tumor material of seven patients. 
Patient characteristics are described in table 3. From five patients, cell cultures 
were established from the primary tumor (OS). In two cases, cells were cultured 
from an OS lung metastasis (LOS). From patient no.1, cells were cultured from the 
primary tumor before (OS-1) and after (OS-1a) chemotherapy. FACS analysis on 
these short term cultures (passage 0-5) was done to asses CAR and EGFR 
expression. All samples were negative for CAR and positive for EGFR (figure 1A). 
The OS cell lines (MG-63, MNNG-HOS, CAL-72 and SaOs-2) were negative (MG-
63, CAL-72), low (MNNG-HOS) or moderately (SaOs-2) positive for CAR (figure 
1B). EGFR was present on all cell lines, ranging from highly (MG-63, MNNG-HOS) 
to moderately (CAL-72, SaOs-2) positive.  
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Os-1 Os-1a Os-2 
Los-5 Os-6 
 
MG-63   
 
 
 
 
 
 
 
 
 
 
CAL-72 SaOs-2 
 
Figure 1 FACS analysis for CAR and EGFR expression on primary OS cells and OS cell lines. 
Samples of primary OS cells (A) or samples of OS cell lines (B) were subjected to  
FACS analysis. CAR fluorescence is depicted as a black line, EGFR fluorescence is  
depicted as dashed gray line and negative controls are depicted as solid  
gray field. Data shown are representative fluorescence histograms of  
one experiment (A) and 3 independent experiments (B). 
1A 
1B 
MNNG-HOS
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Figure 2: Targeting AdCMVluc towards EGFR on OS cell lines  
OS cells were infected with AdCMVLuc at an MOI of 25 pfu/cell in the presence (black 
bars) or absence (white bars) of 425-s11. Data shown are mean luciferase activities 
(in relative light units per mg protein) + standard deviations. from a representative 
experiment done in triplicate. 
 
 
 
OS cell line Percentage GFP expressing cells Relative median GFP expression* 
 Control 
AdCMVGFP 
Targeted 
AdCMVGFP 
Control 
AdCMVGFP 
Targeted 
AdCMVGFP 
MG-63 0.5 19.3 1.0 1.5 
MNNG-HOS 5.5 31.2 1.1 2.7 
CAL-72 9.2 38.2 1.2 4.7 
SaOs-2 5.0 24.0 1.2 2.2  
 
Table 2: Targeting AdCMVGFP towards EGFR on OS cell lines*relative median fluorescence 
intensity of total transduced cell population over control un- transduced cells 
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Targeting adenoviral vectors towards EGFR on primary OS 
 
While cell lines provide a good model for mechanistic studies of gene transfer,  
they have only limited resemblance to primary tumors. Therefore, we repeated the 
infection experiments on primary tumor material. Eight independent short term 
cultures established from seven different patients were transduced in the presence 
or absence of 425-s11 with AdCMVLuc in a range of MOIs. Augmentation by 425-
s11 targeting of the adenoviral vector is shown in table 3. 
All samples showed improved gene transfer when the adenoviral vector was 
targeted (mean 4.3 fold, range 1.7 to 10 fold).  
 
 
Code Age M/F Diagnosis  Targeting ratio* 
OS-1 13 F High grade OS 10.0 
OS-1a   [post chemotherapy COSS 96 protocol] 6.3 
OS-2 23 F Juxtacortacal osteosarcoma 2.0 
OS-3 23 M Moderately differentiated OS 1.8 
OS-4 20 M Chrondoblastic differentiated OS 5.0 
LOS-5 9 M High grade OS, lung metastasis 3.1 
OS-6 7 F High grade OS 4.3 
LOS-7 15 F High grade OS, lung metastasis 1.7 
 
Table 3: Augmentation of AdCMVLuc mediated gene transfer by EGFR targeting on primary 
OS  cells 
*ratio of gene transfer efficiency with 425-s11 bispecific single-chain antibody over gene 
transfer efficiency without 425-s11 bispecific single-chain antibody 
  
Suicide Gene therapy with AdCMVHSV-TK 
 
To examine the therapeutic utility of EGFR targeted adenoviral vectors for OS we 
performed suicide gene therapy experiments with targeted AdCMVHSV-TK.  
Targeting this adenoviral vector towards the EGFR is expected to increase 
transduction efficiency and thereby increase OS cell kill after adding ganciclovir 
(GCV) compared to the non-targeted vector.   
In Figure 3A  results on the cell line MG-63 are depicted. Targeting of AdCMVHSV-
TK indeed resulted in a more efficient cell kill. The IC50 decreased from  23 mM 
GCV for untargeted AdCMVHSV-TK to 2 mM GCV  for EGFR targeted AdCMVHSV-
TK. A comparison of targeted and untargeted AdCMVHSV-TK with 9 mM GCV  on 
four OS cell lines showed that all but SaOs-2 were killed significantly more 
effective by the targeted vector (Figure 3B). More importantly, figure 3C shows 
that also primary OS tumor samples were killed significantly more effective by the 
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targeted AdCMVHSV-TK. These observations are in line with transduction 
efficiencies determined with AdCMVLuc. 
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Figure 3: Suicide Gene 
therapy with AdCMVHSV-TK 
on OS cell lines and primary 
OS. 
MG-63 cells (A), four OS 
cell lines (B) and five 
primary OS cultures (C) 
were transduced with 
AdCMVHSV-TK at an MOI of 
100 pfu/cell in the presence 
(diamonds and black bars) 
or absence (squares and 
white bars) of 425-s11. 
Twenty-four hours post 
infection a range of 
ganciclovir concentrations  
0-243 mM (A), or 9 mM 
GCV(B), or 27 mM GCV (C) 
was added. Cell viability 
was determined by WST-1 
conversion assay on day 7. 
Results are depicted as 
percentage viability of 
untreated control cells.  
Data shown are mean 
values + standard 
deviations of 2 independent 
experiments done in 
triplicate (A), or a 
representative experiment 
in triplicate (B and C).  
Represents a statistical 
difference with a p value < 
0.05. 
 
DISCUSSION 
 
The obstinate clinical course of OS despite aggressive standard therapy demands 
the investigation of new treatment approaches. In this regard, adenoviral vector 
mediated gene transfer of a suicide gene is a potential treatment modality for OS.  
Adenoviral transduction relies on the expression of the adenovirus receptor CAR 
and av integrins on the cell surface. However, CAR is the most important molecule 
in this regard  since low or deficient CAR expression has been shown to predict 
inefficient adenoviral vector mediated gene transfer (Wickham, Mathias et al. 
1993). In this study we have demonstrated that CAR expression is low or even 
absent on primary human OS and OS derived short term cultures. FACS 
experiments on cells directly after digestion of the primary tumor showed the 
 96
Targeted suicide gene therapy of Osteosarcoma 
same CAR expression levels as short term cultured cells (data not shown).These 
findings are in line with observations on other tumors, i.e., glioma (Grill, Van 
Beusechem et al. 2001), ovarian carcinoma (Blackwell, Miller et al. 1999) and 
rhabdomyosarcoma (Cripe, Dunphy et al. 2001). On established human OS cell 
lines, CAR expression was not always representative  for primary OS; MG-63 and 
CAL-72 were CAR negative, while MNNG-HOS and SaOs-2 expressed CAR. Thus, 
similar to findings in other tumor types, CAR expression is very low in primary OS 
and expressed to various levels in OS derived cell lines. Therefore, it may be 
expected that gene therapy for OS using adenoviral vectors with native tropism 
will have limited efficacy. Furthermore, relevant evaluation of adenoviral vector 
based gene therapy strategies requires the use of primary OS material. 
The primary goal of this study is to enhance infection efficiency of OS. In search 
for alternative target molecules on OS we investigated the expression of EGFR. 
The EGFR was shown to be expressed widely on OS cell lines and primary OS. This 
is in agreement with the findings by Oda et al (Oda, Wehrmann et al. 1995). The 
relative expression levels of CAR and EGFR, especially on primary OS, suggested 
that redirecting adenoviral vectors via EGFR would augment gene delivery into OS. 
Although EGFR is also expressed on some non malignant cell types, the 
tumor/normal tissue expression ratio is expected to favor tumor infection  
(Blackwell, Miller et al. 1999;Beusechem van V W 2002). Therefore, we evaluated 
the efficacy of EGFR targeted adenoviral vector mediated gene transfer into OS. 
To this end, we employed recombinant bispecific singlechain Abs consisting of an 
anti-adenovirus-fiber knob scFv and an anti-EGFR scFv. These molecules have 
already been used to target adenoviral vectors towards EGFR on cell lines and 
primary gliomas and meningiomen (Haisma, Grill et al. 2000; Grill, Van 
Beusechem et al. 2001; Beusechem van V W 2002). The Adv targeting via EGFR 
follows a pathway distinct from the native Adv uptake (Beusechem van V W 
2002). We provide evidence here that this targeting approach can also be used for 
OS gene therapy. 
The bispecific single-chain antibody significantly and reproducibly enhanced gene 
transfer into OS cells and primary tumor cell cultures. Moreover, EGFR targeting of 
an adenoviral vector expressing the HSV-TK suicide gene resulted in a significantly 
enhanced cell kill after GCV administration. Thus, EGFR targeting not only 
increased gene transfer efficiency but also enhanced therapeutic efficiency on OS 
in vitro. Obviously, these observations need to be confirmed in in vivo models. In 
conclusion, we have shown that redirecting the adeno viral vector entry into OS 
cells via a CAR independent pathway allows to overcome the inefficient gene 
delivery due to low CAR expression on primary OS. EGFR targeted Adv expression 
of HSV-TK may improve suicide  gene therapy for OS. 
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ABSTRACT 
 
The clinical course of osteosarcoma (OS) demands the development of new 
therapeutic options. Conditionally replicative adenoviruses (CRAds) represent 
promising agents for the treatment of solid tumors, since CRAds have intrinsic 
replication capacity that allows in situ amplification and extensive tumor infection 
through lateral spread. A critical step determining CRAd efficacy is the infection 
efficiency dependent on expression of the primary adenovirus receptor CAR on the 
target cell surface. Recently, we demonstrated that CAR expression is low or 
absent on OS. Therefore, we explored alternative target molecules for CRAds on 
OS cells. 
Here we show that the ανβ3 and ανβ5 integrins are expressed abundantly on 
primary OS cells and that insertion of a cyclic Arg-Gly-Asp (RGD-4C) integrin-
targeting motif into the adenovirus fiber knob augmented adenovirus infection of 
primary OS cells by two orders of magnitude. Based on these observations, the 
CRAd ∆with expanded tropism towards integrins  was tested in OS. Ad5-∆24RGD 
was shown to be highly active in killing human OS cell lines as well as primary cell 
cultures. In addition, intratumoral injections with Ad5-∆24RGD into established 
human OS xenografts, derived directly from a patient with OS refractory for 
chemotherapeutic treatment, caused a significant tumor growth delay. These 
findings encourage further exploration of Ad5-∆24RGD for use in OS treatment. 
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INTRODUCTION 
 
Osteosarcoma (OS) is one of the most common primary tumors of bone. It is 
highly malignant, and typically affects children and young adults (Renard, Veth et 
al. 1999). Despite improvements in the treatment of OS, there are still too many 
patients who cannot benefit from current treatment modalities (Link, Goorin et al. 
1991; Lindner, Ramm et al. 1999). The overall survival with an aggressive 
chemotherapy regimen before and after surgery now varies between 50-65% 
(Bacci, Briccoli et al. 2001; Bacci, Ferrari et al. 2001; Longhi, Fabbri et al. 2001). 
In addition, current chemotherapeutic agents have a broad spectrum of side 
effects (Sluga, Windhager et al. 1999). Therefore, new therapeutic options, such 
as gene therapy are warranted. In the field of adenoviral vector (Adv) based gene 
therapies for OS, several approaches have been explored, such as suicide gene 
therapy (Ko, Cheon et al. 1996), tumor suppressor gene therapy (Xu, Zhou et al. 
1996) and cytokine based gene therapy (Worth, Jia et al. 2000). Results of these 
studies have not yet been translated into clinical trials. Important limitations in 
this regard are the failure of non-replicating Adv to achieve sufficient tumor cell 
transduction and effective solid tumor penetration.  
The development of conditionally replicative adenoviruses (CRAds) has addressed 
these limitations. CRAds represent promising agents for the treatment of solid 
tumors, since CRAds have intrinsic replication capacity that allows in situ 
amplification and extensive tumor infection through lateral spread (Alemany, 
Balague et al. 2000). CRAds have been designed following two different strategies, 
i.e., by controlling expression of essential early adenovirus genes with tumor-
specific promoters (e.g., (Rodriguez, Schuur et al. 1997; Hallenbeck, Chang et al. 
1999)) and by deleting viral genes encoding proteins that are necessary to 
complete the viral lytic cycle in normal cells, but not in cancer cells (Bischoff, Kirn 
et al. 1996; Fueyo, Gomez-Manzano et al. 2000; Heise, Hermiston et al. 2000).  
A critical step determining CRAd efficacy is the infection efficiency dependent on 
expression of the primary adenovirus receptor, the coxsackie and adenovirus 
receptor (CAR) (Douglas, Kim et al. 2001). Low CAR expression on primary tumor 
cells has been described to limit the efficacy of adenovirus-based therapy for 
several types of cancers, including brain, bladder and pancreas cancer (Li, Pong et 
al. 1999; Cripe, Dunphy et al. 2001; Grill, Van Beusechem et al. 2001; Wesseling, 
Bosma et al. 2001). Recently, we demonstrated that also on OS Adv infection 
efficiency is compromised due to low or absent CAR expression (Witlox, Van 
Beusechem et al. 2002). Therefore, other, more effective routes of infection for 
OS should be explored. Previously, it has been shown that incorporation of a cyclic 
Arg-Gly-Asp (RGD-4C) sequence that interacts with αν integrins into the 
adenovirus fiber-knob circumvents low CAR expression by providing an alternative 
viral entry pathway (Dmitriev, Krasnykh et al. 1998). In addition, recent studies 
showed that a CRAd encoding retinoblastoma protein binding-deficient E1A 
proteins and the RGD-4C-fiber, Ad5-∆24RGD, exhibited oncolytic potency on CAR 
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deficient cancer cells (Cripe, Dunphy et al. 2001; Lamfers, Grill et al. 2002). 
Therefore, we hypothesized that Ad5-∆24RGD could also be effective in OS 
tumors. 
In this study, we first explored the expression of integrins on OS cell lines and 
primary OS cells. Next, we tested the effect of the RGD-4C insertion in the fiber 
knob of a non-replicative Adv on OS transduction. Finally, we assessed the efficacy 
of Ad5-∆24RGD on a broad panel of primary OS cell cultures in vitro and on 
primary OS subcutaneous xenografts in vivo. 
 
MATERIALS AND METHODS 
 
Cells and Culture conditions 
 
t  
 
MG-63 (Billiau, Edy et al. 1977) (courtesy of Dr. C. Löwik, Leiden University 
Medical Center, the Netherlands), MNNG-HOS (American Type Culture Collection, 
Manassas, VA) (Rhim, Putman et al. 1977), SaOs-2 (Fogh, Wright et al. 1977), 
(courtesy of Dr. F. van Valen, Westfalische Wilhelms-Universitat Münster, 
Germany) and CAL-72 (Rochet, Dubousset et al. 1999) (courtesy of Dr. J. Gioanni, 
laboratoire de Cancerologie, Faculte de Medicine, Nice, France) OS cell lines were 
maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% 
Fetal Calf Serum (FCS), 50IU/ml penicillin, 50mg/ml streptomycin and 2mM L-
glutamine (all from Life technologies B.V., Breda, the Netherlands), at 37°C in a 
5% CO2 humidified atmosphere.  
 
Patient material
 
Fresh tumor material from patients suspected of having a classic high grade OS 
was processed directly after open biopsy surgery and kept under sterile conditions 
at 4ºC. The biopsies were washed in sterile PBS, cut in small pieces and digested 
with Liver Digestion Medium (Life technologies B.V.) during 4 consecutive 30-
minute incubations in a water bath at 37ºC. After each round of digestion, the 
cells were collected and washed. Finally, all cells were pooled and washed. Cells 
were brought into culture and used for experiments at passage 0-5. Confirmation 
of OS tumor cell morphology of all short-term cultures was confirmed by 
histopathology. Patient characteristics were described previously (Witlox, Van 
Beusechem et al. 2002). 
 
Fluorescence Activa ed Cell Sorter (FACS) analysis for integrin expression
 
OS cells were incubated for 1 hour on ice with anti-integrin αvβ3 and αvβ5 mouse 
monoclonal antibodies (αvβ3 MAB 1962 and αvβ5 MAB 1976, CHEMICON 
International Inc., Temecula, CA), 1:100 diluted in PBS containing 0.1% BSA, 
followed by FITC-conjugated rabbit-anti-mouse IgG antibody 1:100 (DAKO, 
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Glostrüp, Denmark) for one hour on ice. The samples were fixed in PBS/1% 
formaldehyde and analyzed for integrin expression on a FACscan (Becton 
Dickinson) using Cell Quest software within 24 hours after fixation. Integrin 
expression was considered positive when the relative median fluorescence 
intensity of integrin stained cells over control cells was above 2.  
 
Recombinant adenoviruses 
 
A recombinant E1-deleted Adv expressing the luciferase reporter gene under the 
control of the CMV promoter, AdCMVLuc, was provided by Dr R.D. Gerard 
(University of Texas Southwestern Medical Center, Dallas, TX). A similar Adv, 
containing an integrin targeting RGD-4C peptide within the fiber HI-loop, 
AdLucRGD, was described previously (Dmitriev, Krasnykh et al. 1998). The CRAd 
Ad∆24 (van Beusechem, van den Doel et al. 2002) was made by homologous 
recombination in E1-complementing 293 cells between the pXC1 (Microbix 
Biosystems, Toronto, Canada) derivative pXC1-∆24, carrying a 24 bp deletion in 
the pRb-binding CR2 domain in E1A (Fueyo, Gomez-Manzano et al. 2000), and 
pBHG11 (Microbix Biosystems). Ad5-∆24RGD (Suzuki, Fueyo et al. 2001) carries 
the same ∆24 mutation, plus the RGD-4C fiber modification and adenovirus E3 
region from pVK503 (Dmitriev, Krasnykh et al. 1998). Replication deficient Adv 
were propagated on 293 cells; conditionally replicative adenoviruses were 
propagated on A549 cells (ATCC). Viruses were purified using cesium chloride 
gradient banding and titrated in parallel by end-point limiting dilution on 293 cells 
to determine plaque-forming units.  
 
Adenovirus in ection experiments f
 
OS cell lines were plated in a 24 wells plate at 2.5 x104 cells/well. Primary OS cells 
were plated similarly or in a 96 wells plate at 5x103 or 104 cells/well, depending on 
the amount of primary OS cells available. To allow adherence, cells were incubated 
overnight in DMEM/10% FCS medium. Adenoviruses were diluted in DMEM/2.5% 
FCS and cells were infected in triplicate at the indicated multiplicity of infection 
(MOI). One hour after infection, the adenovirus-containing medium was removed 
and fresh DMEM/10% FCS medium was added. Cells were cultured at 37°C until 
analysis of gene transfer by luciferase activity measurement or of cell viability by 
WST-1 conversion assay (see below). 
 
Luciferase activity measurement 
 
Twenty-four hours post infection, cells were assayed for Luciferase expression 
using the Luciferase chemiluminescent Assay System (Promega, Madison, WI). 
Medium was removed from the cells and luciferase reporter lysis buffer was added 
to the wells followed by a freeze thaw step. Luminescence was measured during 
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10 seconds immediately after initiation of the light reaction in a Luminat LB 9507 
luminometer (EG&G Berthold, Bad Wildbad, Germany). Values were protein 
normalized (Bio-Rad Protein Assay, Bio-Rad laboratories, Veenendaal, the 
Netherlands). Results were expressed as Relative Light Units (RLU) per µg protein. 
 
Colorimetric WST-1 Cell Viability Assay 
 
Cell viability was quantified using the colorimetric WST-1 conversion assay, based 
on the cleavage of the tetrazolium salt WST-1 by mitochondrial dehydrogenases in 
viable cells (Roche Diagnostics, Manheim, Germany), seven or eleven days after 
infection. The culture medium was removed and replaced by 100 µl 10% WST-1 in 
culture medium. Culturing was continued until the formation of formazan dye was 
optimal. The A450 was measured on a Bio-Rad (Hercules, CA) model 550 
microplate reader. WST-1 conversion was expressed as percentage of the 
conversion by uninfected control cells. 
 
In vivo experiment 
 
Female athymic nu/nu mice, weighing 25-35 g, obtained from Harlan-CPB 
(Austerlitz, the Netherlands) were used. Animals were kept under pathogen-free 
conditions and fed a standard laboratory diet (Hope Farms, Woerden, the 
Netherlands) ad libitum. The experimental protocols adhered to the rules outlined 
in the Dutch Animal Experimentation Act (1977) and the published ‘Guidelines on 
the protection of experimental animals’ by the council of the E.C. (1986).  OS-1a 
(Witlox, van Beusechem, et al. 2002) tumor pieces (3x3x3 mm), derived directly 
from a patient with OS and propagated subcutaneous in nude mice, were 
xenografted under the skin of nude mice. OS-1a xenografts maintained gross 
histological resemblance to the primary human tumor. In the patient, this tumor 
had been treated according to the COSS96 protocol and did not show any 
response to treatment. When the nodules reached 150-300 mm3, mice were 
injected intra-tumorally on 5 consecutive days with 20µl control medium (n=7) or 
1x107pfu Ad5-∆24RGD (n=6). The tumor was injected from a different angle 
every day. Tumor size was monitored twice a week, using digital calipers. Volume 
was calculated from the average of tumor length and width according to the 
formula: 4/3πr3. The mice were sacrificed when the tumors reached a size of more 
than 1000 mm3. The two-tailed, unequal variance Student’s t-test from SPSS 
(SPSS Inc., Chicago, IL) was used to compare tumor growth rate (TGR; time 
required to reach 5 times the initial tumor volume) between the different 
treatment groups.  
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Microscopic examinations 
 
When the tumor reached a volume of >1000 mm3, mice were sacrificed and 
tumors were dissected. Slides of 4% formalin-fixed and paraffin-embedded tumor 
were routinely stained with hematoxilin-eosin (HE) and immunohistochemically for 
adenovirus hexon with 1:1600-diluted goat anti-adenovirus AB1056 (CHEMICON 
International Inc.), followed by anti-goat-biotine-streptavidine horseradish 
peroxidase (K377, DAKO). An antigen retrieval step with 10mM Tris/1mM EDTA 
was included. Positive anti-adenovirus stained areas were dissected from paraffin 
blocks. The dissected samples were worked up for electron microscopy by a one-
step dehydration-postfixation technique (toluene- OsO4), followed by embedding 
in epoxy resin (van den Bergh Weerman and Dingemans 1984). Samples were 
examined for adenovirus particles by electron microscopy at 24,000 x and 
108,000 x magnification.  
 
RESULTS 
 
Targeting towards αv in egrins enhances in ection of OS cells t f
 
Previously, we examined CAR expression on OS cell lines and primary OS cell 
cultures (Witlox, Van Beusechem et al. 2002). All OS cell lines, except SaOs-2, 
and all primary cells showed low or even absent CAR expression. In search for 
alternative target molecules on OS that would allow more efficient CRAd infection 
we examined αvβ3 and αvβ5 integrin expression by FACS analysis (Table 1). All OS 
cell lines and primary OS cell cultures expressed at least one of these integrins.  
To study the utility of integrins as targets for adenovirus infection of OS, we 
compared the gene transfer efficiency of an adenovirus vector with native tropism 
(AdCMVLuc) to that of a derivative vector with RGD-4C fibers (AdLucRGD). Figure 
1 shows that targeting towards integrins strongly enhanced gene transfer 
efficiency on OS cell lines and primary OS cell cultures. Especially the on average 
two orders of magnitude augmented transduction of primary cells by AdLucRGD 
held promise for the utility of integrin-targeted CRAds for the treatment of OS. 
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                         Relative median  
                             expression* 
 
OS cells αvβ3 αvβ5 
MG-63 3.1 11.6 
MNNG-HOS 2.4 12.6 
CAL-72 2.3 10.5 
SaOs-2 2.9 7.6 
OS-1  5.2 2 
OS-1a 5.2 2 
OS-2 5.8 9.2 
LOS-5 2.6 2.3 
OS-6 6.2 5.4 
OS-6a 2 5 
Table 1: Fluorescence Activated Cell Sorter (FACS) analysis of integrin expression on OS 
cell lines and primary OS cells 
* Relative median fluorescence intensity of integrin stained cells over control (non-stained) 
cells. Values above 2 were considered positive. 
 
 
Figure 1: Targeting an adenovirus vector towards integrins on OS cell lines and 
primary OS cells. 
OS cell lines MG-63, MNNG-HOS, CAL 72, and SaOs-2 and five different primary OS 
cell cultures were transduced with AdCMVLuc (white bars) or AdLucRGD (black bars) 
at an MOI of 100 pfu/cell. Luciferase expression was measured after 24 hours. Data 
shown are mean values + standard deviation from a representative experiment done 
in triplicate. 
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Oncolytic effect of Ad∆24 and Ad5-∆24RGD in vitro 
 
To evaluate the efficacy of the CRAd Ad∆24 on OS cells, we infected four OS cell 
lines at high MOI (Figure 2A). Ad∆24 effectively killed all OS cell lines, suggesting 
that a CRAd with the ∆24-mutation could be effective for treatment of OS. 
However, when we infected the same panel of OS cell lines or OS primary cell 
cultures with Ad∆24 at low MOI only CAR positive SaOs-2 cells were killed (Figure 
2B). In contrast, integrin-targeted Ad5-∆24RGD was highly active in killing all OS 
cell lines and primary cell cultures at low MOI (figure 2B). Thus, only Ad5-∆24RGD 
was capable of effectively killing CAR-deficient primary OS  cells.  
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Figure 2: 
The oncolytic effect of Ad∆24 and Ad5-∆24RGD on OS cell lines and primary OS 
cells . 
OS cell lines and a panel of primary OS cell cultures were mock infected (white 
bars), or infected with Ad∆24 (black bars) or Ad5-∆24RGD (hatched bars) at an MOI 
of 100 pfu/cell (A) or at an MOI of 1 pfu/cell for OS cell lines or 0.1 pfu/cell for 
primary OS cells (B). Cell viability was determined by WST-1 conversion assay on 
day 7 (A) or 11 (B) post infection. Results are depicted as percentage viability 
compared to mock infected cells. Data shown are mean values + standard deviation 
from a representative experiment done in triplicate. 
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Inhibition of OS tumor growth by Ad5-∆24RGD treatment in vivo  
 
Finally, we investigated if Ad5-∆24RGD was also effective against CAR-deficient 
primary human OS tumors in vivo. Nude mice carrying established OS-1a 
xenografts derived from a chemotherapy-resistant primary tumor were treated by 
intra-tumor injections with a total virus dose of 5x107pfu Ad5-∆24RGD. Figure 3 
shows the growth curves of tumors injected with virus or control medium. The 
median TGR was calculated for both treatment groups. Control tumors had a 
median TGR of 14±4 days, whereas tumors injected with Ad5-∆24RGD exhibited a 
significant growth delay (median TGR of 25±4 days; p<0.05).  
 
 
Figure 3: Ad5-∆24RGD efficacy in vivo. 
OS-1a xenografts (150-300 mm3) were injected with PBS (n=7) or 1x107 pfu Ad5-∆24RGD 
(n=6) for 5 consecutive days. The figure shows individual growth curves for each tumor. Mice 
were sacrificed when tumor sizes exceeded 1000 mm3. Arrows indicate days of PBS or Ad5-
∆24RGD injection. 
 
Histological analysis of tumors exceeding 1000 mm3 showed classical OS features 
with osteoid calcified areas. In tumors retrieved from Ad5-∆24RGD-treated 
animals classical OS features could still be observed, together with post-
therapeutic changes of necrosis within viable tumor fields surrounded by fibrosis 
(Figure 4 A). Anti-adenovirus staining revealed viral replication throughout treated 
tumors, mainly in tumor cells at the border of areas with necrosis (Figure 4B). 
Hexon staining was absent in non-treated tumors (data not shown). Areas with 
positive anti-adenovirus staining were sampled for electron microscopy, which  
showed 65 nm dense rounded adenovirus particle inclusions in tumor cells (Figure 
4C,D). Electron microscopy of non-treated tumors did not show such inclusions 
(data not shown). Altogether, these findings show presence and replication of 
Ad5-∆24RGD in treated tumors up to 25 days post-injection. 
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Figure 4:Detection of adenovirus replication in  OS-1a tumor xenografts. 
At a tumor size of >1000 mm3, mice were sacrificed and tumors were dissected. Tumor 
sections of an Ad5-∆24RGD treated tumor were stained with HE (A) and with an anti-
adenovirus hexon antibody (B). Viable tumor fields are surrounded by fibrosis (fb). Large 
areas of necrosis (nc) are surrounded by hexon stained cells (arrows) indicative of 
adenovirus replication. Areas stained positive for hexon were sampled for electron 
microscopy (C,D). Adenovirus particle inclusions are indicated by arrows. Original 
magnifications: 20x (A,B), 24,000x (C) and 108,000x (D). 
 
DISCUSSION 
 
The clinical course of OS demands the development of new therapeutic options. 
CRAds represent promising agents for the treatment of solid tumors. However, 
their efficacy in OS tumors may be hampered by inefficient cell entry because of 
lack of CAR expression (Witlox, Van Beusechem et al. 2002). We thus 
hypothesized that the efficacy of CRAds against OS could be improved by 
expanding their tropism towards αν integrins. This was supported by our findings 
described herein that av integrins are expressed on primary OS cells and that a 
replication-deficient Ad vector, which was genetically modified to expose the RGD-
4C peptide in the fiber knob, exhibited dramatically enhanced gene transfer into 
OS cell lines and, more importantly, into primary OS cells.  
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We chose to investigate the effect of CRAd integrin-targeting using Ad∆24 as 
backbone.  Ad∆24 encodes E1A proteins with a deletion of eight amino acids in the 
pRb-binding CR2 domain that disables their capacity to release E2F from 
preexisting pRb/E2F complexes, thereby conferring selective replication in cells 
with already dysfunctional pRb control (Hallenbeck, Chang, et al. 1999). It has 
already been shown that infection with Ad∆24-type CRAds effectively kills cancer 
cells in vitro and inhibits tumor growth in vivo, while replication is reduced in non-
proliferating normal cells and in cancer cells with restored pRb function 
(Hallenbeck, Chang, et al. 1999; Bischoff, Kirn, et al. 1996). Since genetic 
alterations in the Rb pathway are frequent in OS (Feugeas, Guriec et al. 1996), 
(Benassi, Molendini et al. 1999), Ad∆24-type CRAds appear useful agents for 
treatment of this disease. Notably, however, the concept of integrin-targeting is 
relevant for any kind of CRAd, irrespective of the genome modification conferring 
selective replication. 
Enhancing the infection efficiency of Ad∆24 by integrin targeting translated into 
increased oncolytic effects. On a broad panel of primary OS cells infected at low 
MOI, Ad5-∆24RGD showed complete oncolysis whereas Ad∆24 induced no 
detectable cell kill at all. Since Ad∆24, in contrast to Ad5-∆24RGD, lacks the 
adenovirus E3 region, differences in oncolytic effect may not only be explained by 
the expanded tropism of Ad5-∆24RGD. However, Ad∆24 did effectively kill the 
CAR positive OS cell line SaOs-2 at low MOI, suggesting that the infectivity 
enhancement of Ad5-∆24RGD attributed to its efficacy on CAR negative OS cells.  
Primary cells derived directly from patient tumor samples represent an in vitro 
model closer to the patient compared to cell lines. Therefore, the observation that 
Ad5-∆24RGD showed complete oncolysis of primary OS cells at an MOI of only 0.1 
pfu/cell, while Ad∆24 required 100 pfu/cell for this effect is of significant 
importance. The in vitro efficacy of Ad5-∆24RGD was confirmed in a relevant in 
vivo OS tumor model.  Ad5-∆24RGD caused a significant tumor growth delay of 
human primary, chemotherapy-resistant, CAR-deficient OS xenografts in nude 
mice. Histological analysis showed that Ad5-∆24RGD replicated in OS tumor cells 
for at least 25 days. However, the CRAd did not completely eradicate the 
subcutaneous xenografts. This can best be explained by inefficient dispersion of 
the CRAd through the tumor mass following intra-tumoral injection. Barriers within 
the established tumor, such as connective tissue and tumor matrix, may limit the 
spread of virus (Kuppen, van der Eb et al. 2001). In OS, osteoid calcification could 
be such a hurdle for viral therapy that needs to be overcome.  
Altogether, our data demonstrate that targeting a CRAd towards integrins 
enhances its cytotoxicity on OS dramatically and warrants further exploration of 
Ad5-∆24RGD for its utility in OS treatment. The main challenge in the treatment of 
OS, however, is the eradication of metastases. Patients with OS do not die from 
the primary tumor; they die from metastatic disease, typically in the lungs. 
Notably, we have found that αvβ3 and αvβ5 integrins are expressed on OS lung 
metastases (data not shown). Clearly, intra-tumoral injection as evaluated in this 
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study is not a feasible option for treatment of lung metastases. However, systemic 
delivery is now being explored with several virotherapy agents in clinical trials 
(Reid, Warren et al. 2002), and could thus perhaps be considered to treat OS with 
Ad5-∆24RGD. 
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CHAPTER 6 
ABSTRACT 
 
Osteosarcoma (OS) is a primary bone malignancy generally affecting young 
people. The clinical course of OS demands the development of new therapeutic 
options. Conditionally Replicative Adenoviruses (CRAds) represent promising 
agents for the treatment of solid tumors. Their intrinsic replication capacity allows 
in situ amplification and extensive tumor infection through lateral spread. 
Previously we have shown that the CRAd Ad5-∆24RGD has anti-tumor efficacy 
against primary OS cells in vitro and in vivo (Witlox, Van Beusechem et al. 2004). 
Here, we investigated the effectivety of local or loco regional treatment of MNNG-
HOS tumors growing on the hind limb of rats. These tumors were highly 
aggressive and showed typical characteristics of OS. Intra tumoral injections of 
Ad5-∆24RGD did not inhibit tumor growth in this tumor model. We hypothesized 
that isolated perfusion of the tumors growing on the extremities could be more 
effective. Therefore, we evaluated the efficacy of Ad5-∆24RGD using this 
intravascular delivery route. Because MNNG-HOS was very sensitive to ischemia, 
we used an isolated limb perfusion procedure in which the femoral artery is 
restored in order to reinstate the normal blood supply to the tumor after the 
perfusion. Ad5-∆24RGD administrated via in situ isolated perfusion, significantly 
inhibited tumor growth. Moreover, viral presence could be detected in the 
analyzed tumors by anti-hexon immunohistochemistry particularly around tumor 
vasculature. Thus, in this study we demonstrated that isolated limb perfusion of 
OS xenografts with Ad5-∆24RGD is effective in tumor growth inhibition and may 
be promising for further exploration. 
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INTRODUCTION 
 
Osteosarcoma (OS) is the most common primary bone tumor at an estimated 
incidence of 2 cases per million persons per year. Currently, patients are treated 
with an aggressive neo adjuvant chemotherapy regimen. Improvement of 
chemotherapeutic drug regimens and surgical techniques resulted in an overall 
event-free survival rate of approximately 50-70 % (Lindner, Ramm et al. 1999; 
Renard, Veth et al. 1999; Longhi, Fabbri et al. 2001). Recent trials indicate that 5-
year survival rate has reached a plateau, with little or no improvement by 
conventional treatment modalities (Link, Goorin et al. 1986; Bacci, Briccoli et al. 
2001; Bielack, Kempf-Bielack et al. 2002). Moreover, patients with local 
recurrence after chemotherapy or overt metastatic disease have a much poorer 
outcome. New treatment modalities for OS are therefore warranted, such as viro-
therapy by Conditionally replicative adenoviruses (CRAds). In this regard 
alternative administration routes need to be explored, such as isolated perfusion 
(IP). Adjuvant local treatment can potentially improve local tumor control and 
enhance the safety of the surgical procedure, particularly limb salvage. In 
addition, IP may enclose possibilities for future systemic administration of novel 
therapeutics. 
CRAds represent a potential new treatment modality for solid tumors including 
Osteosarcoma (Alemany, Balague et al. 2000; Hemminki, Kanerva et al. 2003). 
CRAds are developed to selectively replicate in tumor cells thereby causing specific 
tumor cell lyses. Released virus from lysed cells can subsequently infect 
neighboring tumor cells, which results in lateral propagation of CRAds. Recently, 
we demonstrated that the CRAd Ad5-∆24RGD (Suzuki, Fueyo et al. 2001) shows 
anti-tumor efficacy against primary OS cells in vitro and in vivo (Witlox, Van 
Beusechem et al. 2004). This adenovirus contains a 24 bp deletion, which renders 
it replication selective for cells with mutations in the Rb pathway, i.e. most tumor 
cells (Fueyo, Gomez-Manzano et al. 2000). In addition, the insertion of an RGD 
peptide sequence in the fiber-knob redirects viral entry to alpha v beta 3 integrins, 
which are highly expressed on most tumor cells, including OS (Witlox, Van 
Beusechem et al. 2004) and on endothelial cells of tumor neo-vasculature.  
Amongst delivery methods currently used in pre-clinical models, exploring CRAd 
effectivity are intratumoral injection, intravenous administration and intra-
peritoneal delivery. Loco regional administration of a CRAd by means of in situ 
isolated perfusion (IP) of a target organ or extremity is a method that in the 
context of solid tumors including OS may be interesting. Isolated limb Perfusion 
(ILP) with a chemotherapeutic agent was first described by Creech et al. in 1958 
(Creech, Krementz et al. 1958). Vascular isolation and perfusion minimizes 
systemic exposure and thereby reduces unwanted side effects. In patients, 
isolated perfusion with chemotherapeutic agents has been reported to be effective 
in the treatment of non-resectable liver tumors (Alexander, Libutti et al. 2005). 
ILP with TNF-alpha and melphalan was shown to be effective in melanoma and 
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soft tissue sarcoma (Grunhagen, Brunstein et al. 2004; Lans, Grunhagen et al. 
2005). In locally advanced soft tissue sarcoma or bulky melanoma, ILP with TNF-
based chemotherapy resulted in local tumor control and avoided amputation 
(Eggermont, Brunstein et al. 2004). In OS intra-arterial delivery of cisplatin, in 
combination with intravenous administration of doxorubicin and high-dose 
methothrexate has shown superior survival (Wilkins, Cullen et al. 2003). However 
others reported no significant differences in the rates of limb salvages, local 
recurrences and event-free survival when comparing intra-arterial and intra-
venous administration of cisplatin in combination with intravenous administration 
of doxorubicin and high-dose methothrexate in a prospective randomized trial 
(Bacci, Ferrari et al. 2001; Bacci et al. 2001) Both groups did not report increased 
toxicity in intra arterial delivery. 
In the pre-clinical setting, ILP with adenoviral vectors was shown to be effective in 
delivery of recombinant adenovirus carrying therapeutic gene constructs (de Roos, 
de Wilt et al. 2000). Furthermore, soft tissue sarcoma-bearing rats treated with 
interleukin 3 beta gene therapy showed significant tumor growth delay (de Roos, 
de Wilt et al. 2000; de Wilt, Bout et al. 2001). So far, ILP has not been reported in 
the context of oncolytic viral therapy. However, in view of the data mentioned 
above this could be a useful viral administration route. As it is known that 
adenoviral vector gene therapy is hampered by the limited dispersion of the vector 
through the solid tumor, we hypothesized that intravascular administration of 
adenoviruses would be more effective, especially in the context of OS, a highly 
vascularized tumor with a relatively dense extracellular matrix. Moreover vascular 
leakage may add up to the effectivity of this route of administration. 
In the studies presented here first a validated xenograft model for OS using 
human MNNG-HOS cells was established. In this model the ILP procedure as 
described by de Wilt et al (de Wilt, Manusama et al. 1999) was studied. Based on 
these experiments, it was demonstrated that ILP in this rat xenograft tumor model 
requires restoration of the femoral artery. Next, the efficacy of ILP with Ad5-
∆24RGD against OS was investigated. While intra-tumoral injection of Ad5-
∆24RGD in this highly aggressive tumor model had no significant effect, 
administration of the virus via ILP significantly inhibited MMNG-HOS tumor growth.  
 
MATERIALS AND METHODS 
 
Cell lines 
 
MNNG-HOS, OHS, 293 and A549 cells were purchased from the American Type 
and Culture Collection (ATCC, Manassas, VA, USA). Cells were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% Fetal Calf 
Serum (FCS), 50IU/ml penicillin, 50mg/ml streptomycin and 2mM L-glutamine 
(Life technologies B.V., Breda, the Netherlands), at 37°C in a 5% CO2 humidified 
atmosphere. 
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Adenoviruses 
 
f
 
The CRAd Ad5-∆24RGD lacks 24 base pairs encoding 8 amino acids in the pRb-
binding domain of E1A and carries a cyclic RGD epitope in the HI-loop of the fiber 
(Suzuki, Fueyo et al. 2001). This CRAd was propagated on A549 cells and purified 
using cesium chloride gradient banding and titrated by end-point limiting dilution 
on 293 cells.  
A recombinant E1-deleted Adv expressing the luciferase reporter gene under the 
control of the CMV promoter, AdCMVLuc, and a similar virus, containing an 
integrin targeting RGD-4C peptide within the fiber HI-loop, AdLucRGD, (Dmitriev, 
Krasnykh et al. 1998) were provided by Dr DT. Curiel (Gene Therapy Center, 
University of Alabama at Birmingham, AL, USA). 
 
Adenoviral in ection experiments 
 
MNNG-HOS cells were plated in 24 wells plates at 2.5 x104 cells/well. To allow 
adherence, cells were incubated overnight in DMEM/10% FCS medium. 
Adenoviruses were diluted in DMEM/2.5% FCS and cells were infected in triplicate 
at the indicated Multiplicity Of Infection (MOI). One hour after infection, the 
medium was renewed with DMEM/10% FCS and cells were cultured at 37°C until 
analysis of gene transfer by luciferase activity measurement. 
Luciferase expression was measured using the Luciferase chemiluminescent Assay 
System (Promega, Madison, WI). Medium was removed from the cells and 
luciferase reporter lysis buffer was added to the wells followed by a freeze thaw 
step. Luminescence was measured during 10 seconds immediately after initiation 
of the light reaction in a Luminat LB9507 luminometer (EG&G Gerthold, Bad, 
Wildbad, Germany). Values were protein normalized (Bio-Rad Protein Assay, Bio-
Rad laboratories, Veenendaal, the Netherlands). Results were expressed as 
Relative Light Units (RLU) per µg protein. 
 
In vivo experiment 
Male nude rats, weighing 160-180 g, obtained from Harlan-CPB (Horst, the 
Netherlands) were used. Animals were kept under pathogen-free conditions. Rats 
were fed a standard laboratory diet (Hope Farms, Woerden, the Netherlands) ad 
libitum. The experimental protocols adhered to the rules outlined in the Dutch 
Animal Experimentation Act (1977) and the published ‘Guidelines on the 
protection of Experimental animals’ by the council of the E.C. (1986). The protocol 
was approved by the committee on Animal Research of the VU University Medical 
Center. 
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For establishment of xenografts, either 1x107 MNNG-HOS (n=6) or OHS (n=6) 
tumor cells were injected subcutaneously (s.c.) in the hind limb of nude rats, or 
OS-1a tumor pieces (3x3x3mm) (n=6) derived from a patient with OS and 
propagated s.c. in nude mice were implanted s.c. in the flank of nude rats. OS-1a 
patient characteristics have been described previously (Witlox, Van Beusechem et 
al. 2002). Tumor size was monitored twice a week, using digital calipers. Volume 
was calculated from the average of tumor length and width according to the 
formula: 4/3πr3.  
When MNNG-HOS tumors growing on the hind limb of rats reached a volume of 
150-300 mm3, they were either injected intra-tumoral or the hind limb containing 
the tumor was perfused. Intra tumoral injections were given on 5 consecutive 
days with control medium or Ad5-∆24RGD. Injections were given from different 
angles every day, in a volume of 20µl and with a total viral dose of 1 x 109pfu. 
The perfusion technique was performed as described previously (de Roos, de Wilt 
et al. 2000). Briefly, animals were anaesthesized with Hypnorm (Janssen 
Pharmaceutica, Tilburg, the Netherlands) and 50 IU of heparin was injected 
intravenously to prevent coagulation. The femoral artery and vein were cannulated 
with silastic tubing (0.012 inch inner diameter (ID), 0.025 inch outer diameter 
(OD); 0.025 inch ID, 0.047 inch OD respectively, Dow Corning, Michigan, USA). 
Collaterals were occluded by a groin tourniquet and isolation time started when 
the tourniquet was tightened. An oxygen reservoir and a roller pump were 
included into the circuit. The perfusion solution was 5 ml heamaccel (Behring 
Pharma, Amsterdam , the Netherlands) with 1 x 109pfu Ad5-∆24RGD or without 
virus (SHAM). A roller pump (Watson Marlow, Falmouth, UK; type 505U) 
recirculated the perfusate at a flow rate of 2.4 ml/minute. A washout with 5 ml 
oxygenated haemaccel was performed at the end of the perfusion.  
Depending on the experiment, the femoral artery remained ligated (standard ILP 
procedure) or was restored by suturing the cannulation opening (adapted ILP 
procedure (aILP), adapted SHAM procedure (SHAMaILP)).  
Tumor growth was expressed as tumor ratio, calculated by dividing the tumor 
volume on a given day after treatment by the initial tumor volume. The data were 
analyzed either with the unpaired t-test (p-value two-tailed experiments depicted 
in figure 2) ore one-way Analysis of Variance (ANOVA,-experiment depicted in 
figure 4). 
 
Immunohistochemistry  
 
MNNG-HOS tumor of non treated animals were paraffin embedded and stained 
with heamatoxylin and eosin in order to analyze tumor characteristics. 
Frozen MNNG-HOS xenograft samples were sectioned at 4-µ-thick and stained 
immuno-histochemically for integrins αvβ3 and αvβ5 and hexon. Sections were 
fixed in acetone/H2O2. Mouse-anti-human integrin αvβ5 (Clone VNR137 
Invitrogen, Breda, the Netherlands) was used in 1:200 dilution. Mouse-anti-
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human integrin αvβ3 (MAB1976 Chemicon, Hampshire, United Kingdom) was used 
in a dilution of 1:250. Bound primary antibody was detected with secondary 
antibody Rabbit anti-mouse HRPO (P0260 DAKO, Glostrup, Denmark) and AEC 
(K3464 DAKO, Glostrup, Denmark). Finally, sections were counterstained with 
haematoxylin, dehydrated and mounted. Anti-hexon was done accordingly.Goat 
anti hexon (AB1056 Chemicon, Hampshire, United Kingdom) of a dilution of 
1:1000. Sections were preincubated with normal rabbit serum 1:50 (DAKO, 
Glostrup, Denmark), consecutively incubated with the primary antibody and 
detected with secondary antibody Rabbit anti-goat-biotin using the 
StreptABComplex (K0377DAKO, Glostrup, Denmark). Finally, sections were DAB 
(SK-4100 Vector Laboratories, Burlingame USA) stained with peroxidase substrate 
and counterstained as described above. 
 
RESULTS 
 
Establishment of xenograft OS model 
 
In order to evaluate the efficacy of Ad5-∆24RGD against OS in vivo, a xenograft 
OS tumor model in nude rats was established. To this end, two cell lines (MNNG-
HOS and OHS) and one primary (OS-1a) tumor were tested. Subcutaneous 
injection of OHS cells did not result in a reproducible model, since OHS failed to 
grow in all but one rat. Despite the fact that OS1-a has proven to be a validated 
xenograft model in nude mice (Witlox, Van Beusechem et al. 2004), this tumor did 
not grow representatively in nude rats. In contrast, MNNG-HOS demonstrated 
rapid and reproducible growth on the rat hind limb with a take-rate of 85% and a 
tumor doubling time of 0.8 days. The aggressive growth pattern made this an 
attractive model. Despite the fact that due to the rapid growth of MNNG-HOS 
central necrosis frequently occurred when the tumors reached an average volume 
of approximately 1000 mm3. As a result, animals could only be observed for a 
limited period of time, because they had to be sacrificed for animal well fare 
conditions. Histological analysis of the tumors demonstrated extremely high grade 
mitosis, invasive growth and osteoblastic features, characteristic for human OS 
(figure 1A). Previously, it was demonstrated that MNNG-HOS cells in vitro express 
high levels of αvβ3 and αvβ5 integrins and low levels of adenovirus receptor CAR 
(Witlox, Van Beusechem et al. 2004). This was also reflected in the enhanced 
susceptibility of these cells to infection by RGD-modified adenoviruses. Infection 
with AdlucRGD resulted in 20-140 times higher transgene expression compared to 
the control vector Adluc (figure 1B). Importantly, immunohistochemical analysis 
consistently showed these integrins were also expressed in MNNG-HOS tumors in 
vivo. Positive cells were scattered throughout the tumor (data not shown). Thus, 
MNNG-HOS tumors growing on the hind limb of rats represent a highly aggressive 
OS tumor model and were expected to be susceptible to infection with a RGD 
targeted CRAd. 
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Figure 1A: 
 MNNG-HOS characteristics microscopy  
4 µm thick paraffin embedded sections hematoxillin 
eosin stained show:  
1) an overview of MNNG-HOS in which the necrotic 
parts can be observed.  
2) a more detailed part of this tumor (10 times 
magnification) shows invasive growth in 
surrounding muscle.  
3) a second enlarged part of this tumor (40 times 
magnification) shows the high grade of mitosis and 
osteoblastic features. 
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Figure 1B: OS cell line MNNG-HOS was transduced with AdCMVLuc (white bars) or 
AdLucRGD (black bars) at an MOI 10, 50, 100 pfu/cell. Luciferase expression was measured 
after 24 hours and is depicted as relative light units (RLU ) on the y-axis. Data shown are 
mean values + standard deviation from a representative experiment done in triplicate. 
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Intratumoral injection of Ad5-∆24RGD  
 
To evaluate the efficacy of the CRAd Ad5-∆24RGD in this xenograft model, first 
the intratumoral administration route was explored. MNNG-HOS tumors were 
injected on five consecutive days with a total dose of 1x109pfu Ad5-∆24RGD or 
with control medium. The effects of intratumoral (i.t.) injection of Ad5-∆24RGD 
are shown by the tumor growth curves in figure 2. On day 10, the first animal of 
the control group had to be sacrificed due to tumor necrosis; hence animals could 
not be observed for a longer period of time. Despite the fact that MNNG-HOS 
xenografts tumors appeared to be susceptible for RGD targeted infection, growth 
delay could not be observed. Data shown in figure 2 demonstrate that in this fast 
growing tumor 1x109pfu Ad5-∆24RGD i.t. Injection had no significant anti-tumor 
effect compared to control animals. When animals were sacrificed tumors were 
analyzed and immunohistochemistry for hexon was performed. In none of the 
immunohistochemically analyzed tumors positively stained cells could be detected. 
In conclusion, i.t. Ad5-∆24RGD injection was ineffective in this tumor model.  
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Figure 2: Ad5-∆24RGD efficacy in vivo i.t. administration 
MNNG-HOS xenografts (300mm3) were not treated (n=5    ) or injected with Ad5-∆24RGD 
(n=5   )  1x109 pfu divided over 5 consecutive days. Growth curves in tumor ratio for each 
group with SEM are shown. Animals were sacrificed when tumor sizes exceeded 2000 
mm3. 
 
ILP technique and adapted ILP  
ILP may increase the in vivo efficacy of CRAd as an anti tumor agent. The ILP 
procedure is schematically depicted in figure 3. We first evaluated the well-
established ILP procedure described by de Roos et al (de Roos, de Wilt et al. 
2000) in which the femoral artery is ligated. SHAM ILP procedures reduced MNNG-
HOS tumor growth rate tremendously (data not shown), most probably based on 
ischemic effects. This procedure was therefore considered inadequate to study 
therapeutic efficacy of CRAds. To limit ischemic effects, a modification was made 
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in the ILP by restoring the femoral artery after the ILP procedure. To analyze the 
effect of this adaptation, a pilot experiment was performed in which rats bearing 
MNNG-HOS tumors underwent either SHAM ILP or SHAM ILP with restoration of 
the femoral artery (SHAM aILP). This pilot experiment demonstrated that SHAM 
aILP influenced tumor growth rate much less than SHAM ILP (data not shown). 
Hence, to allow proper evaluation of CRAds administered via ILP, in subsequent 
experiments the adapted procedure was used. 
Figure 3: Schematic representation of the isolated limb perfusion setting  
Male nude rat with a MNNG-HOS tumor on the hind limb, perfused via a roller pump with 
oxygenated perfusate whith a tourniquet present. 
 
 
Adapted ILP with Ad5-∆24RGD 
 
The results of the experiments described above led to a final set of experiments, 
in which MNNG-HOS-bearing rats were treated with 1x109 pfu Ad5-∆24RGD via 
aILP. SHAM aILP and untreated animals were inclosed as controls. Tumor volumes 
were monitered for each treatment group until at least one animal had to be 
sacrificed because the tumor excerted 2000 mm3 or exhibited necrosis. As can be 
seen in figure 4A SHAM perfusion resulted in a significant growth retardation 
compared to untreated controls. This almost doubled the evaluation time before 
the first animal had to be sacrificed. 
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Figure 4A: Ad5-∆24RGD efficacy in vivo with restoration of the femoral artery aILP 
MNNG-HOS xenografts (300mm3) were SHAM aILP treated (n=8  ) or aILP with  Ad5-
∆24RGD 1x109 pfu (n=7    ) treated or not treated (n=6    ).  In the ILP groups, the femoral 
artery was restored afther completion of the perfusion. Data represent mean relative tumor 
size compared to start of treatment with SEM. Animals were sacrificed when tumor sizes 
exceeded 2000 mm3 or when spontaneous necrosis occured. 
 
 
On top of this effect Ad5-∆24RGD perfusion reduced MNNG-HOS tumor growth 
further. While SHAM treated tumors continued to grow, Ad5-∆24RGD treated 
tumors stopped growing for about one week after perfusion. Consequently on day 
7 Ad5-∆24RGD treated tumors were 80% smaller than untreated tumors 
(p<0,001) and 50% smaller than SHAM treated tumors (p<0.05). Thereafter, 
tumors in both treatment groups grew with similar kinetics. Complete cures were 
not documented CRAd Treated tumors were analyzed for replicating virus by 
immunohistochemistry for hexon protein. A representative immunohistochemical 
staining is shown in figure 4Bb. A corresponding section stained with hematoxilin 
is shown in figure 4Ba. In all analyzed tumors (n=4), hexon positive cells were 
detected clustered around the remaining vasculature. 
 
 127
CHAPTER 6 
 Figure 4B: representative 4 
µm thick frozen cryosections 
hematoxillin eosin stained (A 
20 times magnification) and 
an identical section anit-
hexon stained (B 20 times 
magnification) show spotted 
staining indicated by an 
arrow. 
  
A 
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In conclusion, a single aILP with Ad5-∆24RGD delivered replicating virus to the 
tumor causing significant tumor growth reduction compared to non treated and 
SHAM a ILP treated animals. 
 
DISCUSSION 
 
The clinical course of OS demands the development of new therapeutic options. 
CRAds represent promising agents for the treatment of solid tumors. Previously 
we have reported that Ad5-∆24RGD could be a possible candidate agent for the 
treatment of OS (Witlox, Van Beusechem et al. 2004). This oncolytic virus has also 
been shown to be effective in preclinical animal models of ovarian cancer and 
malignant glioma (Bauerschmitz, Lam et al. 2002; Lamfers, Grill et al. 2002; 
Fueyo, Alemany et al. 2003; Lam, Kanerva et al. 2004) and is currently advancing 
towards clinical application in phase I trials for these tumors (ASCO). In the 
context of OS, ILP with oncolytic viruses may offer a useful treatment option from 
the point of view that improving local tumor control can enhance the safety of the 
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surgical procedure, particularly limb salvage. In addition, local recurrences may be 
reduced compared to systemic administration. Moreover there will be a reduced 
viral exposure to the rest of the body. Furthermore, intravascular administration 
may increase the efficacy of oncolytic viral therapy by improving the viral delivery 
to and distribution within the (highly) vascularized tumor, resulting in a more 
dispersed and efficient infection of the tumor. Next from these studies valuable 
information concerning intra-arterial administration for metastatic treatment can 
be observed. 
The use of conditionally replicative human adenoviruses dictates the use of a 
human OS tumor model since replication is limited in other species. In this study, 
we describe the establishment of an OS xenograft model using the human cell line 
MNNG-HOS. We show that these rapidly growing tumors have characteristic 
features of OS and express high levels of integrins. However, the rapid growth 
rate of MMNG-HOS tumors led to a high susceptibility to ischemia and 
spontaneous necrosis when tumors reached a critical volume of 1,000 mm3. 
Intratumoral injection of the integrin-targeted CRAd Ad5-∆24RGD showed no 
significant anti-tumor effect. Presumably, the fast-growing nature of this tumor in 
combination with a limited intra-tumoral distribution of the virus by this route of 
delivery limited the therapeutic efficacy of the virus. Reports from Roos et al and 
Milas et al (Milas, Feig et al. 1997; de Roos, de Wilt et al. 2000) demonstrated 
that effective gene transfer to solid tumors using non-replicative adenoviral 
vectors can be achieved by delivery by ILP, contrary to direct intra-tumoral 
injection which resulted in expression only around the needle tract. This lack of 
intra-tumoral penetration of the virus beyond the needle tract has been suggested 
to be one of the major obstacles to successful gene therapy of solid tumors by this 
route (Lang, Bruner et al. 2003). Despite the fact the one of the unique features 
of CRAd virotherapy is its ability to replicate and disperse through the tumor we 
did not observe this in the MNNG-HOS tumor model. A Possible explanation for 
this could be the aggressive behavior of this tumor with very rapid tumor 
doubling. Moreover, a recent study by Pipiya et al (Pipiya, Sauthoff et al. 2005) 
demonstrated that hypoxia appeared to decrease the production of new virus by 
decreasing the synthesis of viral proteins. This may have limited the effect of Ad5-
∆24RGD in this tumor model with high incidence of necrosis. We hypothesized that 
an isolated intra-arterial delivery method might increase the efficacy of Ad5-
∆24RGD in this tumor model.  
MNNG-HOS was suspected to be highly sensitive to ischemia. Indeed, SHAM ILP of 
tumor-bearing rats was found to have a substantial effect on the growth of MNNG-
HOS tumors, most probably due to the fact that ligating the femoral artery 
resulted in hypoxia of the tumor and subsequently to necrosis. Embolization of the 
arterial supply, aimed at creating ischemia of the neoplasm, has already been 
employed in the therapeutic management of patients with primary and secondary 
neoplasms of the liver, kidney, and bone (Wallace, Charnsangavej et al. 1984). To 
be able to study the effect of CRAd perfusion, we adapted the ILP, reinstating the 
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normal blood supply to the tumor by restoring the femoral artery after the 
perfusion was completed. Restoration of the femoral artery resulted in a decreased 
effect of the perfusion technique alone on tumor growth. Although a delay in 
tumor growth was still evident. Using this adapted technique, we could 
demonstrate that Ad5-∆24RGD delivery by ILP significantly inhibited MNNG-HOS 
tumor growth. However, it did not result in complete eradication of the established 
tumors. Notably, the virus was detected in tumors especially around tumor 
vasculature, suggesting limited dispersion. This can partly be explained by the 
physical barriers found within an organized tumor that are not fully characterized 
yet in the context of adenovirus gene therapy. In this regard, Kuppen et al 
(Kuppen, van der Eb et al. 2001) showed that the extra cellular matrix in a tumor 
serves as a barrier for adenovirus binding to tumor cells. Additionally, Sauthoff et 
al (Sauthoff, Hu et al. 2003) showed that adenoviral spread within tumor 
xenografts is impaired by tumor-supporting structures. However, they also 
showed continued viral replication within the tumor, with subsequent systemic 
dissemination and re-infection of tumors via the tumor vasculature. An other 
explanation for incomplete tumor eradication is insufficient viro replication rate in 
face of the rapid tumor expansion. Taken together, despite the fact that MNNG-
HOS xenografts showed to be a fast growing tumor highly susceptible to ischemia 
and spontaneous necrosis, our data demonstrate that Isolated Limb Perfusion with 
the CRAd Ad5-∆24RGD resulted in significant tumor growth delay. We conclude 
that the results presented support further development of Ad5-∆24RGD for the 
treatment of osteosarcoma. 
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CHAPTER 7 
SUMMARY 
 
Before the use of chemotherapy survival of patients with OS was limited to 5-
10%. The introduction of chemotherapy combined with aggressive surgery has 
changed treatment and outcome significantly for patients with OS. 
Notwithstanding these efforts there are still patients who cannot benefit from 
these developments. Subsequently this has led to the search and development of 
new therapeutic options. A better understanding of OS tumor biology has formed a 
gateway to the exploration of novel therapeutics possibly to complement current 
treatment strategies. In this thesis several studies have been described which 
explore adenoviral vector based gene therapy strategies as a possible future 
treatment modality for patients with OS. 
In chapter 1 current knowledge concerning OS is placed in a historical perspective. 
In addition demographics, classification, tumor biology, and existing treatment 
modalities are discussed. Next novel therapeutics including growth factors and 
gene therapy are explored in more detail. Since this thesis focuses on the 
adenovirus, the biological characteristics and the properties of the adenovirus are 
described. Most important gene therapy strategies for OS are aligned. In short, 
mutation compensation, suicide gene therapy, immunopotentiation gene therapy, 
targeting strategies, virotherapy and delivery are discussed. Furthermore 
targeting moieties and CRAd biological working mechanisms are described.  
In chapter 2 the outline of this thesis is presented. 
In chapter 3 the suicide gene expression system, carboxylesterase (CE)/CPT-11 
(irrinotecan) SN-38, as an anti OS agent is explored. In this chapter the 
construction of a non-replicating adenoviral vector expressing the secreted form of 
CE is described (Ad-sCE2).  
The recognition that cell lines are not always representative for the in vivo 
situation has led us to develop primary short-term cultures. These primary OS 
cells were brought into culture after a tumor piece was surgically removed, 
therefore these cells can be considered as representative OS tumor cells. The 
utility of Ad-sCE2, in combination with CPT-11 for the treatment of OS cell lines 
and primary OS cell cultures in vitro and in vivo was evaluated. We found that in 
vitro transduction with Ad-sCE2 sensitized OS cell lines and primary OS tumor 
cells up to 2800-fold to CPT-11 treatment. Progressing towards an in vivo model, 
mice bearing MG-63 derived tumors were treated with Ad-sCE2 + CPT-11. 
Xenografts of treated animals exhibited significant slower growth rate compared to 
animals treated with virus or CPT-11 alone. However this treatment did not result 
in tumor regression or stable disease. These results may partly be explained by 
the limited transduction efficiency. Despite limited transduction efficiency the 
observed tumor growth retardation suggested an effective bystander effect.  
The finding that one of the main limitations of adenoviral-based gene therapy is 
the relatively low expression of the adenovirus receptor CAR, has led to 
exploration of alternate and more effective pathways for adenoviral entry. Our 
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studies showed that OS cell lines and primary tumor cells are CAR negative, thus 
needing an alternate pathway for adenoviral binding. As described in chapter 4, 
one such alternate pathway targets towards the Epidermal Growth Factor Receptor 
(EGFR). EGFR is widely expressed on OS tumor cells therefore being an attractive 
receptor. Our studies indeed showed on OS cell lines, primary OS cells and OS 
tumor samples EGFR expression. Since the HSV-TK ganciclovir system has been 
investigated extensively both in OS as well as in other solid tumors and as such 
exhibiting promising results, this system was evaluated in chapter 4. In 
combination with a targeting strategy this led to the assessment of a non 
replicating adenoviral vector encoding for HSV-TK targeted towards EGFR using a 
bispecific single chain antibody (425-s11). This bispecific single chain antibody 
links the adenovirus to the EGFR and allows CAR independent viral entry. 
Adenovirus transduction experiments in the presence of 425-s11 showed 
significantly enhanced gene transfer. We were able to enhance gene transfer 2.5 
to 10 times in OS primary short-term cultures and OS cell lines. On this basis 
targeted suicide gene therapy experiments with AdCMVHSV-TK in combination 
with ganciclovir were performed. These experiments demonstrated up to 3.5-fold 
enhanced cell kill with the use of targeted AdCMVHSV-TK compared to non-
targeted AdCMVHSV-TK of OS cell lines and primary short-term cultures.  
Based on the study described in chapter 4 it became apparent that adenoviral-
based gene therapy strategies for OS required CAR independent infection 
methods. In addition it also became clear that adenoviral vector based gene 
therapy studies in the context of OS in vivo showed only limited efficacy. A key 
factor in this regard was the failure of non-replicating adenoviral vectors to 
achieve sufficient tumor-cell transduction and effective penetration in solid tumor 
structures. The development of Conditionally Replicating Adenoviruses (CRAds) 
addresses these limitations. Therefore in chapter 5 the oncolytic capacity of the 
CRAd Ad5-∆24RGD was tested on primary OS cells in vitro and in vivo. In addition 
to its oncolytic capacity, this virus utilizes integrins as a primary adenovirus 
attachment site thereby achieving more efficient infection and cell kill of OS cell 
lines and primary OS cells. It was shown that incorporation of a cyclic Arg-Gly-Asp 
(RGD-4c) sequence that interacts with integrins circumvents low CAR expression. 
The recognition that this CRAd encodes retinoblastoma protein binding-deficient 
E1A proteins, Ad5-∆24RGD was postulated as an attractive CRAd, since genetic 
alterations in the retinoblastoma pathway are frequent in OS. In the study 
presented here integrins showed to be abundantly expressed on OS cell lines and 
primary cell cultures. RGD mediated infection augmented adenovirus infection of 
primary OS cells by two orders of magnitude. The CRAd Ad5-∆24RGD was highly 
effective in killing human OS cell lines, as well as primary cell cultures. In addition 
intra tumoral injections with Ad5-∆24RGD into established human OS xenografts 
that were derived from a patient with OS refractory for chemotherapeutic 
treatment caused significant tumor-growth delay. Histological analysis 25 days 
after virus injection showed evidence for Ad5-∆24RGD replication in OS tumor 
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cells. In conclusion this CRAd showed to be effective in OS in vivo, with evidence 
of replication in the tumor cells. 
Towards clinical feasibility and improvement of administration routes an 
intravascular delivery method was evaluated. This led to the evaluation of the 
Isolated Limb Perfusion (ILP) model for intra-arterial CRAd administration. The 
establishment of this model and the efficacy of the CRAd Ad5-∆24RGD in this 
xenograft model are described in chapter 6. In order to evaluate the CRAd in an 
OS xenograft model, 2 human OS cell lines and one patient-derived human OS 
specimen were tested for growth on the hind leg of rats. This resulted in a 
xenograft model with MNNG-HOS cells forming extremely aggressive and fast 
growing tumors. In this tumor model, intra-tumoral injection of Ad5-∆24RGD 
showed no significant anti-tumor effect. We hypothesized that in situ perfusion 
might be more effective. MNNG-HOS tumors appeared to be highly sensitive to 
ischemia. Therefore we adapted the ILP procedure by reinstating the normal blood 
supply to the tumor after the perfusion was completed. Restoration of the femoral 
artery resulted in a decreased effect of the perfusion technique alone on tumor 
growth. Using this adapted technique we demonstrated that Ad5-∆24RGD delivery 
by ILP significantly inhibited MNNG-HOS tumor growth, although this treatment 
did not result in complete eradication of the established tumors. Notably the virus 
was detected by immunohistochemistry especially around the remaining tumor 
vasculature suggesting limited dispersion. The physical barriers existing in a solid 
tumor of osteogenic nature can perhaps explain this. Taken together our results 
suggest that delivery of the oncolytic adenovirus Ad5-∆24RGD to a highly 
aggressive established OS tumor, using an adapted ILP procedure has significant 
anti tumor effects.  
 
In conclusion, based on the work described in this thesis the use of suicide gene 
therapy and targeted suicide gene therapy caused profound anti cancer effects in 
preclinical OS models. Enhancing tumor specificity, tumor infectivity and 
combining this approach with CRAds could further improve this approach. In 
addition the use of Ad5-∆24RGD has perspective for the treatment of OS as shown 
in the in vivo models presented here. The challenge will be to increase the 
oncolytic capacity of CRAds.  
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DISCUSSION AND FUTURE PERSPECTIVES 
 
Gene therapy is regarded by many as a potential revolution in medicine. This is 
because gene therapy initially aimed at treating or eliminating the cause of the 
disease where as other strategies treat symptoms. This was received with 
enormous optimism, suggesting gene therapy as a curative strategy for all kind of 
diseases including cancer. The first gene therapy clinical trial in 1989 was in the 
context of treating a monogenetic disorder by gene replacement. Since then only 
9% of the clinical trials have been in this category. Now cancer has become the 
foremost arena in which gene therapy is applied (Edelstein, Abedi et al. 2004). 
The past 25 years much progress has been made in the approach and knowledge 
regarding adenoviral anti cancer based gene therapy. However, developments in 
the field have been less fast than originally was thought. This is possibly due to 
the, despite emerging techniques, still limited knowledge regarding biological 
processes in cancer and used vectors. Furthermore, stringent safety procedures 
for treated patients and the population have deferred developments since safety 
studies were needed and still are. In addition the high costs, the production 
process of a clinical usable virus batches also delayed the much-needed clinical 
trials. Most clinical gene therapy studies are still in phase-I –II to evaluate toxicity. 
Finally, since for many cancer types effective, although not curative, treatments 
exist new treatment options have to prove themselves in combination therapies. 
Notwithstanding these thresholds studies have developed elegant and successful 
gene therapy strategies, as well for the treatment of cancer as other diseases.  
One of the first success of gene therapy also brought a major tragedy as was 
reported in 2000 when a group in Paris succeeded in correcting Severe Combined 
Immune Deficiency (SCID) in children (Cavazzana-Calvo, Hacein-Bey et al. 2000). 
This disease is characterized by a total lack of T lymphocytes and natural killer 
cells, which defend the body against infections. The disease was corrected by 
using a retrovirus containing the normal gene. Patient’s stem cells were incubated 
with a retroviral vector carrying the normal gene, these transduced stem cells 
were reinfused into the patient. In this way the immune deficiency was corrected. 
Unfortunate two of the treated children (ten) later developed leukemia (Hacein-
Bey-Abina, von Kalle et al. 2003). In short this was due to the fact that the 
integrating normal gene was inserted near an oncogene. This normal gene could 
act, as oncogene under the control of a retroviral promoter, which means that 
transduced cells are only one mutation away from cancer development. Which 
unfortunately occurred in two patients. This success of gene therapy and in the 
same time tragedy of gene therapy resulted in reticence. Notwithstanding the 
impact this had on these patients, the nature of their disease justified this 
experimental therapy. The successfully treated children were able to have a 
relative normal live this in contrast to their life before the treatment, in other 
words despite the tragedy, gene therapy also proved to be successful in treating 
such a sever disease.  
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The overall aim of the studies described in this thesis was to progress towards 
effective gene therapy in OS. Studies focused on gene therapy strategies including 
(targeted) suicide gene therapy, oncolytic viral therapy and delivery. 
Today patients with OS are treated with a multi-modality approach consisting of 
preoperative systemic chemotherapy followed by local surgical therapy and 
postoperative chemotherapy. The use of cytotoxic chemotherapy to cure solid 
tumors only works when a sufficiently high concentration of the anticancer drug 
can be delivered to the malignant cells. However this is often difficult 
predominantly accounting for their toxicity to normal tissue. Suicide gene therapy 
aims at increasing drug selectivity towards cancer cells. The suicide gene therapy 
studies described in this thesis, showed to be effective in OS. Since expression of 
the foreign enzymes will not occur in all cells of the targeted tumor in vivo, a 
bystander cytotoxic effect is required. In this way the prodrug is cleaved to an 
active drug that kills not only tumor cells but also neighboring non-enzyme 
expressing tumor cells. The studies described in this thesis using the secreted 
form of CE addressed this issue efficiently. The secreted form of CE is capable of 
activating the prodrug CPT-11, thereby exerting toxicity to untransduced cells. In 
the context of the HSV-TK/ganciclovir system this bystander effect is caused by 
gap junction-mediated diffusion. Targeting the adenovirus containing HSV-TK 
towards the EGFR showed increased tumor cell toxicity, due to increased 
infectivity. In addition this approach can also increase tumor cell specificity. Other 
ways to improve this approach will be to combine suicide gene therapy with CRAd 
therapy. This has been evaluated by Wildner et al. (Wildner, Morris et al. 1999); 
they constructed a CRAd incorporating TK in the CRAd genome. In several solid 
tumor models this CRAd treatment with ganciclovir resulted in increased survival 
of the treated animals compared to viral treatment without ganciclovir or 
compared to replication deficient TK virus combined with ganciclovir treatment. 
The limitation regarding the suicide gene therapy strategies mentioned above, in 
OS may lay in the fact that the HSV-TK/ganciclovir and CE/CPT-11 systems are 
not effective in the current chemotherapeutic treatment of OS. Therefore, it might 
be interesting to explore other suicide gene systems, which have known anti 
tumor efficacy in OS.  
To increase the efficacy of suicide gene therapy studies we evaluated targeting 
strategies. Our studies exploiting EGFR as an alternative target molecule for 
adenoviral infection prove this to be a useful target. In addition the bispecific 
single chain antibody significantly enhanced gene transfer into OS cells (Witlox, 
Van Beusechem et al. 2002). The disadvantage of a two-component system might 
be overcome by using an adenovirus producing the bispecific single-chain 
antibody. The construction of a CRAd with the ∆24 E1A mutation that produces 
this bispecific single-chain antibody overcomes this disadvantage (van 
Beusechem, Mastenbroek et al. 2003). Therefore it will be interesting to combine 
this CRAd with a suicide gene therapy approach. 
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More in general clinical trials in the field of suicide gene therapy generated overall 
conclusions and direction for improvements; enhanced selectivity towards cancer 
cells, amplification effects, and bystander cell death. In this regard the main 
requirement for the future is efficient targeting and delivery to tumor cells. 
 
The development of CRAds has enclosed important therapeutic gene therapy 
strategies. CRAds replicate in cancer cells and thereby destroy these cells. The 
released progeny viruses can infect and lyse neighboring tumor cells. The use of 
viruses that specifically kill tumor cells while sparing normal cells has emerged 
over the past decade. Viruses have been evolved to maximize their ability to enter 
cells, use the machinery of the host cell to replicate and package their own 
genome. With the advances of molecular biology and the understanding of the 
function of viral genes, it has become possible to genetically re-engineer viruses to 
make them selectively target tumor cells. The CRAd Ad5-∆24RGD tested in 
experiments described in this thesis is defective in pRb binding. Since the pRb 
pathway in OS is frequently altered this is an attractive approach. To enhance 
infection efficiency it was shown that integrins are expressed on OS cells and that 
expanding CRAd tropism towards integrins enhanced gene transfer dramatically 
(Witlox, Van Beusechem et al. 2004). We showed this CRAd to be effective in OS 
xenografts (Witlox, Van Beusechem et al. 2004), however complete responses 
could not be observed. This can partly be explained by limited dispersion through 
solid tumor environment.  
Further improvements, in CRAd therapy would be enhanced selectivity. Selectivity 
could be improved with a tissue specific promoter, such as the osteocalcin 
promoter. In this way a higher dose can be delivered at the tumor site and 
thereby increasing the efficacy. Other ways to improve CRAds is to insert a 
therapeutic gene into the CRAd genome; this can be applicable for suicide gene 
therapy approaches, as mentioned above. Other examples include genes encoding 
immune-potentiating cytokines or genes promoting cell death. Inserting a gene 
promoting cell death was studied by van Beusechem et al. (van Beusechem et al. 
2002). This group described the construction of a CRAd containing p53 in the E3 
region. This CRAd showed enhanced oncolytic potency compared to the control 
CRAd on a broad panel of tested cancer cell lines. The effects were as suspected 
most pronounced on p53 deficient cells. Although molecular studies in OS have 
yielded varied results, understanding the molecular events driving tumor genesis 
in OS may enclose additional concepts for CRAd OS gene therapy.  
Next to improving CRAds, in view of the development of clinical applicable gene 
therapy trials, combination therapy with current effective treatments will be the 
most effective way of improving OS treatment. Although the dream of medical 
doctors and investigators is to develop a single curative drug per cancer type, the 
reality is that combination therapy will be the most effective way of improving 
survival; therefore the development of future gene therapy clinical trials will most 
probably be combination with chemotherapy. Since the mechanism of tumor cell 
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kill is different in gene therapy from chemotherapy, oncolytic virotherapy could 
work synergistically with current modes of treatment. In other types of cancer 
combination of oncolytic virotherapy and chemotherapy has shown greater anti-
tumor efficacy without an increase in toxicity. Conventional chemotherapy for OS 
includes amongst others cisplatin and doxorubicin. A synergistic anti-tumor effect 
of CRAds with doxorubicin or cisplatin has been reported previously for other types 
of cancer (Heise, Sampson-Johannes et al. 1997; You, Yang et al. 2000; Li, Yu et 
al. 2001; Portella, Scala et al. 2002) and CRAd therapy combined with 
chemotherapy has already shown promising results in solid tumors in phase I and 
II clinical trials (Khuri, Nemunaitis et al. 2000; Lamont, Nemunaitis et al. 2000; 
Nemunaitis, Khuri et al. 2001; Reid, Galanis et al. 2001). Furthermore, the 
recognition that tumor cells develop genetic mechanisms that override apoptosis 
caused by chemotherapy damage to their DNA, dictates the finding of alternate 
pathways that would complement therapeutic induction of apoptosis or activate 
other cell death mechanisms. Pivotal in this regard will be the combination time 
schedules in order to maximize the therapeutic efficacy of both treatment 
modalities. In this field additional investigations are needed to establish were in 
the scheme of combination treatment CRAds will have the most benefit (Graat, 
Witlox et al. 2006). 
When exploring gene therapy approaches in the context of OS, next to the 
investigations regarding the most appropriate vector system or CRAd, delivery is a 
key issue. Current cancer gene therapy strategies involve intratumoral, intra-
cavitary or intravascular administration of viral vectors whose gene products 
impede the survival and growth of tumor cells. Future challenge will be to find an 
appropriate and save delivery method in OS primary tumor and lung metastasis. 
Although only partial addressed in this thesis administration is an essential field 
that needs to be further explored. The ILP procedure described in this thesis will 
only be effective addressing the primary tumor. However adjuvant local treatment 
can potentially improve local tumor control and enhance the safety of the surgical 
procedure, particularly limb salvage. In addition isolated perfusion may enclose 
possibilities for future systemic administration of novel therapeutics. In the model 
described in this thesis a significant effect could be observed with viral replication 
present at the site of the tumor. Although not completely successful in eradicating 
xenograft tumors, recent studies unraveling the biology of solid tumors, their 
extra cellular matrix, hypoxic condition, use of angiogenic properties and intra 
tumoral milieu, will eventually lead to increased penetration and replication 
efficacy of CRAds. Furthermore future studies exploring CRAd efficacy against 
tumor vasculature may enclose key issues in solid tumor gene therapy.  
In view of clinical application, studies directed towards OS lung metastasis are 
amongst the next steps to be taken in OS gene therapy. Interesting in this regard 
are studies with aerosolized gene therapy. The advantages of this form of 
administration are the non-invasive means for targeted delivery to different 
regions of the lung; moreover this route of administration delivers a high dose to 
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the target site. In addition this administration route may possibly cause fewer 
adverse effectors compared to intra venous delivery. To study the efficacy of gene 
therapy in OS lung metastasis the development of realistic animal models is of 
great importance. In this regard the lung metastasis model of Kleinerman et al. 
(Jia, Worth et al. 1999) will be interesting to study the efficacy of amongst others 
Ad5-∆24RGD. In addition the canine model developed by Hemminiki et al. 
(Hemminki, Kanerva et al. 2003) will be a valuable model for translational studies 
testing CRAd efficacy in a large animal immunocompetent context. Since the 
effects of virotherapy on the immune system are complex and gene therapy 
approaches can be aimed at improving an anti tumor immune response immune 
competent models are necessary. More over the immunological interaction of 
adenovirus (CRAds) with the host remains an issue of concern. Due to ubiquitous 
nature of adenovirus, a majority of the human population is exposed to 
adenoviruses leading to the development of an adenoviral specific immune 
response (Harvey, Worgall et al. 1999). In patients treated with CRAds flu like 
symptoms were observed. In addition CRAd therapy resulted in induction of 
neutralizing antibodies and pro-inflammatory cytokines serum levels (Nemunaitis, 
Cunningham et al. 2001; Reid, Galanis et al. 2002). Pre-existing immunity against 
adenovirus will significantly reduce the uptake of the vector. In addition the 
cellular immune response, mediated through adenoviral specific CD8 positive T 
cells, eliminates the cells expressing viral and transgene products (Crystal 1995). 
The possibility to study these interactions in an immune competent animal model 
with gross resemblance to the humane situation will be of large value. 
 
In conclusion, the studies described in this thesis have increased our knowledge 
on gene therapy for OS. The results from the studies described here indicate that 
adenoviral based gene therapy and especially CRAd therapy has perspectives for 
OS gene therapy. The efforts in this field of cancer research will eventually result 
in progression towards clinical application for OS. The knowledge from presented 
work enables us to design future research in order to progress towards a well-
designed clinical trial. In the context of a rare tumor type such as OS this will be in 
the setting of intense collaboration and continuous joined efforts between 
scientists and clinicians to complement current treatment strategies. Thereby 
ultimately improve survival of patients with OS. 
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Het osteosarcoma (OS) is de meest voorkomende primaire bot tumor (kanker). 
Deze tumor komt met name voor bij kinderen en adolescenten (gemiddeld zijn 
patiënten 16 jaar oud) of na het vijftigste levensjaar. In Nederland zijn ongeveer 
30 nieuwe patiënten per jaar. De tumor is meestal gelokaliseerd in de 
extremiteiten. Bij oudere patiënten doen de tumoren zich vaker in andere delen 
van het skelet voor. De tumor ontstaat doorgaans in het bovenbeen, in het 
onderbeen, de bovenarm of in de onderarm. Het kwaadaardige karakter van de 
tumor wordt gevormd door de enorme lokale groei, maar vooral ook door de 
metastasering (uitzaaïngen) naar de longen. Naast metastasering naar de longen 
doen zich ook metastasen elders in het bot voor. 
Microscopisch wordt deze tumor gekarakteriseerd door cellen die botweefsel 
vormen met een woekerend aspect.  
Een patiënt met een OS heeft weinig specifieke klinische verschijnselen, behalve 
een  pijnlijk gevoel in het aangedane bot. Na enige tijd ontstaat er nachtpijn en 
vormt zich een pijnlijke en hard aanvoelende zwelling. Bij 20% van de patiënten 
worden, wanneer zij voor het eerst in het ziekenhuis komen, al longmetastases 
ontdekt. De diagnose OS kan bij 50% van de patiënten gesteld worden met 
behulp van een röntgenfoto. Bij de overige 50% is meer geavanceerde onderzoek 
nodig. Uiteindelijk wordt de definitieve diagnose altijd gesteld door het nemen van 
een biopt (het afnemen van een klein stukje weefsel) van de tumor en dit 
microscopisch te onderzoeken. 
De exacte oorzaak van het OS is onbekend. Er zijn een aantal genetische 
aandoeningen waarbij deze vorm van kanker vaker voorkomt. Daarnaast is een 
aantal genen bekend dat vaak afwijkend is bij het OS. Tevens is bekend dat een 
hoge dosis straling ook tot een OS kan leiden, evenals sommige goedaardige 
afwijkingen in het bot. 
Voor de ontdekking van chemotherapie, was de overlevingskans voor patiënten 
met een OS beperkt tot 5-10%. De introductie van chemotherapie in combinatie 
met uitgebreide chirurgie heeft de behandeling en de behandelingsresultaten voor 
patiënten met OS aanzienlijk verbeterd. De behandeling van het OS bestaat uit 
intensieve chemotherapie en chirurgie waarbij de primaire tumor en zonodig de 
metastase verwijderd worden. De ontwikkelingen in de chemotherapie en chirurgie 
hebben ertoe bijgedragen dat amputaties nu minder vaak hoeven worden 
uitgevoerd. Patiënten met alleen een primaire tumor hebben een overlevingskans 
van 60%, patiënten waarbij longmetastasen zijn ontdekt, hebben een 
overlevingskans van rond de 20%.  
Gezien het feit dat er nog een groot aantal patiënten is dat ondanks de huidige 
behandelingen deze ziekte niet overleeft, wordt onderzoek gedaan naar andere 
behandelingsmogelijkheden. Verbeterd inzicht in de biologie van het OS heeft 
mogelijkheden opgeleverd voor onderzoek naar nieuwe strategieën om de huidige 
behandeling aan te vullen. Eén van deze nieuwe behandelingsstrategieën is 
Samenvatting voor niet-ingewijden 
gentherapie. Gentherapie is de behandeling of preventie van ziektes door 
gentransfer. Genetisch materiaal (DNA) wordt overgebracht naar een cel waarin 
het wordt omgezet in mRNA. Vervolgens wordt in het cytoplasma het mRNA 
vertaald en eiwit geproduceerd. Dit eiwit zorgt vervolgens voor een bepaald effect 
in de cel. De studies beschreven in dit proefschrift zijn gebaseerd op het gebruik 
van het adenovirus als vector (“drager”) voor DNA. Het type adenovirus wat 
daarvoor wordt gebruikt veroorzaakt in het dagelijks leven een milde verkoudheid. 
Dit verkoudheid virus is gemodificeerd, ofwel ongevaarlijk gemaakt. Het 
adenovirus dringt de cel binnen via binding aan een membraan-eiwit, zodat het 
DNA de gastcel, de tumor cel, bereikt. Het virus is dus alleen een vervoersmiddel 
voor DNA. Behalve als vervoersmiddel kan het adenovirus ook als anti kanker 
middel worden gebruikt, dit wordt dan een oncolytisch adenovirus genoemd. 
In dit proefschrift worden verschillende onderzoeken beschreven waarin een 
adenovirus bestudeerd wordt als mogelijk transportmiddel en tevens als 
therapeutische behandelingstoepassing voor patiënten met het OS. In dat laatse 
geval is het adenovirus nog steeds in staat om zich te vermenigvuldigen en zo 
tumor cellen te doden (Conditioneel Replicerende Adenovirusen, CRAds). 
In hoofdstuk 1 wordt de huidige kennis over de OS en de tegenwoordige 
behandelmethoden beschreven. Daarnaast worden een aantal nieuwe 
therapeutische mogelijkheden besproken. Vervolgens wordt in meer detail de 
meest recente strategieën van gentherapie voor OS beschreven.  
In hoofdstuk 2 worden de contouren van dit proefschrift weergegeven en wordt de 
inhoud van dit proefschrift in een context geplaatst.  
In Hoofdstuk 3 wordt de studie beschreven waarin onderzocht is of een enzym 
pro-drug systeem gebaseerd op carboxylesterase (CE)/CPT-11 (irrinotecan) 
werkzaam is voor het OS. De ontwikkeling van een adenovirus met het cDNA voor 
het  enzym CE wordt beschreven (Ad-sCE2). Dit enzym zet het CPT-11, een pro-
drug (niet werkzaam), om in SN-38, de werkzame stof. Er is gebruik gemaakt van 
een vorm van CE dat uitgescheiden wordt door de cellen met het idee dat niet 
alleen geïnfecteerde maar ook omringende cellen kunnen worden gedood door 
omzetting van het pro-drug in het toxische drug. De bruikbaarheid van SN-38 
wordt belemmerd door de bijwerkingen, hoofdzakelijk diarree. Een strategie om 
de anti-tumor effecten van SN-38 te verhogen, waarbij de ongewenste neven 
effecten afnemen, bestaat uit het laten plaatsvinden van de omzetting specifiek op 
de plaats van de tumor. Dit kan bewerkstelligd worden door het Ad-sCE2 alleen 
ter plaatse van de tumorcellen te laten komen. Dit is een interessante benadering 
omdat het als doel heeft een voldoende hoog gehalte van een anti-kanker 
geneesmiddel, rechtstreeks op de plaats van de tumor tot stand te brengen 
zonder algemene neven effecten.  
De wetenschap dat cellijnen niet altijd representatief zijn voor de situatie in de 
patiënt, is voor ons aanleiding geweest om zogenaamde korte termijn culturen 
van OS tumorcellen van patiënten te ontwikkelen, hetgeen meer representatief 
voor de situatie in de mens wordt verondersteld. Deze OS cellen werden in kweek 
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gebracht nadat een deel van de tumor chirurgisch was verwijderd. Het effect van 
het Ad-sCE2 in combinatie met CPT-11 is bestudeerd in cellijnen en in korte 
termijn culturen. Dit liet zien dat de tumorcellen gevoelig gemaakt konden worden 
door infectie met het Ad-sCE2 voor CPT-11. Vervolgens werd bij ’naakte’ muizen 
(muizen met een verminderd immuun systeem) met een humane OS tumor 
onderzocht of dit effect ook gezien werd. De tumoren behandeld met virus en 
CPT-11, gaven blijk van een significant langzamere groeisnelheid dan de niet 
behandelde dieren. Deze behandeling leidde echter niet tot complete afname 
(verdwijning) van de tumor.  
De wetenschap dat één van de voornaamste beperkingen van adenovirale 
gentherapie de relatief lage aanwezigheid is van de adenovirus receptor CAR, 
heeft geleid tot onderzoek naar andere meer voorkomend receptoren. Studies 
beschreven in dit proefschrift laten zien dat OS cellijnen en korte termijn culturen 
CAR negatief zijn, waardoor de infectie-efficiëntie benadeeld wordt en een andere 
receptor noodzakelijk is voor adenovirale binding. Zoals omschreven in hoofdstuk 
4, is een dergelijke alternatieve receptor de Epidermale Groeifactor Receptor 
(EGFR). EGFR komt veelvuldig voor op OS tumorcellen en is daarom een 
aantrekkelijke receptor. Wij konden dit bevestigen en laten zien dat in cellijnen, 
korte termijn culturen en tumor steekproeven EGFR veelvuldig voorkwam.  
Het HSV-TK enzym pro-drug ganciclovir systeem is uitgebreid onderzocht in zowel 
OS tumoren als andere solide tumoren. Het pro-drug ganciclovir wordt door het 
enzym HSV-TK omgezet in de werkzame metaboliet. De effectiviteit van dit 
systeem is in hoofdstuk 4 geëvalueerd. Dit in combinatie met een bi-specifiek 
antilichaam (425-s11) wat CAR omzeilt en bindt aan EGFR. Experimenten met het 
adenovirus in aanwezigheid van 425-s11 lieten significant verhoogde infectie-
efficiëntie en genoverdracht zien. Wij waren in staat de genoverdracht 2.5 tot 10 
keer te verhogen in OS cellen. Op basis hiervan werden gerichte gentherapie 
experimenten met AdHSV-TK uitgevoerd in combinatie met ganciclovir. Deze 
experimenten lieten een toename tot 3.5 maal van de vernietiging van OS 
cellijnen en OS korte termijn culturen zien. 
Op basis van de studies zoals hierboven beschreven, werd duidelijk dat de 
effectiviteit van gentherapie strategieën voor OS, gebaseerd op het adenovirus, 
afhankelijk is van de infectie-efficiëntie en de verspreiding en effectiviteit van het 
virus. 
In hoofdstuk 5 is daarom gekeken naar een ander concept  binnen de gentherapie 
(oncolytische adenovirale gentherapie), namelijk het gebruik van Conditioneel 
Replicerende Adenovirusen, CRAds. CRAds zijn adenovirusen die door genetische 
aanpassingen wel in tumorcellen maar niet in gewone cellen kunnen repliceren 
(vermenigvuldigen). Het therapeutisch effect bestaat hieruit dat wanneer CRAds 
de tumorcel infecteren deze in de tumorcel gaan repliceren. Uiteindelijk gaat de 
cel ten gevolge van deze indringer dood en komen duizenden nieuwe virusdeeltjes 
vrij die op hun beurt weer nieuwe tumorcellen kunnen vernietigen.  
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In dit hoofdstuk is tevens gekeken naar een receptor die veel voorkomt op OS 
cellen, namelijk integrine. Deze integrines zijn gebruikt als alternatieve receptor 
voor de CRAd. In plaats van een bi-specifiek antilichaam is in dit geval het 
bindingseiwit RGD in het virus gekloneerd. RGD bindt aan het celmembraan via de 
integrines. Deze CRAd was in staat om alle tumorcellen in vitro te doden evenals 
de tumorcellen uit de primaire culturen. Om deze resultaten in vivo te evalueren is 
een ‘naakte’ muis model ontwikkeld. In dit model is gebruik gemaakt van een 
stukje tumor wat direct afkomstig was van een patiënt met OS, niet goed 
reagerend op chemotherapie. Deze tumor is in naakte muizen geïmplanteerd en 
vervolgens is de CRAd hierin getest. Deze tumoren lieten een duidelijke groei 
afname zien en in sommige zelfs een groeistilstand.  
In hoofdstuk 6 is de effectiviteit van de hierboven beschreven CRAd onderzocht in 
een ratmodel. Het doel hiervan was om te kijken of de effectiviteit van de CRAds 
bleef bestaan bij het intra-arterieel toedienen van de CRAd. Aangezien de 
toediening van virus door injecties in de tumor in de klinsche setting niet mogelijk 
is, wordt gezocht naar andere toedieningsvormen. Ook longmetastasen kunnen 
alleen bereikt kunnen worden door systemische toediening. In het onderzoek 
beschreven in hoofdstuk 6 is gekeken naar intra-arteriele toediening in een 
afgeschermd compartiment. Hiertoe werd een ‘naakte’ rat model ontwikkeld met 
een OS tumor op de achterpoot van de rat. Om te voorkomen dat het virus door 
het gehele lichaam zou circuleren werd de bloedvoorziening van de achterpoot 
geïsoleerd van de rest van het lichaam door een band. De arterie en de vene 
werden gecannuleerd en het virus circuleerde door de achterpoot en door de 
tumor. Om dit model goed werkzaam te laten zijn, moesten een aantal chirurgisch 
technische aanpassingen worden verricht. Uiteindelijk bleek dat er verminderde 
tumor groei was en dat er virusdeeltjes in de tumoren kon worden aangetoond. 
Samenvattend hebben de studies beschreven in dit proefschrift het inzicht ten 
aanzien van gentherapie voor het OS vergroot. Deze kennis maakt het mogelijk 
om goede onderzoeksplannen voor de toekomst te ontwikkelen, zodat dit 
uiteindelijk zal leiden tot klinische toepasbaarheid van nieuwe 
behandelmogelijkheden en verbetering van de overlevingskansen van patiënten 
met een OS. 
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Zonder eindeloos gepipetteer en heel veel ander werk, dat ik alleen dankzij 
daadwerkelijke ondersteuning van velen heb kunnen doen, zou een dankwoord 
overbodig zijn. Is het dankwoord hierdoor misschien het meest gelezen onderdeel 
van een proefschrift? Dat zou droevig kunnen stemmen! Wellicht schetst het ook 
hoe relatief de uiteindelijke inhoud van een proefschrift zou kunnen zijn.  
De eerst woorden van dank gericht aan hen die aan de basis van dit onderzoek 
stonden: 
Prof. dr. P.I.J.M. Wuisman, Paul, jij stelde mij voor om eens een tijdje op het 
gentherapie lab te gaan kijken om te zien of ik onderzoek en dan met name 
gentherapeutisch onderzoek aan het OS interessant zou vinden. Dat tijdje werd 
drie en een half jaar. Een orthopedisch chirurg met interesse voor gentherapie, 
dat is toch op zijn minst bijzonder, nog daargelaten het gepriegel met niet 
zichtbaar DNA. Jouw grote interesse voor het OS maakte dit mogelijk.  
Dr. W.R. Gerritsen, Winald, jouw bijzondere persoonlijke interesse in het OS heeft 
bijgedragen aan mijn enthousiasme voor het onderzoek. Jouw ideeënstroom kon 
ik niet altijd adequaat verwerken. Als het aan jou had gelegen bestond dit 
proefschrift uit wel 20 hoofdstukken. Maar zeilen en paardrijden zijn ook bijzonder 
inspirerend. In ieder geval heb ik veel van je geleerd, niet alleen op 
wetenschappelijk gebied. 
Dr. V.W. van Beusechem, Victor, knap dat jij uit mijn niet altijd even briljante 
uitlatingen toch kon destilleren wat ik bedoelde te zeggen, en nog knapper om 
door mijn artikelen heen te walsen. Je bent dus niet voor niets een koning op de 
dansvloer.  
Eigenlijk heel dichtbij maar soms ongelooflijk ver weg: ‘het AMC’. Samenwerking 
is niet altijd vanzelfsprekend. Echter de samenwerking met dr. G. R. Schaap, 
Gerard en Dr. J. Bras, Hans was en is bijzonder soepel verlopen. Het verzamelen 
van tumormateriaal was zonder jullie nooit gelukt. Gerard, EMSOS congressen 
waren altijd bijzonder interessant en bovendien buitengewoon plezierig. 
Hans, achter een hele stapel werk verscholen had jij een prachtige microscoop, 
waar jij samen met mij heel wat coupes hebt bekeken. Ik heb hier heel veel van 
geleerd. Jouw deskundigheid in het opsporen van virussen in OS cellen bleek een 
ware kunst!   
Uiteraard wil ik de leden van de leescommissie en de promotiecommissie danken 
voor de aandacht besteed aan dit proefschrift. 
De mensen van het gentherapie lab, nooit hebben jullie je geduld verloren, ook 
niet toen ik in de eerste weken vooral gisten in plaats van cellen leek te kweken. 
Prof. Dr. H.J. Haisma, Hidde, mijn eerste onderzoeksstappen heb ik min of meer 
letterlijk aan jouw hand uitgevoerd. Dank voor het weg wijs maken op een VMT 
lab Gentherapie Geneeskundige Oncologie! 
Naast al het pipetteer werk bleek 5 december ook een buitengewoon belangrijke 
gebeurtenis! Ida, Petra, Bonnie en Jeroen dank jullie wel voor het eindeloze 
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geduld, ‘weer zo’n arts die onderzoek komt doen’, en de gezelligheid. De aio’s 
inmiddels allemaal Doctor, Michelle, Dinja en Daniëlle, zonder morren mij 
getolereerd en meer dan dat. Harm, ‘partner in crime’ onderzoek doen is op alle 
vlakken boeiend! Jij hebt ontzettend veel werk verzet en voortgezet, met prachtig 
resultaat! Op naar jouw promotie. 
Dr. M.L.M. Lamfers, Martine die e-mail zomer 2005 was toch wel een noodkreet 
mijnerzijds. Naast het onderzoek natuurlijk genoeg om over te keuvelen, de 
heren, Mats, Anne-Michèle, de laatste mode, ach uiteindelijk deed alles ertoe! De 
rest van de Neurochirurgie gentherapie groep; Prof. dr. C.M.F. Dirven, Clemens en 
neurochirurg in de dop, Sander, het snijdend specialisme schept toch een band. 
Dr. J. Grill, Jacques and Dr. B. Geörger, Birgit an ‘other’ French connection and 
Birgit we really should go horse riding some day. 
Alle anderen leden van de gentherapie: 
Mirjam, it was really nice to share a room and listen to all your fabulous stories. 
Erik, veel geluk met het vaderschap! Goeroe Jan, hoe zit het nu ook al weer 
precies met dat kloneerwerk?! Ondanks of dankzij jouw cynische blik is het toch 
nog goed gekomen, hoewel 1 hoofdstuk ontbreekt. En natuurlijk, Evelien, Renée, 
Tom, Mohamed en Sharif. 
Alle collega’s van de afdeling Orthopaedie VUMC, dank voor de aanmoedigingen en 
de prettige samenwerking. Dr. M. Helder, Marco, dank. Dames van het 
secretariaat, Mevr. E. Haan en mevr. M. Verwey-Deddens, Elise en Margreet, het 
regelen van alle ditjes en datjes en jullie animerende verhalen heb ik bijzonder 
gewaardeerd. Margreet, dank voor alle hulp bij de befaamde “laatste loodjes”. 
De (ex)collega’s uit het Zaans Medisch Centrum, de Maatschap Chirurgie en de 
dames van het gezelligste kamertje van de derde verdieping, na al die tijd op het 
lab was de overgang naar het werk in het ziekenhuis groot. Mede door jullie 
collegialiteit werd het een buitengewoon interessante, maar bovenal ook een 
bijzonder goede en inspirerende tijd in het Zaanse! 
De nieuwe collega’s uit het Onze Lieve Vrouwe Gasthuis, de Maatschap 
Orthopaedie, na een periode van proefschrift schrijfwerk was het ritme van een 
assistent orthopaedie in opleiding weer even wennen. Gelukkig heb ik van jullie 
die ruimte gekregen. Maar het nieuwe werk heeft er mede toe geleid dat dit 
boekje echt af moest en ik mij verheug op de tijd die gaat komen.  
Mijn paranimfen: Mariëlle en Petra, Mariëlle, kwam het nu omdat onze 
achternamen met een W beginnen en wij zo elkaar op de geneeskunde faculteit 
tijdens die leuke practica tegen het lijf liepen? Dat weet jij veel beter dan ik. 
Inmiddels hebben wij al heel wat inspirerende reisjes gemaakt en zijn onze 
vriendschap en culinaire overeenkomsten mij zeer dierbaar. Petra, wat was ik blij 
met jouw aanbod om te helpen dit boekje van een lay-out te voorzien. Geheel 
ervaren sleepte jij mij daar geduldig doorheen. Ik vind dat we toch nog een keer 
een echte berg moeten beklimmen, hoewel, de Ardennen zijn misschien uitdagend 
genoeg. 
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En dan de mensen niet direct betrokken bij het onderzoek maar die zorgen dat je 
de dag met een brede glimlach begint en eindigt. Annelieke, het goede Franse 
leven blijft in alle opzichten voortbestaan.  
Lieve Wendy, een nuchtere kijk op de zaak komt (altijd) goed van pas!  
Ijda, ik ken jou al heel lang en dat alleen al schept een band, van puber meisjes 
tot trotse vrouwen. Ooit dachten wij altijd ‘hip en wild’ te blijven. Wel, misschien 
zijn we dat nooit geweest en in onze huidige burgerlijkheid als hoeksteen van de 
samenleving denk ik, ook voor jou sprekend, zeker zo gelukkig. We staan elkaar 
nog steeds “live” of telefonisch met raad en daad terzijde, en nu kan de 
champagne open!  
Mijn schoonfamilie wil ik bedanken voor alle oppas, noodzakelijke 
vitaminevoorziening in de vorm van vele malen verse, panklare groenten en het 
vertrouwen van jullie allemaal. 
Mijn ouders, Joop en Margot, zonder jullie zou ik nooit geworden zijn wie ik nu 
ben. Dank jullie wel voor eindeloos vertrouwen en liefde. Met veel plezier draag ik 
dit proefschrift aan jullie op! “Hiran, broertje, altijd mee in mijn gedachte, ben jij 
en jouw te korte leven indirect misschien wel een van de grootste motivaties 
geweest om aan dit proefschrift te beginnen en het af te maken.” 
Allerliefste, lieve Anne-Michèle, dankzij jouw geklets en vrolijke gezichtje was het 
afronden van dit proefschrift een feest op zich. Lieve, lieve Ivo, dit proefschrift 
bevat geen 10 hoofdstukken en was niet in 3 jaar klaar! Juist omdat het leven zo 
leuk is om te leven met jou. Jij liet mij gewoon mijn gang gaan en stelde op de 
juiste momenten voor om een rakje te gaan zeilen, uitstekend plan! Kus. 
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